id	sid	tid	token	lemma	pos
dti-3059	1	1	dti	dti	PROPN
dti-3059	1	2	drug	drug	PROPN
dti-3059	1	3	target	target	NOUN
dti-3059	1	4	insights	insight	NOUN
dti-3059	1	5	2024	2024	NUM
dti-3059	1	6	;	;	PUNCT
dti-3059	1	7	18	18	NUM
dti-3059	1	8	:	:	SYM
dti-3059	1	9	20	20	NUM
dti-3059	1	10	-	-	SYM
dti-3059	1	11	26	26	NUM
dti-3059	1	12	issn	issn	PROPN
dti-3059	1	13	1177	1177	NUM
dti-3059	1	14	-	-	SYM
dti-3059	1	15	3928	3928	NUM
dti-3059	1	16	|	|	ADV
dti-3059	1	17	doi	doi	NOUN
dti-3059	1	18	:	:	PUNCT
dti-3059	1	19	10.33393	10.33393	NUM
dti-3059	1	20	/	/	SYM
dti-3059	1	21	dti.2024.3059	dti.2024.3059	PRON
dti-3059	1	22	original	original	ADJ
dti-3059	1	23	research	research	NOUN
dti-3059	1	24	article	article	NOUN
dti-3059	1	25	drug	drug	NOUN
dti-3059	1	26	target	target	NOUN
dti-3059	1	27	insights	insight	NOUN
dti-3059	1	28	issn	issn	VERB
dti-3059	1	29	1177	1177	NUM
dti-3059	1	30	-	-	SYM
dti-3059	1	31	3928	3928	NUM
dti-3059	1	32	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-3059	1	33	©	©	PROPN
dti-3059	1	34	2024	2024	NUM
dti-3059	1	35	the	the	DET
dti-3059	1	36	authors	author	NOUN
dti-3059	1	37	.	.	PUNCT
dti-3059	2	1	this	this	DET
dti-3059	2	2	article	article	NOUN
dti-3059	2	3	is	be	AUX
dti-3059	2	4	published	publish	VERB
dti-3059	2	5	by	by	ADP
dti-3059	2	6	aboutscience	aboutscience	NOUN
dti-3059	2	7	and	and	CCONJ
dti-3059	2	8	licensed	license	VERB
dti-3059	2	9	under	under	ADP
dti-3059	2	10	creative	creative	ADJ
dti-3059	2	11	commons	common	NOUN
dti-3059	2	12	attribution	attribution	NOUN
dti-3059	2	13	-	-	PUNCT
dti-3059	2	14	noncommercial	noncommercial	ADJ
dti-3059	2	15	4.0	4.0	NUM
dti-3059	2	16	international	international	NOUN
dti-3059	2	17	(	(	PUNCT
dti-3059	2	18	cc	cc	NOUN
dti-3059	2	19	by	by	ADP
dti-3059	2	20	-	-	PUNCT
dti-3059	2	21	nc	nc	PROPN
dti-3059	2	22	4.0	4.0	NUM
dti-3059	2	23	)	)	PUNCT
dti-3059	2	24	.	.	PUNCT
dti-3059	3	1	commercial	commercial	ADJ
dti-3059	3	2	use	use	NOUN
dti-3059	3	3	is	be	AUX
dti-3059	3	4	not	not	PART
dti-3059	3	5	permitted	permit	VERB
dti-3059	3	6	and	and	CCONJ
dti-3059	3	7	is	be	AUX
dti-3059	3	8	subject	subject	ADJ
dti-3059	3	9	to	to	ADP
dti-3059	3	10	publisher	publisher	NOUN
dti-3059	3	11	’s	’s	PART
dti-3059	3	12	permissions	permission	NOUN
dti-3059	3	13	.	.	PUNCT
dti-3059	4	1	full	full	ADJ
dti-3059	4	2	information	information	NOUN
dti-3059	4	3	is	be	AUX
dti-3059	4	4	available	available	ADJ
dti-3059	4	5	at	at	ADP
dti-3059	4	6	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-3059	4	7	article	article	NOUN
dti-3059	4	8	type	type	NOUN
dti-3059	4	9	:	:	PUNCT
dti-3059	4	10	original	original	ADJ
dti-3059	4	11	research	research	NOUN
dti-3059	4	12	article	article	NOUN
dti-3059	4	13	doi	doi	NOUN
dti-3059	4	14	:	:	PUNCT
dti-3059	4	15	10.33393	10.33393	NUM
dti-3059	4	16	/	/	SYM
dti-3059	4	17	dti.2024.2670	dti.2024.2670	NOUN
dti-3059	4	18	(	(	PUNCT
dti-3059	4	19	link	link	VERB
dti-3059	4	20	to	to	ADP
dti-3059	4	21	https://doi.org/10.33393/	https://doi.org/10.33393/	PROPN
dti-3059	4	22	dti.2024.2670	dti.2024.2670	NOUN
dti-3059	4	23	)	)	PUNCT
dti-3059	4	24	short	short	ADJ
dti-3059	4	25	title	title	NOUN
dti-3059	4	26	:	:	PUNCT
dti-3059	4	27	(	(	PUNCT
dti-3059	4	28	a	a	X
dti-3059	4	29	:	:	PUNCT
dti-3059	4	30	please	please	INTJ
dti-3059	4	31	provide	provide	VERB
dti-3059	4	32	)	)	PUNCT
dti-3059	4	33	rbd	rbd	NOUN
dti-3059	4	34	mutations	mutation	NOUN
dti-3059	4	35	at	at	ADP
dti-3059	4	36	the	the	DET
dti-3059	4	37	residues	residue	NOUN
dti-3059	4	38	k417	k417	PROPN
dti-3059	4	39	,	,	PUNCT
dti-3059	4	40	e484	e484	PROPN
dti-3059	4	41	,	,	PUNCT
dti-3059	4	42	n501	n501	PROPN
dti-3059	4	43	reduced	reduce	VERB
dti-3059	4	44	immunoreactivity	immunoreactivity	NOUN
dti-3059	4	45	with	with	ADP
dti-3059	4	46	antisera	antisera	NOUN
dti-3059	4	47	from	from	ADP
dti-3059	4	48	vaccinated	vaccinated	ADJ
dti-3059	4	49	and	and	CCONJ
dti-3059	4	50	covid-19	covid-19	PROPN
dti-3059	4	51	recovered	recover	VERB
dti-3059	4	52	patients	patient	NOUN
dti-3059	4	53	dablu	dablu	VERB
dti-3059	4	54	lal	lal	PROPN
dti-3059	4	55	gupta	gupta	PROPN
dti-3059	4	56	1	1	NUM
dti-3059	4	57	,	,	PUNCT
dti-3059	4	58	jhasketan	jhasketan	PROPN
dti-3059	4	59	meher	meher	PROPN
dti-3059	4	60	2	2	NUM
dti-3059	4	61	,	,	PUNCT
dti-3059	4	62	anjan	anjan	PROPN
dti-3059	4	63	kumar	kumar	PROPN
dti-3059	4	64	giri	giri	PROPN
dti-3059	4	65	3	3	NUM
dti-3059	4	66	,	,	PUNCT
dti-3059	4	67	arvind	arvind	PROPN
dti-3059	4	68	k	k	PROPN
dti-3059	4	69	shukla	shukla	PROPN
dti-3059	4	70	4	4	NUM
dti-3059	4	71	,	,	PUNCT
dti-3059	4	72	eli	eli	PROPN
dti-3059	4	73	mohapatra1	mohapatra1	PROPN
dti-3059	4	74	,	,	PUNCT
dti-3059	4	75	manisha	manisha	PROPN
dti-3059	4	76	m	m	PROPN
dti-3059	4	77	ruikar4	ruikar4	PROPN
dti-3059	4	78	,	,	PUNCT
dti-3059	4	79	dn	dn	PROPN
dti-3059	4	80	rao5	rao5	PROPN
dti-3059	4	81	1department	1department	NUM
dti-3059	4	82	of	of	ADP
dti-3059	4	83	biochemistry	biochemistry	NOUN
dti-3059	4	84	,	,	PUNCT
dti-3059	4	85	all	all	DET
dti-3059	4	86	india	india	PROPN
dti-3059	4	87	institute	institute	PROPN
dti-3059	4	88	of	of	ADP
dti-3059	4	89	medical	medical	PROPN
dti-3059	4	90	sciences	sciences	PROPN
dti-3059	4	91	(	(	PUNCT
dti-3059	4	92	aiims	aiims	PROPN
dti-3059	4	93	)	)	PUNCT
dti-3059	4	94	,	,	PUNCT
dti-3059	4	95	raipur	raipur	NOUN
dti-3059	4	96	,	,	PUNCT
dti-3059	4	97	chhattisgarh	chhattisgarh	NOUN
dti-3059	4	98	india	india	PROPN
dti-3059	4	99	2department	2department	PROPN
dti-3059	4	100	of	of	ADP
dti-3059	4	101	general	general	ADJ
dti-3059	4	102	medicine	medicine	NOUN
dti-3059	4	103	,	,	PUNCT
dti-3059	4	104	all	all	DET
dti-3059	4	105	india	india	PROPN
dti-3059	4	106	institute	institute	PROPN
dti-3059	4	107	of	of	ADP
dti-3059	4	108	medical	medical	PROPN
dti-3059	4	109	sciences	sciences	PROPN
dti-3059	4	110	(	(	PUNCT
dti-3059	4	111	aiims	aiims	PROPN
dti-3059	4	112	)	)	PUNCT
dti-3059	4	113	,	,	PUNCT
dti-3059	4	114	raipur	raipur	NOUN
dti-3059	4	115	,	,	PUNCT
dti-3059	4	116	chhattisgarh	chhattisgarh	NOUN
dti-3059	4	117	india	india	PROPN
dti-3059	4	118	3department	3department	PROPN
dti-3059	4	119	of	of	ADP
dti-3059	4	120	community	community	NOUN
dti-3059	4	121	and	and	CCONJ
dti-3059	4	122	family	family	NOUN
dti-3059	4	123	medicine	medicine	NOUN
dti-3059	4	124	,	,	PUNCT
dti-3059	4	125	all	all	DET
dti-3059	4	126	india	india	PROPN
dti-3059	4	127	institute	institute	PROPN
dti-3059	4	128	of	of	ADP
dti-3059	4	129	medical	medical	PROPN
dti-3059	4	130	sciences	sciences	PROPN
dti-3059	4	131	(	(	PUNCT
dti-3059	4	132	aiims	aiims	PROPN
dti-3059	4	133	)	)	PUNCT
dti-3059	4	134	,	,	PUNCT
dti-3059	4	135	raipur	raipur	NOUN
dti-3059	4	136	,	,	PUNCT
dti-3059	4	137	chhattisgarh	chhattisgarh	NOUN
dti-3059	4	138	india	india	PROPN
dti-3059	4	139	4department	4department	NUM
dti-3059	4	140	of	of	ADP
dti-3059	4	141	community	community	NOUN
dti-3059	4	142	medicine	medicine	NOUN
dti-3059	4	143	,	,	PUNCT
dti-3059	4	144	all	all	DET
dti-3059	4	145	india	india	PROPN
dti-3059	4	146	institute	institute	PROPN
dti-3059	4	147	of	of	ADP
dti-3059	4	148	medical	medical	PROPN
dti-3059	4	149	sciences	sciences	PROPN
dti-3059	4	150	(	(	PUNCT
dti-3059	4	151	aiims	aiims	PROPN
dti-3059	4	152	)	)	PUNCT
dti-3059	4	153	,	,	PUNCT
dti-3059	4	154	raipur	raipur	NOUN
dti-3059	4	155	,	,	PUNCT
dti-3059	4	156	chhattisgarh	chhattisgarh	NOUN
dti-3059	4	157	india	india	PROPN
dti-3059	4	158	5department	5department	NUM
dti-3059	4	159	of	of	ADP
dti-3059	4	160	biochemistry	biochemistry	NOUN
dti-3059	4	161	,	,	PUNCT
dti-3059	4	162	all	all	DET
dti-3059	4	163	india	india	PROPN
dti-3059	4	164	institute	institute	PROPN
dti-3059	4	165	of	of	ADP
dti-3059	4	166	medical	medical	PROPN
dti-3059	4	167	sciences	sciences	PROPN
dti-3059	4	168	(	(	PUNCT
dti-3059	4	169	aiims	aiims	PROPN
dti-3059	4	170	)	)	PUNCT
dti-3059	4	171	,	,	PUNCT
dti-3059	4	172	new	new	PROPN
dti-3059	4	173	delhi	delhi	PROPN
dti-3059	4	174	india	india	PROPN
dti-3059	4	175	abstract	abstract	ADJ
dti-3059	4	176	introduction	introduction	NOUN
dti-3059	4	177	:	:	PUNCT
dti-3059	4	178	it	it	PRON
dti-3059	4	179	is	be	AUX
dti-3059	4	180	unclear	unclear	ADJ
dti-3059	4	181	whether	whether	SCONJ
dti-3059	4	182	induced	induce	VERB
dti-3059	4	183	spike	spike	ADJ
dti-3059	4	184	protein	protein	NOUN
dti-3059	4	185	-	-	PUNCT
dti-3059	4	186	specific	specific	ADJ
dti-3059	4	187	antibodies	antibody	NOUN
dti-3059	4	188	due	due	ADP
dti-3059	4	189	to	to	ADP
dti-3059	4	190	infections	infection	NOUN
dti-3059	4	191	with	with	ADP
dti-3059	4	192	sars	sar	NOUN
dti-3059	4	193	-	-	PUNCT
dti-3059	4	194	cov-2	cov-2	NOUN
dti-3059	4	195	or	or	CCONJ
dti-3059	4	196	to	to	ADP
dti-3059	4	197	the	the	DET
dti-3059	4	198	prototypic	prototypic	ADJ
dti-3059	4	199	wuhan	wuhan	PROPN
dti-3059	4	200	isolate	isolate	PROPN
dti-3059	4	201	-	-	PUNCT
dti-3059	4	202	based	base	VERB
dti-3059	4	203	vaccination	vaccination	NOUN
dti-3059	4	204	can	can	AUX
dti-3059	4	205	immune	immune	NOUN
dti-3059	4	206	-	-	PUNCT
dti-3059	4	207	react	react	NOUN
dti-3059	4	208	with	with	ADP
dti-3059	4	209	the	the	DET
dti-3059	4	210	emerging	emerge	VERB
dti-3059	4	211	variants	variant	NOUN
dti-3059	4	212	of	of	ADP
dti-3059	4	213	sars	sar	NOUN
dti-3059	4	214	-	-	PUNCT
dti-3059	4	215	cov-2	cov-2	NOUN
dti-3059	4	216	.	.	PUNCT
dti-3059	5	1	aim	aim	NOUN
dti-3059	5	2	/	/	SYM
dti-3059	5	3	objectives	objective	NOUN
dti-3059	5	4	:	:	PUNCT
dti-3059	5	5	the	the	DET
dti-3059	5	6	main	main	ADJ
dti-3059	5	7	objective	objective	NOUN
dti-3059	5	8	of	of	ADP
dti-3059	5	9	the	the	DET
dti-3059	5	10	study	study	NOUN
dti-3059	5	11	was	be	AUX
dti-3059	5	12	to	to	PART
dti-3059	5	13	measure	measure	VERB
dti-3059	5	14	the	the	DET
dti-3059	5	15	immunoreactivity	immunoreactivity	NOUN
dti-3059	5	16	of	of	ADP
dti-3059	5	17	induced	induced	ADJ
dti-3059	5	18	antibodies	antibody	NOUN
dti-3059	5	19	postvaccination	postvaccination	NOUN
dti-3059	5	20	with	with	ADP
dti-3059	5	21	covishield	covishield	NOUN
dti-3059	5	22	™	™	PROPN
dti-3059	5	23	(	(	PUNCT
dti-3059	5	24	chadox1	chadox1	NOUN
dti-3059	5	25	ncov-19	ncov-19	PROPN
dti-3059	5	26	coronavirus	coronavirus	NOUN
dti-3059	5	27	vaccines	vaccine	NOUN
dti-3059	5	28	)	)	PUNCT
dti-3059	5	29	or	or	CCONJ
dti-3059	5	30	infections	infection	NOUN
dti-3059	5	31	with	with	ADP
dti-3059	5	32	sars	sar	NOUN
dti-3059	5	33	-	-	PUNCT
dti-3059	5	34	cov-2	cov-2	NUM
dti-3059	5	35	by	by	ADP
dti-3059	5	36	using	use	VERB
dti-3059	5	37	selected	select	VERB
dti-3059	5	38	peptides	peptide	NOUN
dti-3059	5	39	of	of	ADP
dti-3059	5	40	the	the	DET
dti-3059	5	41	spike	spike	ADJ
dti-3059	5	42	protein	protein	NOUN
dti-3059	5	43	of	of	ADP
dti-3059	5	44	wild	wild	ADJ
dti-3059	5	45	type	type	NOUN
dti-3059	5	46	and	and	CCONJ
dti-3059	5	47	variants	variant	NOUN
dti-3059	5	48	of	of	ADP
dti-3059	5	49	sars	sar	NOUN
dti-3059	5	50	-	-	PUNCT
dti-3059	5	51	cov-2	cov-2	NOUN
dti-3059	5	52	.	.	PUNCT
dti-3059	6	1	methodology	methodology	NOUN
dti-3059	6	2	:	:	PUNCT
dti-3059	6	3	thirty	thirty	NUM
dti-3059	6	4	patients	patient	NOUN
dti-3059	6	5	who	who	PRON
dti-3059	6	6	had	have	AUX
dti-3059	6	7	recovered	recover	VERB
dti-3059	6	8	from	from	ADP
dti-3059	6	9	sars	sar	NOUN
dti-3059	6	10	-	-	PUNCT
dti-3059	6	11	cov-2	cov-2	PART
dti-3059	6	12	infections	infection	NOUN
dti-3059	6	13	and	and	CCONJ
dti-3059	6	14	30	30	NUM
dti-3059	6	15	individuals	individual	NOUN
dti-3059	6	16	vaccinated	vaccinate	VERB
dti-3059	6	17	with	with	ADP
dti-3059	6	18	both	both	DET
dti-3059	6	19	doses	dose	NOUN
dti-3059	6	20	of	of	ADP
dti-3059	6	21	covishield	covishield	NOUN
dti-3059	6	22	™	™	PROPN
dti-3059	6	23	were	be	AUX
dti-3059	6	24	recruited	recruit	VERB
dti-3059	6	25	for	for	ADP
dti-3059	6	26	the	the	DET
dti-3059	6	27	study	study	NOUN
dti-3059	6	28	.	.	PUNCT
dti-3059	7	1	venous	venous	ADJ
dti-3059	7	2	blood	blood	NOUN
dti-3059	7	3	samples	sample	NOUN
dti-3059	7	4	(	(	PUNCT
dti-3059	7	5	5	5	NUM
dti-3059	7	6	ml	ml	NOUN
dti-3059	7	7	)	)	PUNCT
dti-3059	7	8	were	be	AUX
dti-3059	7	9	collected	collect	VERB
dti-3059	7	10	at	at	ADP
dti-3059	7	11	a	a	DET
dti-3059	7	12	single	single	ADJ
dti-3059	7	13	time	time	NOUN
dti-3059	7	14	point	point	NOUN
dti-3059	7	15	from	from	ADP
dti-3059	7	16	patients	patient	NOUN
dti-3059	7	17	within	within	ADP
dti-3059	7	18	3	3	NUM
dti-3059	7	19	-	-	SYM
dti-3059	7	20	4	4	NUM
dti-3059	7	21	weeks	week	NOUN
dti-3059	7	22	of	of	ADP
dti-3059	7	23	recovery	recovery	NOUN
dti-3059	7	24	from	from	ADP
dti-3059	7	25	sars	sar	NOUN
dti-3059	7	26	-	-	PUNCT
dti-3059	7	27	cov-2	cov-2	PART
dti-3059	7	28	infections	infection	NOUN
dti-3059	7	29	or	or	CCONJ
dti-3059	7	30	receiving	receive	VERB
dti-3059	7	31	both	both	DET
dti-3059	7	32	doses	dose	NOUN
dti-3059	7	33	of	of	ADP
dti-3059	7	34	covishield	covishield	ADJ
dti-3059	7	35	™	™	ADJ
dti-3059	7	36	vaccines	vaccine	NOUN
dti-3059	7	37	.	.	PUNCT
dti-3059	8	1	the	the	DET
dti-3059	8	2	serum	serum	NOUN
dti-3059	8	3	levels	level	NOUN
dti-3059	8	4	of	of	ADP
dti-3059	8	5	total	total	ADJ
dti-3059	8	6	immunoglobulin	immunoglobulin	NOUN
dti-3059	8	7	were	be	AUX
dti-3059	8	8	measured	measure	VERB
dti-3059	8	9	in	in	ADP
dti-3059	8	10	both	both	DET
dti-3059	8	11	study	study	NOUN
dti-3059	8	12	groups	group	NOUN
dti-3059	8	13	.	.	PUNCT
dti-3059	9	1	a	a	DET
dti-3059	9	2	total	total	NOUN
dti-3059	9	3	of	of	ADP
dti-3059	9	4	12	12	NUM
dti-3059	9	5	peptides	peptide	NOUN
dti-3059	9	6	of	of	ADP
dti-3059	9	7	10	10	NUM
dti-3059	9	8	to	to	PART
dti-3059	9	9	24	24	NUM
dti-3059	9	10	amino	amino	ADJ
dti-3059	9	11	acids	acid	NOUN
dti-3059	9	12	length	length	NOUN
dti-3059	9	13	spanning	span	VERB
dti-3059	9	14	to	to	ADP
dti-3059	9	15	the	the	DET
dti-3059	9	16	receptor	receptor	NOUN
dti-3059	9	17	-	-	PUNCT
dti-3059	9	18	binding	bind	VERB
dti-3059	9	19	domain	domain	NOUN
dti-3059	9	20	(	(	PUNCT
dti-3059	9	21	rbd	rbd	NOUN
dti-3059	9	22	)	)	PUNCT
dti-3059	9	23	of	of	ADP
dti-3059	9	24	wild	wild	ADJ
dti-3059	9	25	type	type	NOUN
dti-3059	9	26	of	of	ADP
dti-3059	9	27	sars	sar	NOUN
dti-3059	9	28	-	-	PUNCT
dti-3059	9	29	cov-2	cov-2	NOUN
dti-3059	9	30	and	and	CCONJ
dti-3059	9	31	their	their	PRON
dti-3059	9	32	variants	variant	NOUN
dti-3059	9	33	were	be	AUX
dti-3059	9	34	synthesized	synthesize	VERB
dti-3059	9	35	.	.	PUNCT
dti-3059	10	1	the	the	DET
dti-3059	10	2	serum	serum	NOUN
dti-3059	10	3	levels	level	NOUN
dti-3059	10	4	of	of	ADP
dti-3059	10	5	immune	immune	NOUN
dti-3059	10	6	-	-	PUNCT
dti-3059	10	7	reactive	reactive	ADJ
dti-3059	10	8	antibodies	antibody	NOUN
dti-3059	10	9	were	be	AUX
dti-3059	10	10	measured	measure	VERB
dti-3059	10	11	using	use	VERB
dti-3059	10	12	these	these	DET
dti-3059	10	13	peptides	peptide	NOUN
dti-3059	10	14	.	.	PUNCT
dti-3059	11	1	results	result	NOUN
dti-3059	11	2	:	:	PUNCT
dti-3059	11	3	the	the	DET
dti-3059	11	4	serum	serum	NOUN
dti-3059	11	5	levels	level	NOUN
dti-3059	11	6	of	of	ADP
dti-3059	11	7	total	total	ADJ
dti-3059	11	8	antibodies	antibody	NOUN
dti-3059	11	9	were	be	AUX
dti-3059	11	10	found	find	VERB
dti-3059	11	11	to	to	PART
dti-3059	11	12	be	be	AUX
dti-3059	11	13	significantly	significantly	ADV
dti-3059	11	14	(	(	PUNCT
dti-3059	11	15	p<0.001	p<0.001	X
dti-3059	11	16	)	)	PUNCT
dti-3059	11	17	higher	high	ADJ
dti-3059	11	18	in	in	ADP
dti-3059	11	19	the	the	DET
dti-3059	11	20	vaccinated	vaccinate	VERB
dti-3059	11	21	individuals	individual	NOUN
dti-3059	11	22	as	as	SCONJ
dti-3059	11	23	compared	compare	VERB
dti-3059	11	24	to	to	ADP
dti-3059	11	25	covid-19	covid-19	PROPN
dti-3059	11	26	recovered	recover	VERB
dti-3059	11	27	patients	patient	NOUN
dti-3059	11	28	.	.	PUNCT
dti-3059	12	1	our	our	PRON
dti-3059	12	2	study	study	NOUN
dti-3059	12	3	reported	report	VERB
dti-3059	12	4	that	that	SCONJ
dti-3059	12	5	the	the	DET
dti-3059	12	6	mutations	mutation	NOUN
dti-3059	12	7	in	in	ADP
dti-3059	12	8	the	the	DET
dti-3059	12	9	rbd	rbd	NOUN
dti-3059	12	10	at	at	ADP
dti-3059	12	11	the	the	DET
dti-3059	12	12	residues	residue	NOUN
dti-3059	12	13	k417	k417	PROPN
dti-3059	12	14	,	,	PUNCT
dti-3059	12	15	e484	e484	PROPN
dti-3059	12	16	,	,	PUNCT
dti-3059	12	17	and	and	CCONJ
dti-3059	12	18	n501	n501	PROPN
dti-3059	12	19	have	have	AUX
dti-3059	12	20	been	be	AUX
dti-3059	12	21	associated	associate	VERB
dti-3059	12	22	with	with	ADP
dti-3059	12	23	reduced	reduced	ADJ
dti-3059	12	24	immunoreactivity	immunoreactivity	NOUN
dti-3059	12	25	with	with	ADP
dti-3059	12	26	anti	anti	ADJ
dti-3059	12	27	-	-	NOUN
dti-3059	12	28	sera	sera	NOUN
dti-3059	12	29	of	of	ADP
dti-3059	12	30	vaccinated	vaccinated	ADJ
dti-3059	12	31	people	people	NOUN
dti-3059	12	32	and	and	CCONJ
dti-3059	12	33	covid-19	covid-19	PROPN
dti-3059	12	34	recovered	recover	VERB
dti-3059	12	35	patients	patient	NOUN
dti-3059	12	36	.	.	PUNCT
dti-3059	13	1	conclusion	conclusion	NOUN
dti-3059	13	2	:	:	PUNCT
dti-3059	13	3	the	the	DET
dti-3059	13	4	amino	amino	NOUN
dti-3059	13	5	acid	acid	NOUN
dti-3059	13	6	substitutions	substitution	NOUN
dti-3059	13	7	at	at	ADP
dti-3059	13	8	the	the	DET
dti-3059	13	9	rbd	rbd	NOUN
dti-3059	13	10	of	of	ADP
dti-3059	13	11	sars	sar	NOUN
dti-3059	13	12	-	-	PUNCT
dti-3059	13	13	cov-2	cov-2	PART
dti-3059	13	14	have	have	AUX
dti-3059	13	15	been	be	AUX
dti-3059	13	16	associated	associate	VERB
dti-3059	13	17	with	with	ADP
dti-3059	13	18	a	a	DET
dti-3059	13	19	higher	high	ADJ
dti-3059	13	20	potential	potential	NOUN
dti-3059	13	21	to	to	PART
dti-3059	13	22	escape	escape	VERB
dti-3059	13	23	the	the	DET
dti-3059	13	24	humoral	humoral	ADJ
dti-3059	13	25	immune	immune	ADJ
dti-3059	13	26	response	response	NOUN
dti-3059	13	27	.	.	PUNCT
dti-3059	14	1	keywords	keyword	NOUN
dti-3059	14	2	:	:	PUNCT
dti-3059	14	3	antibodies	antibodie	VERB
dti-3059	14	4	,	,	PUNCT
dti-3059	14	5	covid-19	covid-19	PROPN
dti-3059	14	6	,	,	PUNCT
dti-3059	14	7	immune	immune	ADJ
dti-3059	14	8	escape	escape	NOUN
dti-3059	14	9	,	,	PUNCT
dti-3059	14	10	immunoreactivity	immunoreactivity	NOUN
dti-3059	14	11	,	,	PUNCT
dti-3059	14	12	mutation	mutation	NOUN
dti-3059	14	13	,	,	PUNCT
dti-3059	14	14	sars	sar	NOUN
dti-3059	14	15	-	-	PUNCT
dti-3059	14	16	cov-2	cov-2	PART
dti-3059	14	17	received	receive	VERB
dti-3059	14	18	:	:	PUNCT
dti-3059	14	19	march	march	PROPN
dti-3059	14	20	1	1	NUM
dti-3059	14	21	,	,	PUNCT
dti-3059	14	22	2024	2024	NUM
dti-3059	14	23	accepted	accept	VERB
dti-3059	14	24	:	:	PUNCT
dti-3059	14	25	may	may	AUX
dti-3059	14	26	7	7	NUM
dti-3059	14	27	,	,	PUNCT
dti-3059	14	28	2024	2024	NUM
dti-3059	14	29	published	publish	VERB
dti-3059	14	30	online	online	ADV
dti-3059	14	31	:	:	PUNCT
dti-3059	14	32	may	may	AUX
dti-3059	14	33	31	31	NUM
dti-3059	14	34	,	,	PUNCT
dti-3059	14	35	2024	2024	NUM
dti-3059	14	36	this	this	DET
dti-3059	14	37	article	article	NOUN
dti-3059	14	38	includes	include	VERB
dti-3059	14	39	supplementary	supplementary	ADJ
dti-3059	14	40	material	material	NOUN
dti-3059	14	41	corresponding	corresponding	ADJ
dti-3059	14	42	author	author	NOUN
dti-3059	14	43	:	:	PUNCT
dti-3059	14	44	dablu	dablu	PROPN
dti-3059	14	45	lal	lal	PROPN
dti-3059	14	46	gupta	gupta	PROPN
dti-3059	14	47	email	email	NOUN
dti-3059	14	48	:	:	PUNCT
dti-3059	14	49	dr.dlgupta@aiimsraipur.edu.in	dr.dlgupta@aiimsraipur.edu.in	NUM
dti-3059	14	50	world	world	NOUN
dti-3059	14	51	(	(	PUNCT
dti-3059	14	52	3	3	NUM
dti-3059	14	53	)	)	PUNCT
dti-3059	14	54	.	.	PUNCT
dti-3059	15	1	globally	globally	ADV
dti-3059	15	2	,	,	PUNCT
dti-3059	15	3	the	the	DET
dti-3059	15	4	covid-19	covid-19	PROPN
dti-3059	15	5	pandemic	pandemic	NOUN
dti-3059	15	6	is	be	AUX
dti-3059	15	7	still	still	ADV
dti-3059	15	8	producing	produce	VERB
dti-3059	15	9	a	a	DET
dti-3059	15	10	significant	significant	ADJ
dti-3059	15	11	amount	amount	NOUN
dti-3059	15	12	of	of	ADP
dti-3059	15	13	illness	illness	NOUN
dti-3059	15	14	and	and	CCONJ
dti-3059	15	15	mortality	mortality	NOUN
dti-3059	15	16	(	(	PUNCT
dti-3059	15	17	4	4	NUM
dti-3059	15	18	)	)	PUNCT
dti-3059	15	19	.	.	PUNCT
dti-3059	16	1	according	accord	VERB
dti-3059	16	2	to	to	ADP
dti-3059	16	3	current	current	ADJ
dti-3059	16	4	knowledge	knowledge	NOUN
dti-3059	16	5	,	,	PUNCT
dti-3059	16	6	mildly	mildly	ADV
dti-3059	16	7	symptomatic	symptomatic	ADJ
dti-3059	16	8	people	people	NOUN
dti-3059	16	9	represent	represent	VERB
dti-3059	16	10	around	around	ADV
dti-3059	16	11	80	80	NUM
dti-3059	16	12	%	%	NOUN
dti-3059	16	13	of	of	ADP
dti-3059	16	14	all	all	DET
dti-3059	16	15	instances	instance	NOUN
dti-3059	16	16	of	of	ADP
dti-3059	16	17	covid-19	covid-19	PROPN
dti-3059	16	18	,	,	PUNCT
dti-3059	16	19	which	which	PRON
dti-3059	16	20	can	can	AUX
dti-3059	16	21	range	range	VERB
dti-3059	16	22	in	in	ADP
dti-3059	16	23	severity	severity	NOUN
dti-3059	16	24	from	from	ADP
dti-3059	16	25	asymptomatic	asymptomatic	ADJ
dti-3059	16	26	to	to	ADP
dti-3059	16	27	deadly	deadly	ADJ
dti-3059	16	28	pneumonitis	pneumonitis	NOUN
dti-3059	16	29	(	(	PUNCT
dti-3059	16	30	5	5	NUM
dti-3059	16	31	)	)	PUNCT
dti-3059	16	32	.	.	PUNCT
dti-3059	17	1	the	the	DET
dti-3059	17	2	virus	virus	NOUN
dti-3059	17	3	can	can	AUX
dti-3059	17	4	cause	cause	VERB
dti-3059	17	5	a	a	DET
dti-3059	17	6	range	range	NOUN
dti-3059	17	7	of	of	ADP
dti-3059	17	8	symptoms	symptom	NOUN
dti-3059	17	9	,	,	PUNCT
dti-3059	17	10	from	from	ADP
dti-3059	17	11	mild	mild	ADJ
dti-3059	17	12	to	to	ADP
dti-3059	17	13	severe	severe	ADJ
dti-3059	17	14	,	,	PUNCT
dti-3059	17	15	and	and	CCONJ
dti-3059	17	16	can	can	AUX
dti-3059	17	17	be	be	AUX
dti-3059	17	18	transmitted	transmit	VERB
dti-3059	17	19	through	through	ADP
dti-3059	17	20	the	the	DET
dti-3059	17	21	respiratory	respiratory	ADJ
dti-3059	17	22	tract	tract	NOUN
dti-3059	17	23	(	(	PUNCT
dti-3059	17	24	6	6	NUM
dti-3059	17	25	)	)	PUNCT
dti-3059	17	26	.	.	PUNCT
dti-3059	18	1	it	it	PRON
dti-3059	18	2	has	have	VERB
dti-3059	18	3	significant	significant	ADJ
dti-3059	18	4	impacts	impact	NOUN
dti-3059	18	5	on	on	ADP
dti-3059	18	6	at	at	ADP
dti-3059	18	7	-	-	PUNCT
dti-3059	18	8	risk	risk	NOUN
dti-3059	18	9	patients	patient	NOUN
dti-3059	18	10	and	and	CCONJ
dti-3059	18	11	the	the	DET
dti-3059	18	12	healthcare	healthcare	NOUN
dti-3059	18	13	system	system	NOUN
dti-3059	18	14	,	,	PUNCT
dti-3059	18	15	including	include	VERB
dti-3059	18	16	high	high	ADJ
dti-3059	18	17	costs	cost	NOUN
dti-3059	18	18	,	,	PUNCT
dti-3059	18	19	loss	loss	NOUN
dti-3059	18	20	of	of	ADP
dti-3059	18	21	human	human	ADJ
dti-3059	18	22	resources	resource	NOUN
dti-3059	18	23	,	,	PUNCT
dti-3059	18	24	and	and	CCONJ
dti-3059	18	25	psychological	psychological	ADJ
dti-3059	18	26	problems	problem	NOUN
dti-3059	18	27	(	(	PUNCT
dti-3059	18	28	7	7	NUM
dti-3059	18	29	)	)	PUNCT
dti-3059	18	30	.	.	PUNCT
dti-3059	19	1	covid-19	covid-19	PROPN
dti-3059	19	2	,	,	PUNCT
dti-3059	19	3	caused	cause	VERB
dti-3059	19	4	by	by	ADP
dti-3059	19	5	severe	severe	ADJ
dti-3059	19	6	acute	acute	ADJ
dti-3059	19	7	respiratory	respiratory	ADJ
dti-3059	19	8	syndrome	syndrome	NOUN
dti-3059	19	9	coronavirus	coronavirus	NOUN
dti-3059	19	10	2	2	NUM
dti-3059	19	11	(	(	PUNCT
dti-3059	19	12	sars	sar	NOUN
dti-3059	19	13	-	-	PUNCT
dti-3059	19	14	cov-2	cov-2	NOUN
dti-3059	19	15	)	)	PUNCT
dti-3059	19	16	,	,	PUNCT
dti-3059	19	17	enters	enter	VERB
dti-3059	19	18	human	human	ADJ
dti-3059	19	19	cells	cell	NOUN
dti-3059	19	20	by	by	ADP
dti-3059	19	21	binding	bind	VERB
dti-3059	19	22	the	the	DET
dti-3059	19	23	receptor	receptor	NOUN
dti-3059	19	24	-	-	PUNCT
dti-3059	19	25	binding	bind	VERB
dti-3059	19	26	domain	domain	NOUN
dti-3059	19	27	(	(	PUNCT
dti-3059	19	28	rbd	rbd	NOUN
dti-3059	19	29	)	)	PUNCT
dti-3059	19	30	of	of	ADP
dti-3059	19	31	its	its	PRON
dti-3059	19	32	spike	spike	ADJ
dti-3059	19	33	(	(	PUNCT
dti-3059	19	34	s	s	NOUN
dti-3059	19	35	)	)	PUNCT
dti-3059	19	36	protein	protein	NOUN
dti-3059	19	37	to	to	ADP
dti-3059	19	38	the	the	DET
dti-3059	19	39	angiotensin	angiotensin	NOUN
dti-3059	19	40	-	-	PUNCT
dti-3059	19	41	converting	convert	VERB
dti-3059	19	42	enzyme	enzyme	NOUN
dti-3059	19	43	2	2	NUM
dti-3059	19	44	(	(	PUNCT
dti-3059	19	45	ace2	ace2	NOUN
dti-3059	19	46	)	)	PUNCT
dti-3059	19	47	receptor	receptor	NOUN
dti-3059	19	48	(	(	PUNCT
dti-3059	19	49	8,9	8,9	NUM
dti-3059	19	50	)	)	PUNCT
dti-3059	19	51	.	.	PUNCT
dti-3059	20	1	antibodies	antibody	NOUN
dti-3059	20	2	directed	direct	VERB
dti-3059	20	3	against	against	ADP
dti-3059	20	4	the	the	DET
dti-3059	20	5	s	s	NOUN
dti-3059	20	6	-	-	NOUN
dti-3059	20	7	protein	protein	NOUN
dti-3059	20	8	have	have	VERB
dti-3059	20	9	the	the	DET
dti-3059	20	10	potential	potential	NOUN
dti-3059	20	11	to	to	PART
dti-3059	20	12	neutralize	neutralize	VERB
dti-3059	20	13	the	the	DET
dti-3059	20	14	virus	virus	NOUN
dti-3059	20	15	efficiently	efficiently	ADV
dti-3059	20	16	(	(	PUNCT
dti-3059	20	17	10	10	NUM
dti-3059	20	18	)	)	PUNCT
dti-3059	20	19	.	.	PUNCT
dti-3059	21	1	since	since	SCONJ
dti-3059	21	2	the	the	DET
dti-3059	21	3	first	first	ADJ
dti-3059	21	4	case	case	NOUN
dti-3059	21	5	of	of	ADP
dti-3059	21	6	sars	sar	NOUN
dti-3059	21	7	-	-	PUNCT
dti-3059	21	8	cov-2	cov-2	NOUN
dti-3059	21	9	in	in	ADP
dti-3059	21	10	wuhan	wuhan	PROPN
dti-3059	21	11	,	,	PUNCT
dti-3059	21	12	introduction	introduction	NOUN
dti-3059	21	13	the	the	DET
dti-3059	21	14	coronavirus	coronavirus	NOUN
dti-3059	21	15	disease	disease	NOUN
dti-3059	21	16	2019	2019	NUM
dti-3059	21	17	(	(	PUNCT
dti-3059	21	18	covid-19	covid-19	PROPN
dti-3059	21	19	)	)	PUNCT
dti-3059	21	20	pandemic	pandemic	NOUN
dti-3059	21	21	caused	cause	VERB
dti-3059	21	22	significant	significant	ADJ
dti-3059	21	23	global	global	ADJ
dti-3059	21	24	impact	impact	NOUN
dti-3059	21	25	and	and	CCONJ
dti-3059	21	26	continues	continue	VERB
dti-3059	21	27	to	to	PART
dti-3059	21	28	be	be	AUX
dti-3059	21	29	a	a	DET
dti-3059	21	30	threat	threat	NOUN
dti-3059	21	31	despite	despite	SCONJ
dti-3059	21	32	the	the	DET
dti-3059	21	33	introduction	introduction	NOUN
dti-3059	21	34	of	of	ADP
dti-3059	21	35	vaccines	vaccine	NOUN
dti-3059	21	36	(	(	PUNCT
dti-3059	21	37	1,2	1,2	NUM
dti-3059	21	38	)	)	PUNCT
dti-3059	21	39	.	.	PUNCT
dti-3059	22	1	the	the	DET
dti-3059	22	2	vaccines	vaccine	NOUN
dti-3059	22	3	have	have	AUX
dti-3059	22	4	been	be	AUX
dti-3059	22	5	highly	highly	ADV
dti-3059	22	6	effective	effective	ADJ
dti-3059	22	7	in	in	ADP
dti-3059	22	8	preventing	prevent	VERB
dti-3059	22	9	covid-19	covid-19	PROPN
dti-3059	22	10	around	around	ADP
dti-3059	22	11	the	the	DET
dti-3059	22	12	https://doi.org/10.33393/dti.2024.3059	https://doi.org/10.33393/dti.2024.3059	PROPN
dti-3059	22	13	https://doi.org/dti.2022.2522	https://doi.org/dti.2022.2522	PROPN
dti-3059	22	14	https://creativecommons.org/licenses/by-nc/4.0/legalcode	https://creativecommons.org/licenses/by-nc/4.0/legalcode	NUM
dti-3059	22	15	https://doi.org/10.33393/dti.2024.2670	https://doi.org/10.33393/dti.2024.2670	VERB
dti-3059	22	16	https://doi.org/10.33393/dti.2024.2670	https://doi.org/10.33393/dti.2024.2670	VERB
dti-3059	22	17	https://orcid.org/0000-0003-4394-5138	https://orcid.org/0000-0003-4394-5138	PROPN
dti-3059	22	18	https://orcid.org/0000-0002-5095-3198	https://orcid.org/0000-0002-5095-3198	PROPN
dti-3059	22	19	https://orcid.org/0000-0002-0365-5518	https://orcid.org/0000-0002-0365-5518	PROPN
dti-3059	22	20	https://orcid.org/0000-0001-8336-6830	https://orcid.org/0000-0001-8336-6830	PROPN
dti-3059	22	21	mailto:dr.dlgupta@aiimsraipur.edu.in	mailto:dr.dlgupta@aiimsraipur.edu.in	PROPN
dti-3059	22	22	gupta	gupta	PROPN
dti-3059	22	23	et	et	PROPN
dti-3059	22	24	al	al	PROPN
dti-3059	22	25	drug	drug	PROPN
dti-3059	22	26	target	target	NOUN
dti-3059	22	27	insights	insight	NOUN
dti-3059	22	28	2024	2024	NUM
dti-3059	22	29	;	;	PUNCT
dti-3059	22	30	18	18	NUM
dti-3059	22	31	:	:	SYM
dti-3059	22	32	21	21	NUM
dti-3059	22	33	©	©	ADP
dti-3059	22	34	2024	2024	NUM
dti-3059	22	35	the	the	DET
dti-3059	22	36	authors	author	NOUN
dti-3059	22	37	.	.	PUNCT
dti-3059	23	1	published	publish	VERB
dti-3059	23	2	by	by	ADP
dti-3059	23	3	aboutscience	aboutscience	NOUN
dti-3059	23	4	www.aboutscience.eu	www.aboutscience.eu	PROPN
dti-3059	23	5	china	china	PROPN
dti-3059	23	6	,	,	PUNCT
dti-3059	23	7	over	over	ADP
dti-3059	23	8	774	774	NUM
dti-3059	23	9	million	million	NUM
dti-3059	23	10	infections	infection	NOUN
dti-3059	23	11	have	have	AUX
dti-3059	23	12	been	be	AUX
dti-3059	23	13	documented	document	VERB
dti-3059	23	14	,	,	PUNCT
dti-3059	23	15	leading	lead	VERB
dti-3059	23	16	to	to	ADP
dti-3059	23	17	the	the	DET
dti-3059	23	18	emergence	emergence	NOUN
dti-3059	23	19	of	of	ADP
dti-3059	23	20	seven	seven	NUM
dti-3059	23	21	major	major	ADJ
dti-3059	23	22	lineages	lineage	NOUN
dti-3059	23	23	with	with	ADP
dti-3059	23	24	various	various	ADJ
dti-3059	23	25	variants	variant	NOUN
dti-3059	23	26	(	(	PUNCT
dti-3059	23	27	11,12	11,12	NUM
dti-3059	23	28	)	)	PUNCT
dti-3059	23	29	.	.	PUNCT
dti-3059	24	1	coronaviruses	coronaviruse	NOUN
dti-3059	24	2	have	have	VERB
dti-3059	24	3	a	a	DET
dti-3059	24	4	large	large	ADJ
dti-3059	24	5	rna	rna	NOUN
dti-3059	24	6	genome	genome	NOUN
dti-3059	24	7	and	and	CCONJ
dti-3059	24	8	mutations	mutation	NOUN
dti-3059	24	9	can	can	AUX
dti-3059	24	10	arise	arise	VERB
dti-3059	24	11	naturally	naturally	ADV
dti-3059	24	12	during	during	ADP
dti-3059	24	13	replication	replication	NOUN
dti-3059	24	14	,	,	PUNCT
dti-3059	24	15	leading	lead	VERB
dti-3059	24	16	to	to	ADP
dti-3059	24	17	evolutionary	evolutionary	ADJ
dti-3059	24	18	advantages	advantage	NOUN
dti-3059	24	19	such	such	ADJ
dti-3059	24	20	as	as	ADP
dti-3059	24	21	increased	increase	VERB
dti-3059	24	22	infectivity	infectivity	NOUN
dti-3059	24	23	or	or	CCONJ
dti-3059	24	24	improved	improve	VERB
dti-3059	24	25	receptor	receptor	NOUN
dti-3059	24	26	binding	bind	VERB
dti-3059	24	27	(	(	PUNCT
dti-3059	24	28	13	13	NUM
dti-3059	24	29	)	)	PUNCT
dti-3059	24	30	.	.	PUNCT
dti-3059	25	1	the	the	DET
dti-3059	25	2	omicron	omicron	PROPN
dti-3059	25	3	variant	variant	NOUN
dti-3059	25	4	of	of	ADP
dti-3059	25	5	sarscov-2	sarscov-2	PROPN
dti-3059	25	6	has	have	VERB
dti-3059	25	7	30	30	NUM
dti-3059	25	8	non	non	ADJ
dti-3059	25	9	-	-	ADJ
dti-3059	25	10	synonymous	synonymous	ADJ
dti-3059	25	11	amino	amino	NOUN
dti-3059	25	12	acid	acid	NOUN
dti-3059	25	13	mutations	mutation	NOUN
dti-3059	25	14	in	in	ADP
dti-3059	25	15	the	the	DET
dti-3059	25	16	spike	spike	ADJ
dti-3059	25	17	protein	protein	NOUN
dti-3059	25	18	,	,	PUNCT
dti-3059	25	19	which	which	PRON
dti-3059	25	20	have	have	AUX
dti-3059	25	21	been	be	AUX
dti-3059	25	22	reported	report	VERB
dti-3059	25	23	to	to	PART
dti-3059	25	24	enable	enable	VERB
dti-3059	25	25	immune	immune	ADJ
dti-3059	25	26	evasion	evasion	NOUN
dti-3059	25	27	and	and	CCONJ
dti-3059	25	28	reduce	reduce	VERB
dti-3059	25	29	vaccine	vaccine	NOUN
dti-3059	25	30	effectiveness	effectiveness	NOUN
dti-3059	25	31	(	(	PUNCT
dti-3059	25	32	14	14	NUM
dti-3059	25	33	)	)	PUNCT
dti-3059	25	34	.	.	PUNCT
dti-3059	26	1	variants	variant	NOUN
dti-3059	26	2	of	of	ADP
dti-3059	26	3	concern	concern	NOUN
dti-3059	26	4	(	(	PUNCT
dti-3059	26	5	vocs	vocs	PROPN
dti-3059	26	6	)	)	PUNCT
dti-3059	26	7	,	,	PUNCT
dti-3059	26	8	such	such	ADJ
dti-3059	26	9	as	as	ADP
dti-3059	26	10	b.1.1.7	b.1.1.7	PROPN
dti-3059	26	11	,	,	PUNCT
dti-3059	26	12	b.1.1.298	b.1.1.298	NOUN
dti-3059	26	13	,	,	PUNCT
dti-3059	26	14	b.1.429	b.1.429	NOUN
dti-3059	26	15	,	,	PUNCT
dti-3059	26	16	p.2	p.2	NOUN
dti-3059	26	17	,	,	PUNCT
dti-3059	26	18	p.1	p.1	NOUN
dti-3059	26	19	,	,	PUNCT
dti-3059	26	20	and	and	CCONJ
dti-3059	26	21	b.1.351	b.1.351	NOUN
dti-3059	26	22	,	,	PUNCT
dti-3059	26	23	have	have	VERB
dti-3059	26	24	mutations	mutation	NOUN
dti-3059	26	25	that	that	PRON
dti-3059	26	26	can	can	AUX
dti-3059	26	27	increase	increase	VERB
dti-3059	26	28	transmissibility	transmissibility	NOUN
dti-3059	26	29	,	,	PUNCT
dti-3059	26	30	virulence	virulence	NOUN
dti-3059	26	31	,	,	PUNCT
dti-3059	26	32	or	or	CCONJ
dti-3059	26	33	evade	evade	VERB
dti-3059	26	34	immune	immune	ADJ
dti-3059	26	35	responses	response	NOUN
dti-3059	26	36	(	(	PUNCT
dti-3059	26	37	15,16	15,16	NUM
dti-3059	26	38	)	)	PUNCT
dti-3059	26	39	.	.	PUNCT
dti-3059	27	1	these	these	DET
dti-3059	27	2	variants	variant	NOUN
dti-3059	27	3	mainly	mainly	ADV
dti-3059	27	4	have	have	VERB
dti-3059	27	5	mutations	mutation	NOUN
dti-3059	27	6	in	in	ADP
dti-3059	27	7	the	the	DET
dti-3059	27	8	spike	spike	ADJ
dti-3059	27	9	protein	protein	NOUN
dti-3059	27	10	,	,	PUNCT
dti-3059	27	11	particularly	particularly	ADV
dti-3059	27	12	in	in	ADP
dti-3059	27	13	the	the	DET
dti-3059	27	14	s1	s1	NOUN
dti-3059	27	15	and	and	CCONJ
dti-3059	27	16	rbd	rbd	NOUN
dti-3059	27	17	regions	region	NOUN
dti-3059	27	18	,	,	PUNCT
dti-3059	27	19	which	which	PRON
dti-3059	27	20	are	be	AUX
dti-3059	27	21	the	the	DET
dti-3059	27	22	main	main	ADJ
dti-3059	27	23	targets	target	NOUN
dti-3059	27	24	of	of	ADP
dti-3059	27	25	neutralizing	neutralize	VERB
dti-3059	27	26	antibodies	antibody	NOUN
dti-3059	27	27	.	.	PUNCT
dti-3059	28	1	twelve	twelve	NUM
dti-3059	28	2	vaccines	vaccine	NOUN
dti-3059	28	3	have	have	AUX
dti-3059	28	4	been	be	AUX
dti-3059	28	5	approved	approve	VERB
dti-3059	28	6	for	for	ADP
dti-3059	28	7	use	use	NOUN
dti-3059	28	8	in	in	ADP
dti-3059	28	9	humans	human	NOUN
dti-3059	28	10	since	since	SCONJ
dti-3059	28	11	the	the	DET
dti-3059	28	12	first	first	ADJ
dti-3059	28	13	reported	report	VERB
dti-3059	28	14	case	case	NOUN
dti-3059	28	15	of	of	ADP
dti-3059	28	16	sars	sar	NOUN
dti-3059	28	17	-	-	PUNCT
dti-3059	28	18	cov-2	cov-2	NOUN
dti-3059	28	19	in	in	ADP
dti-3059	28	20	december	december	PROPN
dti-3059	28	21	2019	2019	NUM
dti-3059	28	22	,	,	PUNCT
dti-3059	28	23	with	with	ADP
dti-3059	28	24	high	high	ADJ
dti-3059	28	25	efficacy	efficacy	NOUN
dti-3059	28	26	in	in	ADP
dti-3059	28	27	preventing	prevent	VERB
dti-3059	28	28	covid-19	covid-19	PROPN
dti-3059	28	29	(	(	PUNCT
dti-3059	28	30	17	17	NUM
dti-3059	28	31	)	)	PUNCT
dti-3059	28	32	.	.	PUNCT
dti-3059	29	1	however	however	ADV
dti-3059	29	2	,	,	PUNCT
dti-3059	29	3	the	the	DET
dti-3059	29	4	emergence	emergence	NOUN
dti-3059	29	5	of	of	ADP
dti-3059	29	6	new	new	ADJ
dti-3059	29	7	variants	variant	NOUN
dti-3059	29	8	has	have	AUX
dti-3059	29	9	raised	raise	VERB
dti-3059	29	10	concerns	concern	NOUN
dti-3059	29	11	about	about	ADP
dti-3059	29	12	the	the	DET
dti-3059	29	13	effectiveness	effectiveness	NOUN
dti-3059	29	14	of	of	ADP
dti-3059	29	15	these	these	DET
dti-3059	29	16	vaccines	vaccine	NOUN
dti-3059	29	17	,	,	PUNCT
dti-3059	29	18	with	with	ADP
dti-3059	29	19	some	some	DET
dti-3059	29	20	trials	trial	NOUN
dti-3059	29	21	showing	show	VERB
dti-3059	29	22	reduced	reduce	VERB
dti-3059	29	23	efficacy	efficacy	NOUN
dti-3059	29	24	against	against	ADP
dti-3059	29	25	variant	variant	ADJ
dti-3059	29	26	strains	strain	NOUN
dti-3059	29	27	in	in	ADP
dti-3059	29	28	certain	certain	ADJ
dti-3059	29	29	countries	country	NOUN
dti-3059	29	30	(	(	PUNCT
dti-3059	29	31	18	18	NUM
dti-3059	29	32	)	)	PUNCT
dti-3059	29	33	.	.	PUNCT
dti-3059	30	1	the	the	DET
dti-3059	30	2	emergence	emergence	NOUN
dti-3059	30	3	of	of	ADP
dti-3059	30	4	vocs	vocs	PROPN
dti-3059	30	5	with	with	ADP
dti-3059	30	6	mutations	mutation	NOUN
dti-3059	30	7	in	in	ADP
dti-3059	30	8	the	the	DET
dti-3059	30	9	s	s	NOUN
dti-3059	30	10	-	-	NOUN
dti-3059	30	11	protein	protein	NOUN
dti-3059	30	12	raises	raise	VERB
dti-3059	30	13	concerns	concern	NOUN
dti-3059	30	14	about	about	ADP
dti-3059	30	15	immune	immune	ADJ
dti-3059	30	16	evasion	evasion	NOUN
dti-3059	30	17	.	.	PUNCT
dti-3059	31	1	some	some	DET
dti-3059	31	2	vocs	vocs	PROPN
dti-3059	31	3	,	,	PUNCT
dti-3059	31	4	such	such	ADJ
dti-3059	31	5	as	as	ADP
dti-3059	31	6	b.1.1.7	b.1.1.7	PROPN
dti-3059	31	7	and	and	CCONJ
dti-3059	31	8	b.1.351	b.1.351	NOUN
dti-3059	31	9	,	,	PUNCT
dti-3059	31	10	have	have	AUX
dti-3059	31	11	shown	show	VERB
dti-3059	31	12	reduced	reduce	VERB
dti-3059	31	13	susceptibility	susceptibility	NOUN
dti-3059	31	14	to	to	ADP
dti-3059	31	15	neutralizing	neutralize	VERB
dti-3059	31	16	antibodies	antibody	NOUN
dti-3059	31	17	,	,	PUNCT
dti-3059	31	18	but	but	CCONJ
dti-3059	31	19	the	the	DET
dti-3059	31	20	immunoreactivity	immunoreactivity	NOUN
dti-3059	31	21	of	of	ADP
dti-3059	31	22	induced	induced	ADJ
dti-3059	31	23	antibodies	antibody	NOUN
dti-3059	31	24	after	after	ADP
dti-3059	31	25	vaccination	vaccination	NOUN
dti-3059	31	26	with	with	ADP
dti-3059	31	27	individual	individual	PROPN
dti-3059	31	28	’s	’s	PART
dti-3059	31	29	mutations	mutation	NOUN
dti-3059	31	30	occurred	occur	VERB
dti-3059	31	31	in	in	ADP
dti-3059	31	32	the	the	DET
dti-3059	31	33	rbd	rbd	NOUN
dti-3059	31	34	in	in	ADP
dti-3059	31	35	vocs	vocs	PROPN
dti-3059	31	36	is	be	AUX
dti-3059	31	37	not	not	PART
dti-3059	31	38	well	well	ADV
dti-3059	31	39	understood	understand	VERB
dti-3059	31	40	(	(	PUNCT
dti-3059	31	41	15,19	15,19	NUM
dti-3059	31	42	)	)	PUNCT
dti-3059	31	43	.	.	PUNCT
dti-3059	32	1	the	the	DET
dti-3059	32	2	study	study	NOUN
dti-3059	32	3	focuses	focus	VERB
dti-3059	32	4	on	on	ADP
dti-3059	32	5	understanding	understand	VERB
dti-3059	32	6	the	the	DET
dti-3059	32	7	humoral	humoral	ADJ
dti-3059	32	8	immune	immune	ADJ
dti-3059	32	9	responses	response	NOUN
dti-3059	32	10	to	to	ADP
dti-3059	32	11	sars	sar	NOUN
dti-3059	32	12	-	-	PUNCT
dti-3059	32	13	cov-2	cov-2	NOUN
dti-3059	32	14	in	in	ADP
dti-3059	32	15	covid-19	covid-19	PROPN
dti-3059	32	16	convalescent	convalescent	NOUN
dti-3059	32	17	donors	donor	NOUN
dti-3059	32	18	and	and	CCONJ
dti-3059	32	19	vaccine	vaccine	NOUN
dti-3059	32	20	recipients	recipient	NOUN
dti-3059	32	21	.	.	PUNCT
dti-3059	33	1	this	this	DET
dti-3059	33	2	study	study	NOUN
dti-3059	33	3	investigated	investigate	VERB
dti-3059	33	4	the	the	DET
dti-3059	33	5	levels	level	NOUN
dti-3059	33	6	of	of	ADP
dti-3059	33	7	sars	sar	NOUN
dti-3059	33	8	-	-	PUNCT
dti-3059	33	9	cov-2	cov-2	NOUN
dti-3059	33	10	spike	spike	ADJ
dti-3059	33	11	proteinspecific	proteinspecific	ADJ
dti-3059	33	12	total	total	ADJ
dti-3059	33	13	antibodies	antibody	NOUN
dti-3059	33	14	in	in	ADP
dti-3059	33	15	a	a	DET
dti-3059	33	16	cohort	cohort	NOUN
dti-3059	33	17	of	of	ADP
dti-3059	33	18	individuals	individual	NOUN
dti-3059	33	19	who	who	PRON
dti-3059	33	20	have	have	AUX
dti-3059	33	21	received	receive	VERB
dti-3059	33	22	both	both	DET
dti-3059	33	23	doses	dose	NOUN
dti-3059	33	24	of	of	ADP
dti-3059	33	25	covishield	covishield	ADJ
dti-3059	33	26	™	™	ADJ
dti-3059	33	27	vaccine	vaccine	NOUN
dti-3059	33	28	(	(	PUNCT
dti-3059	33	29	vaccinated	vaccinated	ADJ
dti-3059	33	30	group	group	NOUN
dti-3059	33	31	)	)	PUNCT
dti-3059	33	32	and	and	CCONJ
dti-3059	33	33	patients	patient	NOUN
dti-3059	33	34	who	who	PRON
dti-3059	33	35	have	have	AUX
dti-3059	33	36	recovered	recover	VERB
dti-3059	33	37	from	from	ADP
dti-3059	33	38	sars	sar	NOUN
dti-3059	33	39	-	-	PUNCT
dti-3059	33	40	cov-2	cov-2	PART
dti-3059	33	41	infections	infection	NOUN
dti-3059	33	42	(	(	PUNCT
dti-3059	33	43	recovered	recover	VERB
dti-3059	33	44	group	group	NOUN
dti-3059	33	45	)	)	PUNCT
dti-3059	33	46	.	.	PUNCT
dti-3059	34	1	the	the	DET
dti-3059	34	2	aim	aim	NOUN
dti-3059	34	3	of	of	ADP
dti-3059	34	4	the	the	DET
dti-3059	34	5	study	study	NOUN
dti-3059	34	6	was	be	AUX
dti-3059	34	7	to	to	PART
dti-3059	34	8	compare	compare	VERB
dti-3059	34	9	the	the	DET
dti-3059	34	10	immunoreactivity	immunoreactivity	NOUN
dti-3059	34	11	of	of	ADP
dti-3059	34	12	peptides	peptide	NOUN
dti-3059	34	13	of	of	ADP
dti-3059	34	14	wild	wild	ADJ
dti-3059	34	15	-	-	PUNCT
dti-3059	34	16	type	type	NOUN
dti-3059	34	17	sars	sar	NOUN
dti-3059	34	18	-	-	PUNCT
dti-3059	34	19	cov-2	cov-2	NOUN
dti-3059	34	20	and	and	CCONJ
dti-3059	34	21	peptides	peptide	NOUN
dti-3059	34	22	of	of	ADP
dti-3059	34	23	mutated	mutate	VERB
dti-3059	34	24	sars	sar	NOUN
dti-3059	34	25	-	-	PUNCT
dti-3059	34	26	cov-2	cov-2	NOUN
dti-3059	34	27	with	with	ADP
dti-3059	34	28	antisera	antisera	NOUN
dti-3059	34	29	of	of	ADP
dti-3059	34	30	vaccinated	vaccinated	ADJ
dti-3059	34	31	people	people	NOUN
dti-3059	34	32	and	and	CCONJ
dti-3059	34	33	covid-19	covid-19	PROPN
dti-3059	34	34	recovered	recover	VERB
dti-3059	34	35	patients	patient	NOUN
dti-3059	34	36	to	to	PART
dti-3059	34	37	understand	understand	VERB
dti-3059	34	38	the	the	DET
dti-3059	34	39	effectiveness	effectiveness	NOUN
dti-3059	34	40	of	of	ADP
dti-3059	34	41	vaccination	vaccination	NOUN
dti-3059	34	42	and	and	CCONJ
dti-3059	34	43	potential	potential	ADJ
dti-3059	34	44	immune	immune	ADJ
dti-3059	34	45	evasion	evasion	NOUN
dti-3059	34	46	strategies	strategy	NOUN
dti-3059	34	47	.	.	PUNCT
dti-3059	35	1	materials	material	NOUN
dti-3059	35	2	and	and	CCONJ
dti-3059	35	3	methods	method	NOUN
dti-3059	35	4	sample	sample	NOUN
dti-3059	35	5	size	size	NOUN
dti-3059	35	6	and	and	CCONJ
dti-3059	35	7	study	study	NOUN
dti-3059	35	8	groups	group	NOUN
dti-3059	35	9	a	a	DET
dti-3059	35	10	total	total	NOUN
dti-3059	35	11	of	of	ADP
dti-3059	35	12	60	60	NUM
dti-3059	35	13	individuals	individual	NOUN
dti-3059	35	14	of	of	ADP
dti-3059	35	15	age	age	NOUN
dti-3059	35	16	≥18	≥18	NUM
dti-3059	35	17	years	year	NOUN
dti-3059	35	18	(	(	PUNCT
dti-3059	35	19	30	30	NUM
dti-3059	35	20	patients	patient	NOUN
dti-3059	35	21	recovered	recover	VERB
dti-3059	35	22	from	from	ADP
dti-3059	35	23	covid-19	covid-19	PROPN
dti-3059	35	24	infections	infection	NOUN
dti-3059	35	25	,	,	PUNCT
dti-3059	35	26	30	30	NUM
dti-3059	35	27	received	receive	VERB
dti-3059	35	28	both	both	DET
dti-3059	35	29	doses	dose	NOUN
dti-3059	35	30	of	of	ADP
dti-3059	35	31	covishield	covishield	ADJ
dti-3059	35	32	™	™	ADJ
dti-3059	35	33	vaccine	vaccine	NOUN
dti-3059	35	34	)	)	PUNCT
dti-3059	35	35	were	be	AUX
dti-3059	35	36	recruited	recruit	VERB
dti-3059	35	37	in	in	ADP
dti-3059	35	38	the	the	DET
dti-3059	35	39	present	present	ADJ
dti-3059	35	40	study	study	NOUN
dti-3059	35	41	.	.	PUNCT
dti-3059	36	1	covid-19	covid-19	PROPN
dti-3059	36	2	recovered	recover	VERB
dti-3059	36	3	patients	patient	NOUN
dti-3059	36	4	of	of	ADP
dti-3059	36	5	both	both	DET
dti-3059	36	6	sexes	sex	NOUN
dti-3059	36	7	who	who	PRON
dti-3059	36	8	had	have	AUX
dti-3059	36	9	not	not	PART
dti-3059	36	10	received	receive	VERB
dti-3059	36	11	any	any	DET
dti-3059	36	12	covid-19	covid-19	PROPN
dti-3059	36	13	vaccines	vaccine	NOUN
dti-3059	36	14	were	be	AUX
dti-3059	36	15	recruited	recruit	VERB
dti-3059	36	16	for	for	ADP
dti-3059	36	17	the	the	DET
dti-3059	36	18	covid-19	covid-19	PROPN
dti-3059	36	19	recovered	recovered	ADJ
dti-3059	36	20	group	group	NOUN
dti-3059	36	21	,	,	PUNCT
dti-3059	36	22	while	while	SCONJ
dti-3059	36	23	age	age	NOUN
dti-3059	36	24	-	-	PUNCT
dti-3059	36	25	matched	match	VERB
dti-3059	36	26	individuals	individual	NOUN
dti-3059	36	27	without	without	ADP
dti-3059	36	28	previous	previous	ADJ
dti-3059	36	29	history	history	NOUN
dti-3059	36	30	of	of	ADP
dti-3059	36	31	sars	sar	NOUN
dti-3059	36	32	-	-	PUNCT
dti-3059	36	33	cov-2	cov-2	PART
dti-3059	36	34	infections	infection	NOUN
dti-3059	36	35	who	who	PRON
dti-3059	36	36	have	have	AUX
dti-3059	36	37	received	receive	VERB
dti-3059	36	38	both	both	DET
dti-3059	36	39	doses	dose	NOUN
dti-3059	36	40	of	of	ADP
dti-3059	36	41	covishield	covishield	NOUN
dti-3059	36	42	™	™	PROPN
dti-3059	36	43	were	be	AUX
dti-3059	36	44	recruited	recruit	VERB
dti-3059	36	45	for	for	ADP
dti-3059	36	46	the	the	DET
dti-3059	36	47	vaccinated	vaccinated	ADJ
dti-3059	36	48	group	group	NOUN
dti-3059	36	49	.	.	PUNCT
dti-3059	37	1	patients	patient	NOUN
dti-3059	37	2	on	on	ADP
dti-3059	37	3	immunotherapy	immunotherapy	NOUN
dti-3059	37	4	or	or	CCONJ
dti-3059	37	5	having	have	VERB
dti-3059	37	6	any	any	DET
dti-3059	37	7	kind	kind	NOUN
dti-3059	37	8	of	of	ADP
dti-3059	37	9	organ	organ	NOUN
dti-3059	37	10	transplantations	transplantation	NOUN
dti-3059	37	11	or	or	CCONJ
dti-3059	37	12	immunocompromised	immunocompromise	VERB
dti-3059	37	13	patients	patient	NOUN
dti-3059	37	14	(	(	PUNCT
dti-3059	37	15	patients	patient	NOUN
dti-3059	37	16	with	with	ADP
dti-3059	37	17	human	human	ADJ
dti-3059	37	18	immunodeficiency	immunodeficiency	NOUN
dti-3059	37	19	virus	virus	NOUN
dti-3059	37	20	[	[	X
dti-3059	37	21	hiv	hiv	X
dti-3059	37	22	]	]	X
dti-3059	37	23	infection	infection	NOUN
dti-3059	37	24	,	,	PUNCT
dti-3059	37	25	autoimmunity	autoimmunity	NOUN
dti-3059	37	26	,	,	PUNCT
dti-3059	37	27	chronic	chronic	ADJ
dti-3059	37	28	kidney	kidney	NOUN
dti-3059	37	29	disease	disease	NOUN
dti-3059	37	30	[	[	X
dti-3059	37	31	ckd	ckd	NOUN
dti-3059	37	32	]	]	X
dti-3059	37	33	,	,	PUNCT
dti-3059	37	34	and	and	CCONJ
dti-3059	37	35	any	any	DET
dti-3059	37	36	other	other	ADJ
dti-3059	37	37	immunodeficiency	immunodeficiency	NOUN
dti-3059	37	38	diseases	disease	NOUN
dti-3059	37	39	)	)	PUNCT
dti-3059	37	40	were	be	AUX
dti-3059	37	41	excluded	exclude	VERB
dti-3059	37	42	from	from	ADP
dti-3059	37	43	the	the	DET
dti-3059	37	44	study	study	NOUN
dti-3059	37	45	.	.	PUNCT
dti-3059	38	1	this	this	DET
dti-3059	38	2	study	study	NOUN
dti-3059	38	3	was	be	AUX
dti-3059	38	4	approved	approve	VERB
dti-3059	38	5	by	by	ADP
dti-3059	38	6	the	the	DET
dti-3059	38	7	institute	institute	PROPN
dti-3059	38	8	ethics	ethics	PROPN
dti-3059	38	9	committee	committee	PROPN
dti-3059	38	10	(	(	PUNCT
dti-3059	38	11	iec	iec	PROPN
dti-3059	38	12	)	)	PUNCT
dti-3059	38	13	,	,	PUNCT
dti-3059	38	14	all	all	DET
dti-3059	38	15	india	india	PROPN
dti-3059	38	16	institute	institute	PROPN
dti-3059	38	17	of	of	ADP
dti-3059	38	18	medical	medical	PROPN
dti-3059	38	19	sciences	sciences	PROPN
dti-3059	38	20	,	,	PUNCT
dti-3059	38	21	raipur	raipur	NOUN
dti-3059	38	22	,	,	PUNCT
dti-3059	38	23	chhattisgarh	chhattisgarh	PROPN
dti-3059	38	24	,	,	PUNCT
dti-3059	38	25	india	india	PROPN
dti-3059	38	26	(	(	PUNCT
dti-3059	38	27	1936	1936	NUM
dti-3059	38	28	/	/	SYM
dti-3059	38	29	iec	iec	NOUN
dti-3059	38	30	-	-	PUNCT
dti-3059	38	31	aiimsrpr/2021	aiimsrpr/2021	NOUN
dti-3059	38	32	)	)	PUNCT
dti-3059	38	33	.	.	PUNCT
dti-3059	39	1	the	the	DET
dti-3059	39	2	completely	completely	ADV
dti-3059	39	3	filled	fill	VERB
dti-3059	39	4	up	up	ADP
dti-3059	39	5	and	and	CCONJ
dti-3059	39	6	signed	sign	VERB
dti-3059	39	7	written	write	VERB
dti-3059	39	8	consent	consent	NOUN
dti-3059	39	9	form	form	NOUN
dti-3059	39	10	was	be	AUX
dti-3059	39	11	obtained	obtain	VERB
dti-3059	39	12	from	from	ADP
dti-3059	39	13	each	each	DET
dti-3059	39	14	participant	participant	NOUN
dti-3059	39	15	before	before	ADP
dti-3059	39	16	taking	take	VERB
dti-3059	39	17	the	the	DET
dti-3059	39	18	blood	blood	NOUN
dti-3059	39	19	sample	sample	NOUN
dti-3059	39	20	for	for	ADP
dti-3059	39	21	the	the	DET
dti-3059	39	22	study	study	NOUN
dti-3059	39	23	.	.	PUNCT
dti-3059	40	1	disease	disease	NOUN
dti-3059	40	2	severity	severity	NOUN
dti-3059	40	3	patients	patient	NOUN
dti-3059	40	4	who	who	PRON
dti-3059	40	5	tested	test	VERB
dti-3059	40	6	positive	positive	ADJ
dti-3059	40	7	for	for	ADP
dti-3059	40	8	sars	sar	NOUN
dti-3059	40	9	-	-	PUNCT
dti-3059	40	10	cov-2	cov-2	PART
dti-3059	40	11	infection	infection	NOUN
dti-3059	40	12	by	by	ADP
dti-3059	40	13	reverse	reverse	ADJ
dti-3059	40	14	transcriptase	transcriptase	NOUN
dti-3059	40	15	-	-	PUNCT
dti-3059	40	16	polymerase	polymerase	NOUN
dti-3059	40	17	chain	chain	NOUN
dti-3059	40	18	reaction	reaction	NOUN
dti-3059	40	19	(	(	PUNCT
dti-3059	40	20	rt	rt	NOUN
dti-3059	40	21	-	-	PUNCT
dti-3059	40	22	pcr	pcr	NOUN
dti-3059	40	23	)	)	PUNCT
dti-3059	40	24	and	and	CCONJ
dti-3059	40	25	got	get	AUX
dti-3059	40	26	admitted	admit	VERB
dti-3059	40	27	to	to	ADP
dti-3059	40	28	the	the	DET
dti-3059	40	29	institute	institute	NOUN
dti-3059	40	30	from	from	ADP
dti-3059	40	31	october	october	PROPN
dti-3059	40	32	2021	2021	NUM
dti-3059	40	33	to	to	ADP
dti-3059	40	34	december	december	PROPN
dti-3059	40	35	2022	2022	NUM
dti-3059	40	36	were	be	AUX
dti-3059	40	37	included	include	VERB
dti-3059	40	38	in	in	ADP
dti-3059	40	39	the	the	DET
dti-3059	40	40	study	study	NOUN
dti-3059	40	41	.	.	PUNCT
dti-3059	41	1	covid-19	covid-19	PROPN
dti-3059	41	2	recovered	recover	VERB
dti-3059	41	3	patients	patient	NOUN
dti-3059	41	4	were	be	AUX
dti-3059	41	5	divided	divide	VERB
dti-3059	41	6	into	into	ADP
dti-3059	41	7	severe	severe	ADJ
dti-3059	41	8	and	and	CCONJ
dti-3059	41	9	mild	mild	ADJ
dti-3059	41	10	groups	group	NOUN
dti-3059	41	11	:	:	PUNCT
dti-3059	41	12	severe	severe	ADJ
dti-3059	41	13	cases	case	NOUN
dti-3059	41	14	were	be	AUX
dti-3059	41	15	defined	define	VERB
dti-3059	41	16	as	as	ADP
dti-3059	41	17	those	those	PRON
dti-3059	41	18	requiring	require	VERB
dti-3059	41	19	invasive	invasive	ADJ
dti-3059	41	20	mechanical	mechanical	ADJ
dti-3059	41	21	ventilation	ventilation	NOUN
dti-3059	41	22	or	or	CCONJ
dti-3059	41	23	high	high	ADJ
dti-3059	41	24	-	-	PUNCT
dti-3059	41	25	flow	flow	NOUN
dti-3059	41	26	nasal	nasal	NOUN
dti-3059	41	27	oxygen	oxygen	NOUN
dti-3059	41	28	,	,	PUNCT
dti-3059	41	29	and	and	CCONJ
dti-3059	41	30	mild	mild	ADJ
dti-3059	41	31	cases	case	NOUN
dti-3059	41	32	as	as	ADP
dti-3059	41	33	neither	neither	CCONJ
dti-3059	41	34	requiring	require	VERB
dti-3059	41	35	oxygen	oxygen	NOUN
dti-3059	41	36	nor	nor	CCONJ
dti-3059	41	37	in	in	ADP
dti-3059	41	38	-	-	PUNCT
dti-3059	41	39	patient	patient	NOUN
dti-3059	41	40	hospital	hospital	NOUN
dti-3059	41	41	care	care	NOUN
dti-3059	41	42	.	.	PUNCT
dti-3059	42	1	sample	sample	NOUN
dti-3059	42	2	collection	collection	NOUN
dti-3059	42	3	a	a	DET
dti-3059	42	4	total	total	NOUN
dti-3059	42	5	of	of	ADP
dti-3059	42	6	5	5	NUM
dti-3059	42	7	ml	ml	NOUN
dti-3059	42	8	whole	whole	ADJ
dti-3059	42	9	blood	blood	NOUN
dti-3059	42	10	sample	sample	NOUN
dti-3059	42	11	was	be	AUX
dti-3059	42	12	collected	collect	VERB
dti-3059	42	13	in	in	ADP
dti-3059	42	14	a	a	DET
dti-3059	42	15	plain	plain	ADJ
dti-3059	42	16	vial	vial	NOUN
dti-3059	42	17	by	by	ADP
dti-3059	42	18	venipuncture	venipuncture	NOUN
dti-3059	42	19	within	within	ADP
dti-3059	42	20	3	3	NUM
dti-3059	42	21	to	to	PART
dti-3059	42	22	4	4	NUM
dti-3059	42	23	weeks	week	NOUN
dti-3059	42	24	of	of	ADP
dti-3059	42	25	recovery	recovery	NOUN
dti-3059	42	26	from	from	ADP
dti-3059	42	27	covid-19	covid-19	PROPN
dti-3059	42	28	infections	infection	NOUN
dti-3059	42	29	,	,	PUNCT
dti-3059	42	30	while	while	SCONJ
dti-3059	42	31	the	the	DET
dti-3059	42	32	same	same	ADJ
dti-3059	42	33	amount	amount	NOUN
dti-3059	42	34	of	of	ADP
dti-3059	42	35	blood	blood	NOUN
dti-3059	42	36	sample	sample	NOUN
dti-3059	42	37	was	be	AUX
dti-3059	42	38	collected	collect	VERB
dti-3059	42	39	within	within	ADP
dti-3059	42	40	3	3	NUM
dti-3059	42	41	to	to	PART
dti-3059	42	42	4	4	NUM
dti-3059	42	43	weeks	week	NOUN
dti-3059	42	44	postvaccination	postvaccination	NOUN
dti-3059	42	45	with	with	ADP
dti-3059	42	46	both	both	DET
dti-3059	42	47	doses	dose	NOUN
dti-3059	42	48	of	of	ADP
dti-3059	42	49	covishield	covishield	NOUN
dti-3059	42	50	™	™	PROPN
dti-3059	42	51	.	.	PUNCT
dti-3059	43	1	the	the	DET
dti-3059	43	2	serum	serum	NOUN
dti-3059	43	3	was	be	AUX
dti-3059	43	4	collected	collect	VERB
dti-3059	43	5	to	to	PART
dti-3059	43	6	measure	measure	VERB
dti-3059	43	7	the	the	DET
dti-3059	43	8	levels	level	NOUN
dti-3059	43	9	of	of	ADP
dti-3059	43	10	total	total	ADJ
dti-3059	43	11	antibodies	antibody	NOUN
dti-3059	43	12	and	and	CCONJ
dti-3059	43	13	immunoreactivity	immunoreactivity	NOUN
dti-3059	43	14	of	of	ADP
dti-3059	43	15	antibodies	antibody	NOUN
dti-3059	43	16	with	with	ADP
dti-3059	43	17	selected	select	VERB
dti-3059	43	18	peptides	peptide	NOUN
dti-3059	43	19	of	of	ADP
dti-3059	43	20	spike	spike	ADJ
dti-3059	43	21	protein	protein	NOUN
dti-3059	43	22	of	of	ADP
dti-3059	43	23	wild	wild	ADJ
dti-3059	43	24	type	type	NOUN
dti-3059	43	25	and	and	CCONJ
dti-3059	43	26	variants	variant	NOUN
dti-3059	43	27	of	of	ADP
dti-3059	43	28	sars	sar	NOUN
dti-3059	43	29	-	-	PUNCT
dti-3059	43	30	cov-2	cov-2	NOUN
dti-3059	43	31	.	.	PUNCT
dti-3059	44	1	serum	serum	NOUN
dti-3059	44	2	isolation	isolation	NOUN
dti-3059	44	3	the	the	DET
dti-3059	44	4	blood	blood	NOUN
dti-3059	44	5	samples	sample	NOUN
dti-3059	44	6	collected	collect	VERB
dti-3059	44	7	in	in	ADP
dti-3059	44	8	the	the	DET
dti-3059	44	9	plain	plain	ADJ
dti-3059	44	10	vial	vial	NOUN
dti-3059	44	11	were	be	AUX
dti-3059	44	12	kept	keep	VERB
dti-3059	44	13	for	for	ADP
dti-3059	44	14	30	30	NUM
dti-3059	44	15	minutes	minute	NOUN
dti-3059	44	16	for	for	ADP
dti-3059	44	17	clotting	clotting	NOUN
dti-3059	44	18	.	.	PUNCT
dti-3059	45	1	after	after	ADP
dti-3059	45	2	that	that	PRON
dti-3059	45	3	,	,	PUNCT
dti-3059	45	4	it	it	PRON
dti-3059	45	5	was	be	AUX
dti-3059	45	6	centrifuged	centrifuge	VERB
dti-3059	45	7	at	at	ADP
dti-3059	45	8	1,500	1,500	NUM
dti-3059	45	9	rpm	rpm	NOUN
dti-3059	45	10	for	for	ADP
dti-3059	45	11	10	10	NUM
dti-3059	45	12	minutes	minute	NOUN
dti-3059	45	13	at	at	ADP
dti-3059	45	14	4	4	NUM
dti-3059	45	15	°	°	NOUN
dti-3059	45	16	c	c	NOUN
dti-3059	45	17	.	.	PUNCT
dti-3059	46	1	the	the	DET
dti-3059	46	2	resulting	result	VERB
dti-3059	46	3	supernatant	supernatant	NOUN
dti-3059	46	4	called	call	VERB
dti-3059	46	5	serum	serum	NOUN
dti-3059	46	6	was	be	AUX
dti-3059	46	7	separated	separate	VERB
dti-3059	46	8	into	into	ADP
dti-3059	46	9	fresh	fresh	ADJ
dti-3059	46	10	eppendorf	eppendorf	ADJ
dti-3059	46	11	tubes	tube	NOUN
dti-3059	46	12	and	and	CCONJ
dti-3059	46	13	stored	store	VERB
dti-3059	46	14	at	at	ADP
dti-3059	46	15	−80	−80	PROPN
dti-3059	46	16	°	°	ADP
dti-3059	46	17	c	c	NOUN
dti-3059	46	18	till	till	SCONJ
dti-3059	46	19	further	further	ADJ
dti-3059	46	20	use	use	NOUN
dti-3059	46	21	.	.	PUNCT
dti-3059	47	1	determination	determination	NOUN
dti-3059	47	2	of	of	ADP
dti-3059	47	3	serum	serum	NOUN
dti-3059	47	4	levels	level	NOUN
dti-3059	47	5	of	of	ADP
dti-3059	47	6	total	total	ADJ
dti-3059	47	7	antibodies	antibody	NOUN
dti-3059	47	8	the	the	DET
dti-3059	47	9	serum	serum	NOUN
dti-3059	47	10	levels	level	NOUN
dti-3059	47	11	of	of	ADP
dti-3059	47	12	total	total	ADJ
dti-3059	47	13	antibodies	antibody	NOUN
dti-3059	47	14	(	(	PUNCT
dti-3059	47	15	immunoglobulin	immunoglobulin	NOUN
dti-3059	47	16	,	,	PUNCT
dti-3059	47	17	ig	ig	PROPN
dti-3059	47	18	)	)	PUNCT
dti-3059	47	19	were	be	AUX
dti-3059	47	20	measured	measure	VERB
dti-3059	47	21	in	in	ADP
dti-3059	47	22	the	the	DET
dti-3059	47	23	collected	collect	VERB
dti-3059	47	24	serum	serum	NOUN
dti-3059	47	25	samples	sample	NOUN
dti-3059	47	26	of	of	ADP
dti-3059	47	27	the	the	DET
dti-3059	47	28	vaccinated	vaccinate	VERB
dti-3059	47	29	individuals	individual	NOUN
dti-3059	47	30	and	and	CCONJ
dti-3059	47	31	covid-19	covid-19	PROPN
dti-3059	47	32	recovered	recover	VERB
dti-3059	47	33	patients	patient	NOUN
dti-3059	47	34	.	.	PUNCT
dti-3059	48	1	human	human	ADJ
dti-3059	48	2	sars	sar	NOUN
dti-3059	48	3	-	-	PUNCT
dti-3059	48	4	cov-2	cov-2	NOUN
dti-3059	48	5	spike	spike	X
dti-3059	48	6	(	(	PUNCT
dti-3059	48	7	trimer	trimer	NOUN
dti-3059	48	8	)	)	PUNCT
dti-3059	48	9	ig	ig	PROPN
dti-3059	48	10	total	total	ADJ
dti-3059	48	11	enzyme	enzyme	NOUN
dti-3059	48	12	-	-	PUNCT
dti-3059	48	13	linked	link	VERB
dti-3059	48	14	immunosorbent	immunosorbent	NOUN
dti-3059	48	15	assay	assay	PROPN
dti-3059	48	16	(	(	PUNCT
dti-3059	48	17	elisa	elisa	NOUN
dti-3059	48	18	)	)	PUNCT
dti-3059	48	19	kit	kit	NOUN
dti-3059	48	20	(	(	PUNCT
dti-3059	48	21	invitrogen	invitrogen	PROPN
dti-3059	48	22	,	,	PUNCT
dti-3059	48	23	thermofisher	thermofisher	ADJ
dti-3059	48	24	scientific	scientific	NOUN
dti-3059	48	25	)	)	PUNCT
dti-3059	48	26	was	be	AUX
dti-3059	48	27	used	use	VERB
dti-3059	48	28	for	for	ADP
dti-3059	48	29	the	the	DET
dti-3059	48	30	estimation	estimation	NOUN
dti-3059	48	31	of	of	ADP
dti-3059	48	32	total	total	ADJ
dti-3059	48	33	immunoglobulins	immunoglobulin	NOUN
dti-3059	48	34	as	as	ADP
dti-3059	48	35	per	per	ADP
dti-3059	48	36	recommended	recommend	VERB
dti-3059	48	37	standard	standard	ADJ
dti-3059	48	38	protocol	protocol	NOUN
dti-3059	48	39	.	.	PUNCT
dti-3059	49	1	ten	ten	NUM
dti-3059	49	2	healthy	healthy	ADJ
dti-3059	49	3	serum	serum	NOUN
dti-3059	49	4	samples	sample	NOUN
dti-3059	49	5	collected	collect	VERB
dti-3059	49	6	before	before	ADP
dti-3059	49	7	2019	2019	NUM
dti-3059	49	8	were	be	AUX
dti-3059	49	9	used	use	VERB
dti-3059	49	10	as	as	ADP
dti-3059	49	11	controls	control	NOUN
dti-3059	49	12	to	to	PART
dti-3059	49	13	investigate	investigate	VERB
dti-3059	49	14	the	the	DET
dti-3059	49	15	specificity	specificity	NOUN
dti-3059	49	16	and	and	CCONJ
dti-3059	49	17	sensitivity	sensitivity	NOUN
dti-3059	49	18	of	of	ADP
dti-3059	49	19	elisa	elisa	PROPN
dti-3059	49	20	kit	kit	PROPN
dti-3059	49	21	.	.	PROPN
dti-3059	50	1	peptide	peptide	ADJ
dti-3059	50	2	synthesis	synthesis	NOUN
dti-3059	50	3	and	and	CCONJ
dti-3059	50	4	purification	purification	NOUN
dti-3059	50	5	a	a	DET
dti-3059	50	6	total	total	NOUN
dti-3059	50	7	of	of	ADP
dti-3059	50	8	12	12	NUM
dti-3059	50	9	peptides	peptide	NOUN
dti-3059	50	10	(	(	PUNCT
dti-3059	50	11	six	six	NUM
dti-3059	50	12	for	for	ADP
dti-3059	50	13	the	the	DET
dti-3059	50	14	wild	wild	ADJ
dti-3059	50	15	-	-	PUNCT
dti-3059	50	16	type	type	NOUN
dti-3059	50	17	wuhan	wuhan	PROPN
dti-3059	50	18	isolates	isolate	NOUN
dti-3059	50	19	and	and	CCONJ
dti-3059	50	20	six	six	NUM
dti-3059	50	21	for	for	ADP
dti-3059	50	22	the	the	DET
dti-3059	50	23	sars	sar	NOUN
dti-3059	50	24	-	-	PUNCT
dti-3059	50	25	cov-2	cov-2	NOUN
dti-3059	50	26	variants	variant	NOUN
dti-3059	50	27	)	)	PUNCT
dti-3059	50	28	of	of	ADP
dti-3059	50	29	rbd	rbd	NOUN
dti-3059	50	30	of	of	ADP
dti-3059	50	31	the	the	DET
dti-3059	50	32	spike	spike	ADJ
dti-3059	50	33	protein	protein	NOUN
dti-3059	50	34	were	be	AUX
dti-3059	50	35	selected	select	VERB
dti-3059	50	36	based	base	VERB
dti-3059	50	37	on	on	ADP
dti-3059	50	38	the	the	DET
dti-3059	50	39	available	available	ADJ
dti-3059	50	40	sequence	sequence	NOUN
dti-3059	50	41	of	of	ADP
dti-3059	50	42	sars	sar	NOUN
dti-3059	50	43	-	-	PUNCT
dti-3059	50	44	cov-2	cov-2	NOUN
dti-3059	50	45	through	through	ADP
dti-3059	50	46	uniport	uniport	NOUN
dti-3059	50	47	software	software	NOUN
dti-3059	50	48	.	.	PUNCT
dti-3059	51	1	these	these	DET
dti-3059	51	2	peptides	peptide	NOUN
dti-3059	51	3	were	be	AUX
dti-3059	51	4	commercially	commercially	ADV
dti-3059	51	5	synthesized	synthesize	VERB
dti-3059	51	6	and	and	CCONJ
dti-3059	51	7	obtained	obtain	VERB
dti-3059	51	8	to	to	PART
dti-3059	51	9	test	test	VERB
dti-3059	51	10	the	the	DET
dti-3059	51	11	antibody	antibody	NOUN
dti-3059	51	12	responses	response	NOUN
dti-3059	51	13	.	.	PUNCT
dti-3059	52	1	the	the	DET
dti-3059	52	2	peptides	peptide	NOUN
dti-3059	52	3	p1	p1	NOUN
dti-3059	52	4	,	,	PUNCT
dti-3059	52	5	p3	p3	PROPN
dti-3059	52	6	,	,	PUNCT
dti-3059	52	7	p5	p5	ADJ
dti-3059	52	8	,	,	PUNCT
dti-3059	52	9	p7	p7	ADJ
dti-3059	52	10	,	,	PUNCT
dti-3059	52	11	p9	p9	PROPN
dti-3059	52	12	,	,	PUNCT
dti-3059	52	13	and	and	CCONJ
dti-3059	52	14	p11	p11	NOUN
dti-3059	52	15	matched	match	VERB
dti-3059	52	16	with	with	ADP
dti-3059	52	17	wild	wild	ADJ
dti-3059	52	18	-	-	PUNCT
dti-3059	52	19	type	type	NOUN
dti-3059	52	20	sars	sar	NOUN
dti-3059	52	21	-	-	PUNCT
dti-3059	52	22	cov-2	cov-2	NOUN
dti-3059	52	23	sequence	sequence	NOUN
dti-3059	52	24	,	,	PUNCT
dti-3059	52	25	while	while	SCONJ
dti-3059	52	26	peptides	peptide	NOUN
dti-3059	52	27	p2	p2	NOUN
dti-3059	52	28	,	,	PUNCT
dti-3059	52	29	p4	p4	ADJ
dti-3059	52	30	,	,	PUNCT
dti-3059	52	31	p6	p6	PROPN
dti-3059	52	32	,	,	PUNCT
dti-3059	52	33	p8	p8	PROPN
dti-3059	52	34	,	,	PUNCT
dti-3059	52	35	p10	p10	NOUN
dti-3059	52	36	,	,	PUNCT
dti-3059	52	37	and	and	CCONJ
dti-3059	52	38	p12	p12	NOUN
dti-3059	52	39	matched	match	VERB
dti-3059	52	40	with	with	ADP
dti-3059	52	41	variants	variant	NOUN
dti-3059	52	42	of	of	ADP
dti-3059	52	43	sars	sar	NOUN
dti-3059	52	44	-	-	PUNCT
dti-3059	52	45	cov-2	cov-2	PART
dti-3059	52	46	(	(	PUNCT
dti-3059	52	47	tab	tab	NOUN
dti-3059	52	48	.	.	NOUN
dti-3059	52	49	1	1	NUM
dti-3059	52	50	)	)	PUNCT
dti-3059	52	51	.	.	PUNCT
dti-3059	53	1	the	the	DET
dti-3059	53	2	peptides	peptide	NOUN
dti-3059	53	3	p1	p1	NOUN
dti-3059	53	4	and	and	CCONJ
dti-3059	53	5	p2	p2	PROPN
dti-3059	53	6	sars	sar	NOUN
dti-3059	53	7	-	-	PUNCT
dti-3059	53	8	cov-2	cov-2	NOUN
dti-3059	53	9	variants	variant	NOUN
dti-3059	53	10	and	and	CCONJ
dti-3059	53	11	immune	immune	ADJ
dti-3059	53	12	escape22	escape22	ADV
dti-3059	54	1	©	©	ADP
dti-3059	54	2	2024	2024	NUM
dti-3059	54	3	the	the	DET
dti-3059	54	4	authors	author	NOUN
dti-3059	54	5	.	.	PUNCT
dti-3059	55	1	drug	drug	NOUN
dti-3059	55	2	target	target	NOUN
dti-3059	55	3	insights	insight	NOUN
dti-3059	55	4	issn	issn	VERB
dti-3059	55	5	1177	1177	NUM
dti-3059	55	6	-	-	SYM
dti-3059	55	7	3928	3928	NUM
dti-3059	55	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-3059	55	9	represent	represent	VERB
dti-3059	55	10	wild	wild	ADJ
dti-3059	55	11	-	-	PUNCT
dti-3059	55	12	type	type	NOUN
dti-3059	55	13	and	and	CCONJ
dti-3059	55	14	mutated	mutate	VERB
dti-3059	55	15	sars	sar	NOUN
dti-3059	55	16	-	-	PUNCT
dti-3059	55	17	cov-2	cov-2	NOUN
dti-3059	55	18	,	,	PUNCT
dti-3059	55	19	respectively	respectively	ADV
dti-3059	55	20	.	.	PUNCT
dti-3059	56	1	both	both	DET
dti-3059	56	2	peptides	peptide	NOUN
dti-3059	56	3	p1	p1	NOUN
dti-3059	56	4	and	and	CCONJ
dti-3059	56	5	p2	p2	PROPN
dti-3059	56	6	have	have	VERB
dti-3059	56	7	same	same	ADJ
dti-3059	56	8	number	number	NOUN
dti-3059	56	9	of	of	ADP
dti-3059	56	10	amino	amino	ADJ
dti-3059	56	11	acids	acid	NOUN
dti-3059	56	12	and	and	CCONJ
dti-3059	56	13	same	same	ADJ
dti-3059	56	14	sequences	sequence	NOUN
dti-3059	56	15	of	of	ADP
dti-3059	56	16	amino	amino	ADJ
dti-3059	56	17	acids	acid	NOUN
dti-3059	56	18	(	(	PUNCT
dti-3059	56	19	411	411	NUM
dti-3059	56	20	-	-	NUM
dti-3059	56	21	424	424	NUM
dti-3059	56	22	)	)	PUNCT
dti-3059	56	23	,	,	PUNCT
dti-3059	56	24	but	but	CCONJ
dti-3059	56	25	differ	differ	VERB
dti-3059	56	26	from	from	ADP
dti-3059	56	27	each	each	DET
dti-3059	56	28	other	other	ADJ
dti-3059	56	29	at	at	ADP
dti-3059	56	30	single	single	ADJ
dti-3059	56	31	amino	amino	NOUN
dti-3059	56	32	acid	acid	NOUN
dti-3059	56	33	residue	residue	NOUN
dti-3059	56	34	at	at	ADP
dti-3059	56	35	position	position	NOUN
dti-3059	56	36	417	417	NUM
dti-3059	56	37	.	.	PUNCT
dti-3059	57	1	likewise	likewise	ADV
dti-3059	57	2	,	,	PUNCT
dti-3059	57	3	peptides	peptide	NOUN
dti-3059	57	4	p3	p3	NOUN
dti-3059	57	5	and	and	CCONJ
dti-3059	57	6	p4	p4	PROPN
dti-3059	57	7	have	have	VERB
dti-3059	57	8	same	same	ADJ
dti-3059	57	9	amino	amino	NOUN
dti-3059	57	10	acid	acid	NOUN
dti-3059	57	11	sequence	sequence	NOUN
dti-3059	57	12	and	and	CCONJ
dti-3059	57	13	length	length	NOUN
dti-3059	57	14	(	(	PUNCT
dti-3059	57	15	470	470	NUM
dti-3059	57	16	-	-	SYM
dti-3059	57	17	483	483	NUM
dti-3059	57	18	)	)	PUNCT
dti-3059	57	19	,	,	PUNCT
dti-3059	57	20	but	but	CCONJ
dti-3059	57	21	differ	differ	VERB
dti-3059	57	22	from	from	ADP
dti-3059	57	23	each	each	DET
dti-3059	57	24	other	other	ADJ
dti-3059	57	25	at	at	ADP
dti-3059	57	26	two	two	NUM
dti-3059	57	27	residues	residue	NOUN
dti-3059	57	28	at	at	ADP
dti-3059	57	29	positions	position	NOUN
dti-3059	57	30	477	477	NUM
dti-3059	57	31	and	and	CCONJ
dti-3059	57	32	478	478	NUM
dti-3059	57	33	in	in	ADP
dti-3059	57	34	wild	wild	ADJ
dti-3059	57	35	-	-	PUNCT
dti-3059	57	36	type	type	NOUN
dti-3059	57	37	and	and	CCONJ
dti-3059	57	38	mutated	mutate	VERB
dti-3059	57	39	sars	sar	NOUN
dti-3059	57	40	-	-	PUNCT
dti-3059	57	41	cov-2	cov-2	NOUN
dti-3059	57	42	,	,	PUNCT
dti-3059	57	43	respectively	respectively	ADV
dti-3059	57	44	.	.	PUNCT
dti-3059	58	1	the	the	DET
dti-3059	58	2	peptides	peptide	NOUN
dti-3059	58	3	p5	p5	ADJ
dti-3059	58	4	and	and	CCONJ
dti-3059	58	5	p6	p6	PROPN
dti-3059	58	6	show	show	VERB
dti-3059	58	7	wild	wild	ADJ
dti-3059	58	8	-	-	PUNCT
dti-3059	58	9	type	type	NOUN
dti-3059	58	10	and	and	CCONJ
dti-3059	58	11	mutated	mutate	VERB
dti-3059	58	12	sars	sar	NOUN
dti-3059	58	13	-	-	PUNCT
dti-3059	58	14	cov-2	cov-2	NOUN
dti-3059	58	15	,	,	PUNCT
dti-3059	58	16	respectively	respectively	ADV
dti-3059	58	17	,	,	PUNCT
dti-3059	58	18	at	at	ADP
dti-3059	58	19	residue	residue	NOUN
dti-3059	58	20	484	484	NUM
dti-3059	58	21	.	.	PUNCT
dti-3059	59	1	both	both	DET
dti-3059	59	2	peptides	peptide	NOUN
dti-3059	59	3	have	have	VERB
dti-3059	59	4	a	a	DET
dti-3059	59	5	single	single	ADJ
dti-3059	59	6	amino	amino	NOUN
dti-3059	59	7	acid	acid	NOUN
dti-3059	59	8	difference	difference	NOUN
dti-3059	59	9	at	at	ADP
dti-3059	59	10	residue	residue	NOUN
dti-3059	59	11	484	484	NUM
dti-3059	59	12	.	.	PUNCT
dti-3059	60	1	similarly	similarly	ADV
dti-3059	60	2	,	,	PUNCT
dti-3059	60	3	peptides	peptide	NOUN
dti-3059	60	4	p7	p7	PROPN
dti-3059	60	5	,	,	PUNCT
dti-3059	60	6	p9	p9	PROPN
dti-3059	60	7	,	,	PUNCT
dti-3059	60	8	p11	p11	NOUN
dti-3059	60	9	of	of	ADP
dti-3059	60	10	wild	wild	ADJ
dti-3059	60	11	-	-	PUNCT
dti-3059	60	12	type	type	NOUN
dti-3059	60	13	sars	sar	NOUN
dti-3059	60	14	-	-	PUNCT
dti-3059	60	15	cov-2	cov-2	PART
dti-3059	60	16	and	and	CCONJ
dti-3059	60	17	peptides	peptide	NOUN
dti-3059	60	18	p8	p8	PROPN
dti-3059	60	19	,	,	PUNCT
dti-3059	60	20	p10	p10	NOUN
dti-3059	60	21	,	,	PUNCT
dti-3059	60	22	and	and	CCONJ
dti-3059	60	23	p12	p12	NOUN
dti-3059	60	24	of	of	ADP
dti-3059	60	25	sars	sar	NOUN
dti-3059	60	26	-	-	PUNCT
dti-3059	60	27	cov-2	cov-2	PART
dti-3059	60	28	variants	variant	NOUN
dti-3059	60	29	have	have	VERB
dti-3059	60	30	same	same	ADJ
dti-3059	60	31	length	length	NOUN
dti-3059	60	32	and	and	CCONJ
dti-3059	60	33	sequence	sequence	NOUN
dti-3059	60	34	of	of	ADP
dti-3059	60	35	amino	amino	ADJ
dti-3059	60	36	acids	acid	NOUN
dti-3059	60	37	,	,	PUNCT
dti-3059	60	38	but	but	CCONJ
dti-3059	60	39	differ	differ	VERB
dti-3059	60	40	from	from	ADP
dti-3059	60	41	one	one	NUM
dti-3059	60	42	another	another	DET
dti-3059	60	43	by	by	ADP
dti-3059	60	44	one	one	NUM
dti-3059	60	45	or	or	CCONJ
dti-3059	60	46	more	more	ADJ
dti-3059	60	47	than	than	ADP
dti-3059	60	48	one	one	NUM
dti-3059	60	49	amino	amino	NOUN
dti-3059	60	50	acid	acid	NOUN
dti-3059	60	51	(	(	PUNCT
dti-3059	60	52	tab	tab	NOUN
dti-3059	60	53	.	.	NOUN
dti-3059	60	54	1	1	NUM
dti-3059	60	55	)	)	PUNCT
dti-3059	60	56	.	.	PUNCT
dti-3059	61	1	direct	direct	ADJ
dti-3059	61	2	binding	bind	VERB
dti-3059	61	3	assay	assay	NOUN
dti-3059	61	4	to	to	PART
dti-3059	61	5	check	check	VERB
dti-3059	61	6	the	the	DET
dti-3059	61	7	immunoreactivity	immunoreactivity	NOUN
dti-3059	61	8	of	of	ADP
dti-3059	61	9	peptides	peptide	NOUN
dti-3059	61	10	with	with	ADP
dti-3059	61	11	sarscov-2	sarscov-2	NUM
dti-3059	61	12	anti	anti	ADJ
dti-3059	61	13	-	-	ADJ
dti-3059	61	14	sera	sera	ADJ
dti-3059	61	15	and	and	CCONJ
dti-3059	61	16	vaccine	vaccine	NOUN
dti-3059	61	17	anti	anti	ADJ
dti-3059	61	18	-	-	NOUN
dti-3059	61	19	sera	sera	ADJ
dti-3059	61	20	,	,	PUNCT
dti-3059	61	21	direct	direct	ADJ
dti-3059	61	22	binding	bind	VERB
dti-3059	61	23	assay	assay	NOUN
dti-3059	61	24	was	be	AUX
dti-3059	61	25	performed	perform	VERB
dti-3059	61	26	using	use	VERB
dti-3059	61	27	standard	standard	ADJ
dti-3059	61	28	elisa	elisa	NOUN
dti-3059	61	29	protocol	protocol	NOUN
dti-3059	61	30	.	.	PUNCT
dti-3059	62	1	the	the	DET
dti-3059	62	2	elisa	elisa	NOUN
dti-3059	62	3	plate	plate	NOUN
dti-3059	62	4	was	be	AUX
dti-3059	62	5	coated	coat	VERB
dti-3059	62	6	with	with	ADP
dti-3059	62	7	individual	individual	ADJ
dti-3059	62	8	peptides	peptide	NOUN
dti-3059	62	9	(	(	PUNCT
dti-3059	62	10	200	200	NUM
dti-3059	62	11	ng	ng	PROPN
dti-3059	62	12	/	/	SYM
dti-3059	62	13	well	well	NOUN
dti-3059	62	14	)	)	PUNCT
dti-3059	62	15	of	of	ADP
dti-3059	62	16	spike	spike	ADJ
dti-3059	62	17	protein	protein	NOUN
dti-3059	62	18	.	.	PUNCT
dti-3059	63	1	after	after	ADP
dti-3059	63	2	blocking	block	VERB
dti-3059	63	3	and	and	CCONJ
dti-3059	63	4	washing	washing	NOUN
dti-3059	63	5	sars	sar	NOUN
dti-3059	63	6	-	-	PUNCT
dti-3059	63	7	cov-2	cov-2	NOUN
dti-3059	63	8	anti	anti	ADJ
dti-3059	63	9	-	-	ADJ
dti-3059	63	10	sera	sera	ADJ
dti-3059	63	11	and	and	CCONJ
dti-3059	63	12	vaccine	vaccine	NOUN
dti-3059	63	13	anti	anti	ADJ
dti-3059	63	14	-	-	ADJ
dti-3059	63	15	sera	sera	NOUN
dti-3059	63	16	were	be	AUX
dti-3059	63	17	added	add	VERB
dti-3059	63	18	at	at	ADP
dti-3059	63	19	a	a	DET
dti-3059	63	20	dilution	dilution	NOUN
dti-3059	63	21	of	of	ADP
dti-3059	63	22	1:200	1:200	NUM
dti-3059	63	23	onto	onto	ADP
dti-3059	63	24	the	the	DET
dti-3059	63	25	elisa	elisa	NOUN
dti-3059	63	26	plate	plate	NOUN
dti-3059	63	27	and	and	CCONJ
dti-3059	63	28	incubated	incubate	VERB
dti-3059	63	29	at	at	ADP
dti-3059	63	30	37	37	NUM
dti-3059	63	31	°	°	ADP
dti-3059	63	32	c	c	NOUN
dti-3059	63	33	for	for	ADP
dti-3059	63	34	2	2	NUM
dti-3059	63	35	hours	hour	NOUN
dti-3059	63	36	.	.	PUNCT
dti-3059	64	1	after	after	ADP
dti-3059	64	2	washing	washing	NOUN
dti-3059	64	3	,	,	PUNCT
dti-3059	64	4	anti	anti	ADJ
dti-3059	64	5	-	-	ADJ
dti-3059	64	6	human	human	ADJ
dti-3059	64	7	igg	igg	NOUN
dti-3059	64	8	antibody	antibody	NOUN
dti-3059	64	9	conjugated	conjugate	VERB
dti-3059	64	10	with	with	ADP
dti-3059	64	11	horse	horse	NOUN
dti-3059	64	12	radish	radish	ADJ
dti-3059	64	13	peroxidase	peroxidase	NOUN
dti-3059	64	14	(	(	PUNCT
dti-3059	64	15	hrp	hrp	PROPN
dti-3059	64	16	;	;	PUNCT
dti-3059	64	17	1:200	1:200	NUM
dti-3059	64	18	dilutions	dilution	NOUN
dti-3059	64	19	)	)	PUNCT
dti-3059	64	20	was	be	AUX
dti-3059	64	21	added	add	VERB
dti-3059	64	22	and	and	CCONJ
dti-3059	64	23	incubated	incubate	VERB
dti-3059	64	24	for	for	ADP
dti-3059	64	25	1	1	NUM
dti-3059	64	26	hour	hour	NOUN
dti-3059	64	27	at	at	ADP
dti-3059	64	28	37	37	NUM
dti-3059	64	29	°	°	NOUN
dti-3059	64	30	c	c	NOUN
dti-3059	64	31	.	.	PUNCT
dti-3059	65	1	washing	washing	NOUN
dti-3059	65	2	step	step	NOUN
dti-3059	65	3	was	be	AUX
dti-3059	65	4	repeated	repeat	VERB
dti-3059	65	5	after	after	SCONJ
dti-3059	65	6	incubation	incubation	NOUN
dti-3059	65	7	and	and	CCONJ
dti-3059	65	8	100	100	NUM
dti-3059	65	9	μl	μl	ADJ
dti-3059	65	10	/	/	SYM
dti-3059	65	11	well	well	ADV
dti-3059	65	12	substrate	substrate	NOUN
dti-3059	65	13	solution	solution	NOUN
dti-3059	65	14	(	(	PUNCT
dti-3059	65	15	tmb	tmb	NOUN
dti-3059	65	16	)	)	PUNCT
dti-3059	65	17	was	be	AUX
dti-3059	65	18	added	add	VERB
dti-3059	65	19	.	.	PUNCT
dti-3059	66	1	the	the	DET
dti-3059	66	2	color	color	NOUN
dti-3059	66	3	was	be	AUX
dti-3059	66	4	developed	develop	VERB
dti-3059	66	5	within	within	ADP
dti-3059	66	6	10	10	NUM
dti-3059	66	7	-	-	SYM
dti-3059	66	8	15	15	NUM
dti-3059	66	9	minutes	minute	NOUN
dti-3059	66	10	.	.	PUNCT
dti-3059	67	1	the	the	DET
dti-3059	67	2	color	color	NOUN
dti-3059	67	3	reaction	reaction	NOUN
dti-3059	67	4	was	be	AUX
dti-3059	67	5	stopped	stop	VERB
dti-3059	67	6	by	by	ADP
dti-3059	67	7	adding	add	VERB
dti-3059	67	8	50	50	NUM
dti-3059	67	9	μl	μl	ADV
dti-3059	67	10	/	/	SYM
dti-3059	67	11	well	well	NOUN
dti-3059	67	12	of	of	ADP
dti-3059	67	13	2n	2n	NUM
dti-3059	67	14	h2so4	h2so4	PROPN
dti-3059	67	15	.	.	PUNCT
dti-3059	68	1	the	the	DET
dti-3059	68	2	plate	plate	NOUN
dti-3059	68	3	was	be	AUX
dti-3059	68	4	read	read	VERB
dti-3059	68	5	at	at	ADP
dti-3059	68	6	450	450	NUM
dti-3059	68	7	nm	nm	NOUN
dti-3059	68	8	in	in	ADP
dti-3059	68	9	the	the	DET
dti-3059	68	10	elisa	elisa	NOUN
dti-3059	68	11	reader	reader	NOUN
dti-3059	68	12	.	.	PUNCT
dti-3059	69	1	statistical	statistical	ADJ
dti-3059	69	2	analysis	analysis	NOUN
dti-3059	69	3	data	data	NOUN
dti-3059	69	4	visualization	visualization	NOUN
dti-3059	69	5	was	be	AUX
dti-3059	69	6	performed	perform	VERB
dti-3059	69	7	via	via	ADP
dti-3059	69	8	graphpad	graphpad	NOUN
dti-3059	69	9	prism	prism	NOUN
dti-3059	69	10	version	version	PROPN
dti-3059	69	11	8.0	8.0	NUM
dti-3059	69	12	(	(	PUNCT
dti-3059	69	13	graphpad	graphpad	NOUN
dti-3059	69	14	software	software	NOUN
dti-3059	69	15	,	,	PUNCT
dti-3059	69	16	san	san	PROPN
dti-3059	69	17	diego	diego	PROPN
dti-3059	69	18	,	,	PUNCT
dti-3059	69	19	ca	ca	PROPN
dti-3059	69	20	,	,	PUNCT
dti-3059	69	21	usa	usa	PROPN
dti-3059	69	22	)	)	PUNCT
dti-3059	69	23	and	and	CCONJ
dti-3059	69	24	stata	stata	VERB
dti-3059	69	25	12	12	NUM
dti-3059	69	26	(	(	PUNCT
dti-3059	69	27	stata	stata	NOUN
dti-3059	69	28	software	software	NOUN
dti-3059	69	29	,	,	PUNCT
dti-3059	69	30	chicago	chicago	PROPN
dti-3059	69	31	,	,	PUNCT
dti-3059	69	32	usa	usa	PROPN
dti-3059	69	33	)	)	PUNCT
dti-3059	69	34	for	for	ADP
dti-3059	69	35	windows	window	NOUN
dti-3059	69	36	10.0	10.0	NUM
dti-3059	69	37	.	.	PUNCT
dti-3059	70	1	result	result	NOUN
dti-3059	70	2	was	be	AUX
dti-3059	70	3	expressed	express	VERB
dti-3059	70	4	as	as	ADP
dti-3059	70	5	mean	mean	ADJ
dti-3059	70	6	and	and	CCONJ
dti-3059	70	7	standard	standard	ADJ
dti-3059	70	8	deviation	deviation	NOUN
dti-3059	70	9	(	(	PUNCT
dti-3059	70	10	sd	sd	NOUN
dti-3059	70	11	)	)	PUNCT
dti-3059	70	12	for	for	ADP
dti-3059	70	13	normal	normal	ADJ
dti-3059	70	14	distribution	distribution	NOUN
dti-3059	70	15	,	,	PUNCT
dti-3059	70	16	or	or	CCONJ
dti-3059	70	17	median	median	NOUN
dti-3059	70	18	and	and	CCONJ
dti-3059	70	19	interquartile	interquartile	ADJ
dti-3059	70	20	range	range	NOUN
dti-3059	70	21	for	for	ADP
dti-3059	70	22	skewed	skewed	ADJ
dti-3059	70	23	distribution	distribution	NOUN
dti-3059	70	24	.	.	PUNCT
dti-3059	71	1	for	for	ADP
dti-3059	71	2	two	two	NUM
dti-3059	71	3	-	-	PUNCT
dti-3059	71	4	group	group	NOUN
dti-3059	71	5	analysis	analysis	NOUN
dti-3059	71	6	,	,	PUNCT
dti-3059	71	7	we	we	PRON
dti-3059	71	8	used	use	VERB
dti-3059	71	9	the	the	DET
dti-3059	71	10	mann	mann	PROPN
dti-3059	71	11	-	-	PUNCT
dti-3059	71	12	whitney	whitney	PROPN
dti-3059	71	13	u	u	NOUN
dti-3059	71	14	-	-	NOUN
dti-3059	71	15	test	test	NOUN
dti-3059	71	16	for	for	ADP
dti-3059	71	17	continuous	continuous	ADJ
dti-3059	71	18	variables	variable	NOUN
dti-3059	71	19	.	.	PUNCT
dti-3059	72	1	the	the	DET
dti-3059	72	2	level	level	NOUN
dti-3059	72	3	of	of	ADP
dti-3059	72	4	significance	significance	NOUN
dti-3059	72	5	(	(	PUNCT
dti-3059	72	6	p	p	NOUN
dti-3059	72	7	-	-	PUNCT
dti-3059	72	8	value	value	NOUN
dti-3059	72	9	)	)	PUNCT
dti-3059	72	10	in	in	ADP
dti-3059	72	11	the	the	DET
dti-3059	72	12	mean	mean	ADJ
dti-3059	72	13	antibody	antibody	NOUN
dti-3059	72	14	titer	titer	NOUN
dti-3059	72	15	was	be	AUX
dti-3059	72	16	compared	compare	VERB
dti-3059	72	17	and	and	CCONJ
dti-3059	72	18	analyzed	analyze	VERB
dti-3059	72	19	with	with	ADP
dti-3059	72	20	the	the	DET
dti-3059	72	21	student	student	NOUN
dti-3059	72	22	’s	’s	PART
dti-3059	72	23	t	t	PROPN
dti-3059	72	24	-	-	PUNCT
dti-3059	72	25	test	test	NOUN
dti-3059	72	26	.	.	PUNCT
dti-3059	73	1	results	result	VERB
dti-3059	73	2	clinical	clinical	ADJ
dti-3059	73	3	and	and	CCONJ
dti-3059	73	4	demographic	demographic	ADJ
dti-3059	73	5	details	detail	NOUN
dti-3059	73	6	the	the	DET
dti-3059	73	7	study	study	NOUN
dti-3059	73	8	analyzed	analyze	VERB
dti-3059	73	9	30	30	NUM
dti-3059	73	10	covid-19	covid-19	PROPN
dti-3059	73	11	recovered	recover	VERB
dti-3059	73	12	subjects	subject	NOUN
dti-3059	73	13	and	and	CCONJ
dti-3059	73	14	30	30	NUM
dti-3059	73	15	individuals	individual	NOUN
dti-3059	73	16	vaccinated	vaccinate	VERB
dti-3059	73	17	with	with	ADP
dti-3059	73	18	both	both	DET
dti-3059	73	19	doses	dose	NOUN
dti-3059	73	20	of	of	ADP
dti-3059	73	21	covishield	covishield	NOUN
dti-3059	73	22	™	™	PROPN
dti-3059	73	23	.	.	PUNCT
dti-3059	74	1	the	the	DET
dti-3059	74	2	clinical	clinical	ADJ
dti-3059	74	3	and	and	CCONJ
dti-3059	74	4	demographic	demographic	ADJ
dti-3059	74	5	details	detail	NOUN
dti-3059	74	6	are	be	AUX
dti-3059	74	7	shown	show	VERB
dti-3059	74	8	in	in	ADP
dti-3059	74	9	table	table	NOUN
dti-3059	74	10	2	2	NUM
dti-3059	74	11	.	.	PUNCT
dti-3059	75	1	the	the	DET
dti-3059	75	2	median	median	ADJ
dti-3059	75	3	age	age	NOUN
dti-3059	75	4	of	of	ADP
dti-3059	75	5	the	the	DET
dti-3059	75	6	covid-19	covid-19	PROPN
dti-3059	75	7	recovered	recovered	ADJ
dti-3059	75	8	patients	patient	NOUN
dti-3059	75	9	was	be	AUX
dti-3059	75	10	48.5	48.5	NUM
dti-3059	75	11	years	year	NOUN
dti-3059	75	12	,	,	PUNCT
dti-3059	75	13	with	with	ADP
dti-3059	75	14	a	a	DET
dti-3059	75	15	range	range	NOUN
dti-3059	75	16	of	of	ADP
dti-3059	75	17	23	23	NUM
dti-3059	75	18	to	to	PART
dti-3059	75	19	76	76	NUM
dti-3059	75	20	years	year	NOUN
dti-3059	75	21	,	,	PUNCT
dti-3059	75	22	while	while	SCONJ
dti-3059	75	23	the	the	DET
dti-3059	75	24	median	median	ADJ
dti-3059	75	25	age	age	NOUN
dti-3059	75	26	of	of	ADP
dti-3059	75	27	vaccinated	vaccinated	ADJ
dti-3059	75	28	group	group	NOUN
dti-3059	75	29	was	be	AUX
dti-3059	75	30	45	45	NUM
dti-3059	75	31	years	year	NOUN
dti-3059	75	32	,	,	PUNCT
dti-3059	75	33	with	with	ADP
dti-3059	75	34	a	a	DET
dti-3059	75	35	range	range	NOUN
dti-3059	75	36	of	of	ADP
dti-3059	75	37	18	18	NUM
dti-3059	75	38	to	to	PART
dti-3059	75	39	74	74	NUM
dti-3059	75	40	years	year	NOUN
dti-3059	75	41	.	.	PUNCT
dti-3059	76	1	the	the	DET
dti-3059	76	2	distributions	distribution	NOUN
dti-3059	76	3	of	of	ADP
dti-3059	76	4	patients	patient	NOUN
dti-3059	76	5	based	base	VERB
dti-3059	76	6	on	on	ADP
dti-3059	76	7	their	their	PRON
dti-3059	76	8	age	age	NOUN
dti-3059	76	9	<	<	X
dti-3059	76	10	65	65	NUM
dti-3059	76	11	years	year	NOUN
dti-3059	76	12	and	and	CCONJ
dti-3059	76	13	>	>	SYM
dti-3059	76	14	65	65	NUM
dti-3059	76	15	years	year	NOUN
dti-3059	76	16	in	in	ADP
dti-3059	76	17	both	both	DET
dti-3059	76	18	groups	group	NOUN
dti-3059	76	19	are	be	AUX
dti-3059	76	20	shown	show	VERB
dti-3059	76	21	in	in	ADP
dti-3059	76	22	table	table	NOUN
dti-3059	76	23	2	2	NUM
dti-3059	76	24	.	.	PUNCT
dti-3059	76	25	out	out	ADP
dti-3059	76	26	of	of	ADP
dti-3059	76	27	the	the	DET
dti-3059	76	28	participants	participant	NOUN
dti-3059	76	29	,	,	PUNCT
dti-3059	76	30	33.33	33.33	NUM
dti-3059	76	31	%	%	NOUN
dti-3059	76	32	and	and	CCONJ
dti-3059	76	33	40	40	NUM
dti-3059	76	34	%	%	NOUN
dti-3059	76	35	females	female	NOUN
dti-3059	76	36	were	be	AUX
dti-3059	76	37	found	find	VERB
dti-3059	76	38	in	in	ADP
dti-3059	76	39	covid-19	covid-19	PROPN
dti-3059	76	40	recovered	recover	VERB
dti-3059	76	41	group	group	NOUN
dti-3059	76	42	and	and	CCONJ
dti-3059	76	43	vaccinated	vaccinated	ADJ
dti-3059	76	44	group	group	NOUN
dti-3059	76	45	,	,	PUNCT
dti-3059	76	46	respectively	respectively	ADV
dti-3059	76	47	.	.	PUNCT
dti-3059	77	1	based	base	VERB
dti-3059	77	2	on	on	ADP
dti-3059	77	3	disease	disease	NOUN
dti-3059	77	4	severity	severity	NOUN
dti-3059	77	5	,	,	PUNCT
dti-3059	77	6	covid-19	covid-19	PROPN
dti-3059	77	7	recovered	recover	VERB
dti-3059	77	8	patients	patient	NOUN
dti-3059	77	9	were	be	AUX
dti-3059	77	10	divided	divide	VERB
dti-3059	77	11	into	into	ADP
dti-3059	77	12	severe	severe	ADJ
dti-3059	77	13	and	and	CCONJ
dti-3059	77	14	mild	mild	ADJ
dti-3059	77	15	groups	group	NOUN
dti-3059	77	16	.	.	PUNCT
dti-3059	78	1	out	out	ADP
dti-3059	78	2	of	of	ADP
dti-3059	78	3	the	the	DET
dti-3059	78	4	covid-19	covid-19	PROPN
dti-3059	78	5	recovered	recover	VERB
dti-3059	78	6	patients	patient	NOUN
dti-3059	78	7	43.33	43.33	NUM
dti-3059	78	8	%	%	NOUN
dti-3059	78	9	were	be	AUX
dti-3059	78	10	severe	severe	ADJ
dti-3059	78	11	and	and	CCONJ
dti-3059	78	12	required	require	VERB
dti-3059	78	13	intensive	intensive	ADJ
dti-3059	78	14	care	care	NOUN
dti-3059	78	15	unit	unit	NOUN
dti-3059	78	16	(	(	PUNCT
dti-3059	78	17	icu	icu	PROPN
dti-3059	78	18	)	)	PUNCT
dti-3059	78	19	support	support	NOUN
dti-3059	78	20	in	in	ADP
dti-3059	78	21	the	the	DET
dti-3059	78	22	hospital	hospital	NOUN
dti-3059	78	23	.	.	PUNCT
dti-3059	79	1	the	the	DET
dti-3059	79	2	most	most	ADV
dti-3059	79	3	prevalent	prevalent	ADJ
dti-3059	79	4	comorbidities	comorbiditie	NOUN
dti-3059	79	5	among	among	ADP
dti-3059	79	6	the	the	DET
dti-3059	79	7	covid-19	covid-19	PROPN
dti-3059	79	8	recovered	recovered	ADJ
dti-3059	79	9	patients	patient	NOUN
dti-3059	79	10	were	be	AUX
dti-3059	79	11	obesity	obesity	NOUN
dti-3059	79	12	(	(	PUNCT
dti-3059	79	13	26.67	26.67	NUM
dti-3059	79	14	%	%	NOUN
dti-3059	79	15	)	)	PUNCT
dti-3059	79	16	,	,	PUNCT
dti-3059	79	17	diabetes	diabetes	NOUN
dti-3059	79	18	(	(	PUNCT
dti-3059	79	19	23.33	23.33	NUM
dti-3059	79	20	%	%	NOUN
dti-3059	79	21	)	)	PUNCT
dti-3059	79	22	,	,	PUNCT
dti-3059	79	23	and	and	CCONJ
dti-3059	79	24	hypertension	hypertension	NOUN
dti-3059	79	25	(	(	PUNCT
dti-3059	79	26	6.67	6.67	NUM
dti-3059	79	27	%	%	NOUN
dti-3059	79	28	)	)	PUNCT
dti-3059	79	29	,	,	PUNCT
dti-3059	79	30	and	and	CCONJ
dti-3059	79	31	some	some	PRON
dti-3059	79	32	of	of	ADP
dti-3059	79	33	the	the	DET
dti-3059	79	34	patients	patient	NOUN
dti-3059	79	35	required	require	VERB
dti-3059	79	36	intensive	intensive	ADJ
dti-3059	79	37	care	care	NOUN
dti-3059	79	38	and	and	CCONJ
dti-3059	79	39	intubation	intubation	NOUN
dti-3059	79	40	table	table	NOUN
dti-3059	79	41	1	1	NUM
dti-3059	79	42	list	list	NOUN
dti-3059	79	43	of	of	ADP
dti-3059	79	44	the	the	DET
dti-3059	79	45	peptides	peptide	NOUN
dti-3059	79	46	of	of	ADP
dti-3059	79	47	the	the	DET
dti-3059	79	48	rbd	rbd	NOUN
dti-3059	79	49	from	from	ADP
dti-3059	79	50	wild	wild	ADJ
dti-3059	79	51	type	type	NOUN
dti-3059	79	52	and	and	CCONJ
dti-3059	79	53	sars	sar	NOUN
dti-3059	79	54	-	-	PUNCT
dti-3059	79	55	cov-2	cov-2	PART
dti-3059	79	56	variants	variant	NOUN
dti-3059	79	57	s.	s.	PROPN
dti-3059	80	1	no	no	DET
dti-3059	80	2	peptides	peptide	NOUN
dti-3059	80	3	sequences	sequence	NOUN
dti-3059	80	4	of	of	ADP
dti-3059	80	5	amino	amino	ADJ
dti-3059	80	6	acids	acid	NOUN
dti-3059	80	7	in	in	ADP
dti-3059	80	8	the	the	DET
dti-3059	80	9	rbd	rbd	NOUN
dti-3059	80	10	of	of	ADP
dti-3059	80	11	sars	sar	NOUN
dti-3059	80	12	-	-	PUNCT
dti-3059	80	13	cov-2	cov-2	NOUN
dti-3059	80	14	sequence	sequence	NOUN
dti-3059	80	15	number	number	NOUN
dti-3059	80	16	mutating	mutate	VERB
dti-3059	80	17	sites	site	NOUN
dti-3059	80	18	voc	voc	NOUN
dti-3059	80	19	/	/	SYM
dti-3059	80	20	wild	wild	ADJ
dti-3059	80	21	type	type	NOUN
dti-3059	80	22	1	1	NUM
dti-3059	80	23	p1	p1	NOUN
dti-3059	80	24	apgqtgkiadynyk	apgqtgkiadynyk	VERB
dti-3059	80	25	411	411	NUM
dti-3059	80	26	-	-	SYM
dti-3059	80	27	424	424	NUM
dti-3059	80	28	k417	k417	PROPN
dti-3059	80	29	wild	wild	ADJ
dti-3059	80	30	2	2	NUM
dti-3059	80	31	p2	p2	NOUN
dti-3059	80	32	apgqtgniadynyk	apgqtgniadynyk	NOUN
dti-3059	80	33	411	411	NUM
dti-3059	80	34	-	-	SYM
dti-3059	80	35	424	424	NUM
dti-3059	80	36	417n	417n	PROPN
dti-3059	80	37	common	common	ADJ
dti-3059	80	38	site	site	NOUN
dti-3059	80	39	of	of	ADP
dti-3059	80	40	mutation	mutation	NOUN
dti-3059	80	41	for	for	ADP
dti-3059	80	42	delta	delta	NOUN
dti-3059	80	43	and	and	CCONJ
dti-3059	80	44	omicron	omicron	PROPN
dti-3059	80	45	3	3	PROPN
dti-3059	80	46	p3	p3	PROPN
dti-3059	80	47	teiyqagstpcngv	teiyqagstpcngv	X
dti-3059	80	48	470	470	NUM
dti-3059	80	49	-	-	SYM
dti-3059	80	50	483	483	NUM
dti-3059	80	51	s477	s477	PROPN
dti-3059	80	52	,	,	PUNCT
dti-3059	80	53	t478	t478	PROPN
dti-3059	80	54	wild	wild	ADJ
dti-3059	80	55	4	4	NUM
dti-3059	80	56	p4	p4	ADJ
dti-3059	80	57	teiyqagnkpcngv	teiyqagnkpcngv	NOUN
dti-3059	80	58	470	470	NUM
dti-3059	80	59	-	-	SYM
dti-3059	80	60	483	483	NUM
dti-3059	80	61	477n	477n	NOUN
dti-3059	80	62	,	,	PUNCT
dti-3059	80	63	478k	478k	NOUN
dti-3059	80	64	common	common	ADJ
dti-3059	80	65	site	site	NOUN
dti-3059	80	66	of	of	ADP
dti-3059	80	67	mutation	mutation	NOUN
dti-3059	80	68	for	for	ADP
dti-3059	80	69	delta	delta	NOUN
dti-3059	80	70	and	and	CCONJ
dti-3059	80	71	omicron	omicron	PROPN
dti-3059	80	72	5	5	NUM
dti-3059	80	73	p5	p5	ADJ
dti-3059	80	74	pcngvegfncyfpl	pcngvegfncyfpl	ADJ
dti-3059	80	75	479	479	NUM
dti-3059	80	76	-	-	SYM
dti-3059	80	77	492	492	NUM
dti-3059	80	78	e484	e484	PROPN
dti-3059	80	79	wild	wild	ADJ
dti-3059	80	80	6	6	NUM
dti-3059	80	81	p6	p6	NOUN
dti-3059	80	82	pcngvagfncyfpl	pcngvagfncyfpl	NOUN
dti-3059	80	83	479	479	NUM
dti-3059	80	84	-	-	SYM
dti-3059	80	85	492	492	NUM
dti-3059	80	86	484a	484a	PROPN
dti-3059	80	87	common	common	ADJ
dti-3059	80	88	site	site	NOUN
dti-3059	80	89	of	of	ADP
dti-3059	80	90	mutation	mutation	NOUN
dti-3059	80	91	for	for	ADP
dti-3059	80	92	delta	delta	NOUN
dti-3059	80	93	and	and	CCONJ
dti-3059	80	94	omicron	omicron	PROPN
dti-3059	80	95	7	7	NUM
dti-3059	80	96	p7	p7	PROPN
dti-3059	80	97	plqsygfqptngvg	plqsygfqptngvg	NOUN
dti-3059	80	98	491	491	NUM
dti-3059	80	99	-	-	SYM
dti-3059	80	100	504	504	NUM
dti-3059	80	101	n501	n501	NOUN
dti-3059	80	102	wild	wild	ADJ
dti-3059	80	103	8	8	NUM
dti-3059	80	104	p8	p8	PROPN
dti-3059	80	105	plqsygfqptygvg	plqsygfqptygvg	NOUN
dti-3059	80	106	491	491	NUM
dti-3059	80	107	-	-	SYM
dti-3059	80	108	504	504	NUM
dti-3059	80	109	501y	501y	NUM
dti-3059	80	110	common	common	ADJ
dti-3059	80	111	site	site	NOUN
dti-3059	80	112	of	of	ADP
dti-3059	80	113	mutation	mutation	NOUN
dti-3059	80	114	for	for	ADP
dti-3059	80	115	delta	delta	NOUN
dti-3059	80	116	and	and	CCONJ
dti-3059	80	117	omicron	omicron	PROPN
dti-3059	80	118	9	9	NUM
dti-3059	80	119	p9	p9	PROPN
dti-3059	80	120	wnsnnldskvsgnyn	wnsnnldskvsgnyn	PROPN
dti-3059	80	121	436	436	NUM
dti-3059	80	122	-	-	SYM
dti-3059	80	123	450	450	NUM
dti-3059	80	124	n440	n440	PROPN
dti-3059	80	125	,	,	PUNCT
dti-3059	80	126	g446	g446	AUX
dti-3059	80	127	wild	wild	ADJ
dti-3059	80	128	10	10	NUM
dti-3059	80	129	p10	p10	NOUN
dti-3059	80	130	wnsnkldskvsgnyn	wnsnkldskvsgnyn	ADJ
dti-3059	80	131	436	436	NUM
dti-3059	80	132	-	-	SYM
dti-3059	80	133	450	450	NUM
dti-3059	80	134	440k	440k	NUM
dti-3059	80	135	,	,	PUNCT
dti-3059	80	136	446s	446s	PROPN
dti-3059	80	137	omicron	omicron	PROPN
dti-3059	80	138	11	11	NUM
dti-3059	80	139	p11	p11	NOUN
dti-3059	80	140	yfplqsygfqptngvgyqpyr	yfplqsygfqptngvgyqpyr	NOUN
dti-3059	80	141	489	489	NUM
dti-3059	80	142	-	-	SYM
dti-3059	80	143	509	509	NUM
dti-3059	80	144	q493	q493	PROPN
dti-3059	80	145	,	,	PUNCT
dti-3059	80	146	g496	g496	PROPN
dti-3059	80	147	,	,	PUNCT
dti-3059	80	148	q498	q498	PROPN
dti-3059	80	149	,	,	PUNCT
dti-3059	80	150	n501	n501	PROPN
dti-3059	80	151	,	,	PUNCT
dti-3059	80	152	y505	y505	PROPN
dti-3059	80	153	wild	wild	ADJ
dti-3059	80	154	12	12	NUM
dti-3059	80	155	p12	p12	NOUN
dti-3059	80	156	yfplrsysfrptygvghqpyr	yfplrsysfrptygvghqpyr	NOUN
dti-3059	80	157	489	489	NUM
dti-3059	80	158	-	-	PUNCT
dti-3059	80	159	509	509	NUM
dti-3059	80	160	493r	493r	PROPN
dti-3059	80	161	,	,	PUNCT
dti-3059	80	162	496s	496s	NOUN
dti-3059	80	163	,	,	PUNCT
dti-3059	80	164	498r	498r	NUM
dti-3059	80	165	,	,	PUNCT
dti-3059	80	166	501y	501y	NUM
dti-3059	80	167	,	,	PUNCT
dti-3059	80	168	505h	505h	PROPN
dti-3059	80	169	omicron	omicron	PROPN
dti-3059	80	170	rbd	rbd	NOUN
dti-3059	80	171	=	=	NOUN
dti-3059	80	172	receptor	receptor	NOUN
dti-3059	80	173	-	-	PUNCT
dti-3059	80	174	binding	bind	VERB
dti-3059	80	175	domain	domain	NOUN
dti-3059	80	176	;	;	PUNCT
dti-3059	80	177	voc	voc	NOUN
dti-3059	80	178	=	=	SYM
dti-3059	80	179	variants	variant	NOUN
dti-3059	80	180	of	of	ADP
dti-3059	80	181	concern	concern	NOUN
dti-3059	80	182	.	.	PUNCT
dti-3059	81	1	the	the	DET
dti-3059	81	2	sites	site	NOUN
dti-3059	81	3	of	of	ADP
dti-3059	81	4	amino	amino	NOUN
dti-3059	81	5	acid	acid	NOUN
dti-3059	81	6	variations	variation	NOUN
dti-3059	81	7	in	in	ADP
dti-3059	81	8	the	the	DET
dti-3059	81	9	peptide	peptide	NOUN
dti-3059	81	10	sequences	sequence	NOUN
dti-3059	81	11	are	be	AUX
dti-3059	81	12	highlighted	highlight	VERB
dti-3059	81	13	in	in	ADP
dti-3059	81	14	bold	bold	PROPN
dti-3059	81	15	.	.	PUNCT
dti-3059	82	1	gupta	gupta	PROPN
dti-3059	82	2	et	et	PROPN
dti-3059	82	3	al	al	PROPN
dti-3059	82	4	drug	drug	PROPN
dti-3059	82	5	target	target	NOUN
dti-3059	82	6	insights	insight	NOUN
dti-3059	82	7	2024	2024	NUM
dti-3059	82	8	;	;	PUNCT
dti-3059	82	9	18	18	NUM
dti-3059	82	10	:	:	SYM
dti-3059	82	11	23	23	NUM
dti-3059	82	12	©	©	ADP
dti-3059	82	13	2024	2024	NUM
dti-3059	82	14	the	the	DET
dti-3059	82	15	authors	author	NOUN
dti-3059	82	16	.	.	PUNCT
dti-3059	83	1	published	publish	VERB
dti-3059	83	2	by	by	ADP
dti-3059	83	3	aboutscience	aboutscience	NOUN
dti-3059	83	4	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-3059	83	5	due	due	ADP
dti-3059	83	6	to	to	ADP
dti-3059	83	7	the	the	DET
dti-3059	83	8	severity	severity	NOUN
dti-3059	83	9	of	of	ADP
dti-3059	83	10	their	their	PRON
dti-3059	83	11	condition	condition	NOUN
dti-3059	83	12	.	.	PUNCT
dti-3059	84	1	obesity	obesity	NOUN
dti-3059	84	2	,	,	PUNCT
dti-3059	84	3	hypertension	hypertension	NOUN
dti-3059	84	4	,	,	PUNCT
dti-3059	84	5	and	and	CCONJ
dti-3059	84	6	diabetes	diabetes	NOUN
dti-3059	84	7	were	be	AUX
dti-3059	84	8	the	the	DET
dti-3059	84	9	most	most	ADV
dti-3059	84	10	common	common	ADJ
dti-3059	84	11	comorbidities	comorbiditie	NOUN
dti-3059	84	12	observed	observe	VERB
dti-3059	84	13	in	in	ADP
dti-3059	84	14	the	the	DET
dti-3059	84	15	patients	patient	NOUN
dti-3059	84	16	who	who	PRON
dti-3059	84	17	required	require	VERB
dti-3059	84	18	icu	icu	PROPN
dti-3059	84	19	support	support	NOUN
dti-3059	84	20	.	.	PUNCT
dti-3059	85	1	serum	serum	NOUN
dti-3059	85	2	levels	level	NOUN
dti-3059	85	3	of	of	ADP
dti-3059	85	4	total	total	ADJ
dti-3059	85	5	antibodies	antibody	NOUN
dti-3059	85	6	in	in	ADP
dti-3059	85	7	covid-19	covid-19	PROPN
dti-3059	85	8	recovered	recover	VERB
dti-3059	85	9	patients	patient	NOUN
dti-3059	85	10	and	and	CCONJ
dti-3059	85	11	vaccinated	vaccinated	ADJ
dti-3059	85	12	individuals	individual	NOUN
dti-3059	85	13	the	the	DET
dti-3059	85	14	sensitivity	sensitivity	NOUN
dti-3059	85	15	and	and	CCONJ
dti-3059	85	16	specificity	specificity	NOUN
dti-3059	85	17	of	of	ADP
dti-3059	85	18	human	human	ADJ
dti-3059	85	19	sars	sar	NOUN
dti-3059	85	20	-	-	PUNCT
dti-3059	85	21	cov-2	cov-2	NOUN
dti-3059	85	22	spike	spike	X
dti-3059	85	23	(	(	PUNCT
dti-3059	85	24	trimer	trimer	NOUN
dti-3059	85	25	)	)	PUNCT
dti-3059	85	26	ig	ig	PROPN
dti-3059	85	27	total	total	ADJ
dti-3059	85	28	elisa	elisa	PROPN
dti-3059	85	29	kit	kit	NOUN
dti-3059	85	30	(	(	PUNCT
dti-3059	85	31	invitrogen	invitrogen	PROPN
dti-3059	85	32	;	;	PUNCT
dti-3059	85	33	thermofisher	thermofisher	PROPN
dti-3059	85	34	scientific	scientific	NOUN
dti-3059	85	35	)	)	PUNCT
dti-3059	85	36	were	be	AUX
dti-3059	85	37	tested	test	VERB
dti-3059	85	38	by	by	ADP
dti-3059	85	39	the	the	DET
dti-3059	85	40	serum	serum	NOUN
dti-3059	85	41	sample	sample	NOUN
dti-3059	85	42	collected	collect	VERB
dti-3059	85	43	before	before	ADP
dti-3059	85	44	2019	2019	NUM
dti-3059	85	45	as	as	ADP
dti-3059	85	46	a	a	DET
dti-3059	85	47	control	control	NOUN
dti-3059	85	48	.	.	PUNCT
dti-3059	86	1	sars	sar	NOUN
dti-3059	86	2	-	-	PUNCT
dti-3059	86	3	cov-2	cov-2	NOUN
dti-3059	86	4	spike	spike	ADJ
dti-3059	86	5	protein	protein	NOUN
dti-3059	86	6	-	-	PUNCT
dti-3059	86	7	specific	specific	ADJ
dti-3059	86	8	total	total	ADJ
dti-3059	86	9	antibodies	antibody	NOUN
dti-3059	86	10	were	be	AUX
dti-3059	86	11	measured	measure	VERB
dti-3059	86	12	3	3	NUM
dti-3059	86	13	-	-	SYM
dti-3059	86	14	4	4	NUM
dti-3059	86	15	weeks	week	NOUN
dti-3059	86	16	after	after	ADP
dti-3059	86	17	the	the	DET
dti-3059	86	18	recovery	recovery	NOUN
dti-3059	86	19	from	from	ADP
dti-3059	86	20	sars	sar	NOUN
dti-3059	86	21	-	-	PUNCT
dti-3059	86	22	cov-2	cov-2	PART
dti-3059	86	23	infections	infection	NOUN
dti-3059	86	24	and	and	CCONJ
dti-3059	86	25	after	after	ADP
dti-3059	86	26	receiving	receive	VERB
dti-3059	86	27	the	the	DET
dti-3059	86	28	second	second	ADJ
dti-3059	86	29	dose	dose	NOUN
dti-3059	86	30	of	of	ADP
dti-3059	86	31	covishield	covishield	ADJ
dti-3059	86	32	™	™	ADJ
dti-3059	86	33	vaccine	vaccine	NOUN
dti-3059	86	34	.	.	PUNCT
dti-3059	87	1	the	the	DET
dti-3059	87	2	median	median	PROPN
dti-3059	87	3	(	(	PUNCT
dti-3059	87	4	iqr	iqr	NOUN
dti-3059	87	5	)	)	PUNCT
dti-3059	87	6	serum	serum	NOUN
dti-3059	87	7	levels	level	NOUN
dti-3059	87	8	of	of	ADP
dti-3059	87	9	sars	sar	NOUN
dti-3059	87	10	-	-	PUNCT
dti-3059	87	11	cov-2	cov-2	NOUN
dti-3059	87	12	spike	spike	ADJ
dti-3059	87	13	-	-	PUNCT
dti-3059	87	14	specific	specific	ADJ
dti-3059	87	15	total	total	ADJ
dti-3059	87	16	antibodies	antibody	NOUN
dti-3059	87	17	were	be	AUX
dti-3059	87	18	found	find	VERB
dti-3059	87	19	to	to	PART
dti-3059	87	20	be	be	AUX
dti-3059	87	21	1275	1275	NUM
dti-3059	87	22	u	u	NOUN
dti-3059	87	23	/	/	SYM
dti-3059	87	24	ml	ml	PROPN
dti-3059	87	25	(	(	PUNCT
dti-3059	87	26	650	650	NUM
dti-3059	87	27	-	-	SYM
dti-3059	87	28	2000	2000	NUM
dti-3059	87	29	u	u	NOUN
dti-3059	87	30	/	/	SYM
dti-3059	87	31	ml	ml	PROPN
dti-3059	87	32	)	)	PUNCT
dti-3059	87	33	and	and	CCONJ
dti-3059	87	34	2100	2100	NUM
dti-3059	87	35	u	u	NOUN
dti-3059	87	36	/	/	SYM
dti-3059	87	37	ml	ml	PROPN
dti-3059	87	38	(	(	PUNCT
dti-3059	87	39	13003000	13003000	NUM
dti-3059	87	40	u	u	NOUN
dti-3059	87	41	/	/	SYM
dti-3059	87	42	ml	ml	NOUN
dti-3059	87	43	)	)	PUNCT
dti-3059	87	44	in	in	ADP
dti-3059	87	45	covid-19	covid-19	PROPN
dti-3059	87	46	recovered	recover	VERB
dti-3059	87	47	patients	patient	NOUN
dti-3059	87	48	and	and	CCONJ
dti-3059	87	49	vaccinated	vaccinated	ADJ
dti-3059	87	50	individuals	individual	NOUN
dti-3059	87	51	,	,	PUNCT
dti-3059	87	52	respectively	respectively	ADV
dti-3059	87	53	.	.	PUNCT
dti-3059	88	1	the	the	DET
dti-3059	88	2	serum	serum	NOUN
dti-3059	88	3	levels	level	NOUN
dti-3059	88	4	of	of	ADP
dti-3059	88	5	total	total	ADJ
dti-3059	88	6	antibodies	antibody	NOUN
dti-3059	88	7	were	be	AUX
dti-3059	88	8	found	find	VERB
dti-3059	88	9	to	to	PART
dti-3059	88	10	be	be	AUX
dti-3059	88	11	significantly	significantly	ADV
dti-3059	88	12	(	(	PUNCT
dti-3059	88	13	p<0.001	p<0.001	X
dti-3059	88	14	)	)	PUNCT
dti-3059	88	15	higher	high	ADJ
dti-3059	88	16	in	in	ADP
dti-3059	88	17	the	the	DET
dti-3059	88	18	vaccinated	vaccinate	VERB
dti-3059	88	19	individuals	individual	NOUN
dti-3059	88	20	as	as	SCONJ
dti-3059	88	21	compared	compare	VERB
dti-3059	88	22	to	to	ADP
dti-3059	88	23	covid-19	covid-19	PROPN
dti-3059	88	24	recovered	recover	VERB
dti-3059	88	25	patients	patient	NOUN
dti-3059	88	26	(	(	PUNCT
dti-3059	88	27	fig	fig	NOUN
dti-3059	88	28	.	.	PUNCT
dti-3059	88	29	1	1	NUM
dti-3059	88	30	)	)	PUNCT
dti-3059	88	31	.	.	PUNCT
dti-3059	89	1	immunoreactivity	immunoreactivity	NOUN
dti-3059	89	2	of	of	ADP
dti-3059	89	3	peptides	peptide	NOUN
dti-3059	89	4	with	with	ADP
dti-3059	89	5	anti	anti	ADJ
dti-3059	89	6	-	-	NOUN
dti-3059	89	7	sera	sera	NOUN
dti-3059	89	8	of	of	ADP
dti-3059	89	9	vaccinated	vaccinated	ADJ
dti-3059	89	10	and	and	CCONJ
dti-3059	89	11	covid-19	covid-19	PROPN
dti-3059	89	12	recovered	recover	VERB
dti-3059	89	13	patients	patient	NOUN
dti-3059	89	14	the	the	DET
dti-3059	89	15	individual	individual	ADJ
dti-3059	89	16	peptides	peptide	NOUN
dti-3059	89	17	(	(	PUNCT
dti-3059	89	18	p1	p1	NOUN
dti-3059	89	19	,	,	PUNCT
dti-3059	89	20	p3	p3	PROPN
dti-3059	89	21	,	,	PUNCT
dti-3059	89	22	p5	p5	ADJ
dti-3059	89	23	,	,	PUNCT
dti-3059	89	24	p7	p7	ADJ
dti-3059	89	25	,	,	PUNCT
dti-3059	89	26	p9	p9	PROPN
dti-3059	89	27	,	,	PUNCT
dti-3059	89	28	and	and	CCONJ
dti-3059	89	29	p11	p11	NOUN
dti-3059	89	30	)	)	PUNCT
dti-3059	89	31	of	of	ADP
dti-3059	89	32	wild	wild	ADJ
dti-3059	89	33	-	-	PUNCT
dti-3059	89	34	type	type	NOUN
dti-3059	89	35	sars	sar	NOUN
dti-3059	89	36	-	-	PUNCT
dti-3059	89	37	cov-2	cov-2	NOUN
dti-3059	89	38	and	and	CCONJ
dti-3059	89	39	peptides	peptide	NOUN
dti-3059	89	40	(	(	PUNCT
dti-3059	89	41	p2	p2	NOUN
dti-3059	89	42	,	,	PUNCT
dti-3059	89	43	p4	p4	ADJ
dti-3059	89	44	,	,	PUNCT
dti-3059	89	45	p6	p6	PROPN
dti-3059	89	46	,	,	PUNCT
dti-3059	89	47	p8	p8	PROPN
dti-3059	89	48	,	,	PUNCT
dti-3059	89	49	p10	p10	NOUN
dti-3059	89	50	,	,	PUNCT
dti-3059	89	51	and	and	CCONJ
dti-3059	89	52	p12	p12	ADJ
dti-3059	89	53	)	)	PUNCT
dti-3059	89	54	were	be	AUX
dti-3059	89	55	coated	coat	VERB
dti-3059	89	56	in	in	ADP
dti-3059	89	57	the	the	DET
dti-3059	89	58	high	high	ADV
dti-3059	89	59	-	-	PUNCT
dti-3059	89	60	binding	bind	VERB
dti-3059	89	61	microtiter	microtiter	NOUN
dti-3059	89	62	plate	plate	NOUN
dti-3059	89	63	to	to	PART
dti-3059	89	64	assess	assess	VERB
dti-3059	89	65	the	the	DET
dti-3059	89	66	immunoreactivity	immunoreactivity	NOUN
dti-3059	89	67	with	with	ADP
dti-3059	89	68	anti	anti	ADJ
dti-3059	89	69	-	-	ADJ
dti-3059	89	70	sera	sera	NOUN
dti-3059	89	71	obtained	obtain	VERB
dti-3059	89	72	from	from	ADP
dti-3059	89	73	vaccinated	vaccinated	ADJ
dti-3059	89	74	people	people	NOUN
dti-3059	89	75	and	and	CCONJ
dti-3059	89	76	covid-19	covid-19	PROPN
dti-3059	89	77	recovered	recover	VERB
dti-3059	89	78	patients	patient	NOUN
dti-3059	89	79	.	.	PUNCT
dti-3059	90	1	the	the	DET
dti-3059	90	2	immunoreactivity	immunoreactivity	NOUN
dti-3059	90	3	of	of	ADP
dti-3059	90	4	peptides	peptide	NOUN
dti-3059	90	5	with	with	ADP
dti-3059	90	6	antibodies	antibody	NOUN
dti-3059	90	7	was	be	AUX
dti-3059	90	8	observed	observe	VERB
dti-3059	90	9	by	by	ADP
dti-3059	90	10	taking	take	VERB
dti-3059	90	11	the	the	DET
dti-3059	90	12	optical	optical	ADJ
dti-3059	90	13	density	density	NOUN
dti-3059	90	14	(	(	PUNCT
dti-3059	90	15	od	od	NOUN
dti-3059	90	16	)	)	PUNCT
dti-3059	90	17	at	at	ADP
dti-3059	90	18	592	592	NUM
dti-3059	90	19	nm	nm	NOUN
dti-3059	90	20	.	.	PUNCT
dti-3059	91	1	the	the	DET
dti-3059	91	2	difference	difference	NOUN
dti-3059	91	3	in	in	ADP
dti-3059	91	4	the	the	DET
dti-3059	91	5	od	od	PROPN
dti-3059	91	6	value	value	NOUN
dti-3059	91	7	with	with	ADP
dti-3059	91	8	corresponding	correspond	VERB
dti-3059	91	9	peptides	peptide	NOUN
dti-3059	91	10	of	of	ADP
dti-3059	91	11	wild	wild	ADJ
dti-3059	91	12	types	type	NOUN
dti-3059	91	13	and	and	CCONJ
dti-3059	91	14	mutated	mutate	VERB
dti-3059	91	15	peptides	peptide	NOUN
dti-3059	91	16	was	be	AUX
dti-3059	91	17	reported	report	VERB
dti-3059	91	18	.	.	PUNCT
dti-3059	92	1	the	the	DET
dti-3059	92	2	significant	significant	ADJ
dti-3059	92	3	(	(	PUNCT
dti-3059	92	4	p<0.05	p<0.05	NOUN
dti-3059	92	5	)	)	PUNCT
dti-3059	92	6	difference	difference	NOUN
dti-3059	92	7	in	in	ADP
dti-3059	92	8	the	the	DET
dti-3059	92	9	immunoreactivity	immunoreactivity	NOUN
dti-3059	92	10	of	of	ADP
dti-3059	92	11	peptides	peptide	NOUN
dti-3059	92	12	of	of	ADP
dti-3059	92	13	wild	wild	ADJ
dti-3059	92	14	type	type	NOUN
dti-3059	92	15	(	(	PUNCT
dti-3059	92	16	p1	p1	NOUN
dti-3059	92	17	,	,	PUNCT
dti-3059	92	18	p5	p5	ADJ
dti-3059	92	19	,	,	PUNCT
dti-3059	92	20	p7	p7	ADJ
dti-3059	92	21	)	)	PUNCT
dti-3059	92	22	with	with	ADP
dti-3059	92	23	peptides	peptide	NOUN
dti-3059	92	24	(	(	PUNCT
dti-3059	92	25	p2	p2	X
dti-3059	92	26	,	,	PUNCT
dti-3059	92	27	p6	p6	PROPN
dti-3059	92	28	,	,	PUNCT
dti-3059	92	29	p8	p8	PROPN
dti-3059	92	30	)	)	PUNCT
dti-3059	92	31	of	of	ADP
dti-3059	92	32	mutated	mutate	VERB
dti-3059	92	33	sars	sar	NOUN
dti-3059	92	34	-	-	PUNCT
dti-3059	92	35	cov-2	cov-2	NUM
dti-3059	92	36	is	be	AUX
dti-3059	92	37	reported	report	VERB
dti-3059	92	38	in	in	ADP
dti-3059	92	39	figure	figure	NOUN
dti-3059	92	40	2	2	NUM
dti-3059	92	41	.	.	PUNCT
dti-3059	93	1	as	as	SCONJ
dti-3059	93	2	compared	compare	VERB
dti-3059	93	3	to	to	ADP
dti-3059	93	4	wild	wild	ADJ
dti-3059	93	5	-	-	PUNCT
dti-3059	93	6	type	type	NOUN
dti-3059	93	7	peptide	peptide	NOUN
dti-3059	93	8	sequence	sequence	NOUN
dti-3059	93	9	(	(	PUNCT
dti-3059	93	10	p1	p1	PROPN
dti-3059	93	11	)	)	PUNCT
dti-3059	93	12	,	,	PUNCT
dti-3059	93	13	the	the	DET
dti-3059	93	14	mutated	mutate	VERB
dti-3059	93	15	peptide	peptide	NOUN
dti-3059	93	16	sequence	sequence	NOUN
dti-3059	93	17	(	(	PUNCT
dti-3059	93	18	p2	p2	PROPN
dti-3059	93	19	)	)	PUNCT
dti-3059	93	20	has	have	VERB
dti-3059	93	21	single	single	ADJ
dti-3059	93	22	amino	amino	NOUN
dti-3059	93	23	acid	acid	NOUN
dti-3059	93	24	mutation	mutation	NOUN
dti-3059	93	25	in	in	ADP
dti-3059	93	26	the	the	DET
dti-3059	93	27	rbd	rbd	NOUN
dti-3059	93	28	at	at	ADP
dti-3059	93	29	position	position	NOUN
dti-3059	93	30	417	417	NUM
dti-3059	93	31	,	,	PUNCT
dti-3059	93	32	which	which	PRON
dti-3059	93	33	significantly	significantly	ADV
dti-3059	93	34	reduced	reduce	VERB
dti-3059	93	35	the	the	DET
dti-3059	93	36	immunoreactivity	immunoreactivity	NOUN
dti-3059	93	37	with	with	ADP
dti-3059	93	38	anti	anti	ADJ
dti-3059	93	39	-	-	NOUN
dti-3059	93	40	sera	sera	NOUN
dti-3059	93	41	of	of	ADP
dti-3059	93	42	vaccinated	vaccinated	ADJ
dti-3059	93	43	people	people	NOUN
dti-3059	93	44	and	and	CCONJ
dti-3059	93	45	covid-19	covid-19	PROPN
dti-3059	93	46	recovered	recover	VERB
dti-3059	93	47	patients	patient	NOUN
dti-3059	93	48	(	(	PUNCT
dti-3059	93	49	fig	fig	NOUN
dti-3059	93	50	.	.	PUNCT
dti-3059	94	1	2a	2a	NUM
dti-3059	94	2	)	)	PUNCT
dti-3059	94	3	.	.	PUNCT
dti-3059	95	1	likewise	likewise	ADV
dti-3059	95	2	,	,	PUNCT
dti-3059	95	3	the	the	DET
dti-3059	95	4	peptide	peptide	ADJ
dti-3059	95	5	sequence	sequence	NOUN
dti-3059	95	6	(	(	PUNCT
dti-3059	95	7	p6	p6	PROPN
dti-3059	95	8	)	)	PUNCT
dti-3059	95	9	has	have	VERB
dti-3059	95	10	a	a	DET
dti-3059	95	11	single	single	ADJ
dti-3059	95	12	amino	amino	NOUN
dti-3059	95	13	acid	acid	NOUN
dti-3059	95	14	mutation	mutation	NOUN
dti-3059	95	15	at	at	ADP
dti-3059	95	16	residue	residue	NOUN
dti-3059	95	17	484	484	NUM
dti-3059	95	18	in	in	ADP
dti-3059	95	19	the	the	DET
dti-3059	95	20	rbd	rbd	NOUN
dti-3059	95	21	of	of	ADP
dti-3059	95	22	sars	sar	NOUN
dti-3059	95	23	-	-	PUNCT
dti-3059	95	24	cov-2	cov-2	NOUN
dti-3059	95	25	,	,	PUNCT
dti-3059	95	26	which	which	DET
dti-3059	95	27	significantly	significantly	ADV
dti-3059	95	28	(	(	PUNCT
dti-3059	95	29	p<0.05	p<0.05	NOUN
dti-3059	95	30	)	)	PUNCT
dti-3059	95	31	reduced	reduce	VERB
dti-3059	95	32	the	the	DET
dti-3059	95	33	immunoreactivity	immunoreactivity	NOUN
dti-3059	95	34	with	with	ADP
dti-3059	95	35	antisera	antisera	NOUN
dti-3059	95	36	of	of	ADP
dti-3059	95	37	vaccinated	vaccinated	ADJ
dti-3059	95	38	people	people	NOUN
dti-3059	95	39	and	and	CCONJ
dti-3059	95	40	covid-19	covid-19	PROPN
dti-3059	95	41	recovered	recover	VERB
dti-3059	95	42	patients	patient	NOUN
dti-3059	95	43	(	(	PUNCT
dti-3059	95	44	fig	fig	NOUN
dti-3059	95	45	.	.	PUNCT
dti-3059	95	46	2b	2b	NUM
dti-3059	95	47	)	)	PUNCT
dti-3059	95	48	.	.	PUNCT
dti-3059	96	1	similar	similar	ADJ
dti-3059	96	2	to	to	ADP
dti-3059	96	3	the	the	DET
dti-3059	96	4	mutated	mutate	VERB
dti-3059	96	5	peptide	peptide	NOUN
dti-3059	96	6	sequences	sequence	NOUN
dti-3059	96	7	p2	p2	NOUN
dti-3059	96	8	and	and	CCONJ
dti-3059	96	9	p6	p6	PROPN
dti-3059	96	10	of	of	ADP
dti-3059	96	11	sars	sar	NOUN
dti-3059	96	12	-	-	PUNCT
dti-3059	96	13	cov-2	cov-2	PART
dti-3059	96	14	variants	variant	NOUN
dti-3059	96	15	,	,	PUNCT
dti-3059	96	16	the	the	DET
dti-3059	96	17	peptide	peptide	ADJ
dti-3059	96	18	sequence	sequence	NOUN
dti-3059	96	19	(	(	PUNCT
dti-3059	96	20	p8	p8	PROPN
dti-3059	96	21	)	)	PUNCT
dti-3059	96	22	has	have	VERB
dti-3059	96	23	single	single	ADJ
dti-3059	96	24	amino	amino	NOUN
dti-3059	96	25	acid	acid	NOUN
dti-3059	96	26	mutation	mutation	NOUN
dti-3059	96	27	in	in	ADP
dti-3059	96	28	the	the	DET
dti-3059	96	29	rbd	rbd	NOUN
dti-3059	96	30	at	at	ADP
dti-3059	96	31	the	the	DET
dti-3059	96	32	residue	residue	NOUN
dti-3059	96	33	501	501	NUM
dti-3059	96	34	.	.	PUNCT
dti-3059	97	1	this	this	DET
dti-3059	97	2	mutation	mutation	NOUN
dti-3059	97	3	also	also	ADV
dti-3059	97	4	reduced	reduce	VERB
dti-3059	97	5	the	the	DET
dti-3059	97	6	immunoreactivity	immunoreactivity	NOUN
dti-3059	97	7	with	with	ADP
dti-3059	97	8	anti	anti	ADJ
dti-3059	97	9	-	-	NOUN
dti-3059	97	10	sera	sera	NOUN
dti-3059	97	11	of	of	ADP
dti-3059	97	12	the	the	DET
dti-3059	97	13	vaccinated	vaccinated	ADJ
dti-3059	97	14	people	people	NOUN
dti-3059	97	15	and	and	CCONJ
dti-3059	97	16	covid-19	covid-19	PROPN
dti-3059	97	17	recovered	recover	VERB
dti-3059	97	18	patients	patient	NOUN
dti-3059	97	19	(	(	PUNCT
dti-3059	97	20	fig	fig	NOUN
dti-3059	97	21	.	.	PUNCT
dti-3059	97	22	2c	2c	NUM
dti-3059	97	23	)	)	PUNCT
dti-3059	97	24	.	.	PUNCT
dti-3059	98	1	finally	finally	ADV
dti-3059	98	2	,	,	PUNCT
dti-3059	98	3	we	we	PRON
dti-3059	98	4	have	have	AUX
dti-3059	98	5	tested	test	VERB
dti-3059	98	6	the	the	DET
dti-3059	98	7	immunoreactivity	immunoreactivity	NOUN
dti-3059	98	8	of	of	ADP
dti-3059	98	9	peptide	peptide	ADJ
dti-3059	98	10	pools	pool	NOUN
dti-3059	98	11	(	(	PUNCT
dti-3059	98	12	p1	p1	NOUN
dti-3059	98	13	,	,	PUNCT
dti-3059	98	14	p5	p5	ADJ
dti-3059	98	15	,	,	PUNCT
dti-3059	98	16	and	and	CCONJ
dti-3059	98	17	p7	p7	ADJ
dti-3059	98	18	)	)	PUNCT
dti-3059	98	19	of	of	ADP
dti-3059	98	20	wild	wild	ADJ
dti-3059	98	21	-	-	PUNCT
dti-3059	98	22	type	type	NOUN
dti-3059	98	23	sars	sar	NOUN
dti-3059	98	24	-	-	PUNCT
dti-3059	98	25	cov-2	cov-2	PART
dti-3059	98	26	and	and	CCONJ
dti-3059	98	27	peptide	peptide	NOUN
dti-3059	98	28	pools	pool	NOUN
dti-3059	98	29	(	(	PUNCT
dti-3059	98	30	p2	p2	X
dti-3059	98	31	,	,	PUNCT
dti-3059	98	32	p6	p6	PROPN
dti-3059	98	33	,	,	PUNCT
dti-3059	98	34	and	and	CCONJ
dti-3059	98	35	p8	p8	PROPN
dti-3059	98	36	)	)	PUNCT
dti-3059	98	37	of	of	ADP
dti-3059	98	38	sars	sar	NOUN
dti-3059	98	39	-	-	PUNCT
dti-3059	98	40	cov-2	cov-2	NOUN
dti-3059	98	41	variants	variant	NOUN
dti-3059	98	42	with	with	ADP
dti-3059	98	43	the	the	DET
dti-3059	98	44	anti	anti	NOUN
dti-3059	98	45	-	-	NOUN
dti-3059	98	46	sera	sera	NOUN
dti-3059	98	47	of	of	ADP
dti-3059	98	48	vaccinated	vaccinated	ADJ
dti-3059	98	49	people	people	NOUN
dti-3059	98	50	and	and	CCONJ
dti-3059	98	51	covid-19	covid-19	PROPN
dti-3059	98	52	recovered	recover	VERB
dti-3059	98	53	patients	patient	NOUN
dti-3059	98	54	.	.	PUNCT
dti-3059	99	1	our	our	PRON
dti-3059	99	2	finding	finding	NOUN
dti-3059	99	3	showed	show	VERB
dti-3059	99	4	a	a	DET
dti-3059	99	5	significant	significant	ADJ
dti-3059	99	6	(	(	PUNCT
dti-3059	99	7	p<0.05	p<0.05	NOUN
dti-3059	99	8	)	)	PUNCT
dti-3059	99	9	reduction	reduction	NOUN
dti-3059	99	10	in	in	ADP
dti-3059	99	11	immunoreactivity	immunoreactivity	NOUN
dti-3059	99	12	of	of	ADP
dti-3059	99	13	anti	anti	ADJ
dti-3059	99	14	-	-	NOUN
dti-3059	99	15	sera	sera	NOUN
dti-3059	99	16	of	of	ADP
dti-3059	99	17	vaccinated	vaccinated	ADJ
dti-3059	99	18	and	and	CCONJ
dti-3059	99	19	covid-19	covid-19	PROPN
dti-3059	99	20	recovered	recover	VERB
dti-3059	99	21	patients	patient	NOUN
dti-3059	99	22	with	with	ADP
dti-3059	99	23	peptide	peptide	ADJ
dti-3059	99	24	pools	pool	NOUN
dti-3059	99	25	of	of	ADP
dti-3059	99	26	sarc	sarc	NOUN
dti-3059	99	27	-	-	PUNCT
dti-3059	99	28	cov-2	cov-2	NOUN
dti-3059	99	29	variants	variant	NOUN
dti-3059	99	30	(	(	PUNCT
dti-3059	99	31	fig	fig	NOUN
dti-3059	99	32	.	.	PUNCT
dti-3059	100	1	2d	2d	NOUN
dti-3059	100	2	)	)	PUNCT
dti-3059	100	3	.	.	PUNCT
dti-3059	101	1	the	the	DET
dti-3059	101	2	amino	amino	NOUN
dti-3059	101	3	acid	acid	NOUN
dti-3059	101	4	mutations	mutation	NOUN
dti-3059	101	5	in	in	ADP
dti-3059	101	6	the	the	DET
dti-3059	101	7	rbd	rbd	NOUN
dti-3059	101	8	of	of	ADP
dti-3059	101	9	sarscov-2	sarscov-2	NUM
dti-3059	101	10	variants	variant	NOUN
dti-3059	101	11	at	at	ADP
dti-3059	101	12	residues	residue	NOUN
dti-3059	101	13	477	477	NUM
dti-3059	101	14	,	,	PUNCT
dti-3059	101	15	478	478	NUM
dti-3059	101	16	for	for	ADP
dti-3059	101	17	peptide	peptide	ADJ
dti-3059	101	18	sequence	sequence	NOUN
dti-3059	101	19	p4	p4	ADJ
dti-3059	101	20	and	and	CCONJ
dti-3059	101	21	at	at	ADP
dti-3059	101	22	residues	residue	NOUN
dti-3059	101	23	400	400	NUM
dti-3059	101	24	,	,	PUNCT
dti-3059	101	25	446	446	NUM
dti-3059	101	26	for	for	ADP
dti-3059	101	27	peptide	peptide	ADJ
dti-3059	101	28	sequence	sequence	NOUN
dti-3059	101	29	p10	p10	NOUN
dti-3059	101	30	did	do	AUX
dti-3059	101	31	not	not	PART
dti-3059	101	32	reduce	reduce	VERB
dti-3059	101	33	the	the	DET
dti-3059	101	34	immunoreactivity	immunoreactivity	NOUN
dti-3059	101	35	with	with	ADP
dti-3059	101	36	anti	anti	ADJ
dti-3059	101	37	-	-	NOUN
dti-3059	101	38	sera	sera	NOUN
dti-3059	101	39	of	of	ADP
dti-3059	101	40	vaccinated	vaccinated	ADJ
dti-3059	101	41	people	people	NOUN
dti-3059	101	42	and	and	CCONJ
dti-3059	101	43	covid-19	covid-19	PROPN
dti-3059	101	44	recovered	recover	VERB
dti-3059	101	45	patients	patient	NOUN
dti-3059	101	46	(	(	PUNCT
dti-3059	101	47	supplementary	supplementary	ADJ
dti-3059	101	48	figure	figure	NOUN
dti-3059	101	49	1	1	NUM
dti-3059	101	50	,	,	PUNCT
dti-3059	101	51	a	a	PRON
dti-3059	101	52	and	and	CCONJ
dti-3059	101	53	b	b	NOUN
dti-3059	101	54	)	)	PUNCT
dti-3059	101	55	.	.	PUNCT
dti-3059	102	1	however	however	ADV
dti-3059	102	2	,	,	PUNCT
dti-3059	102	3	the	the	DET
dti-3059	102	4	mutated	mutate	VERB
dti-3059	102	5	peptide	peptide	NOUN
dti-3059	102	6	sequence	sequence	NOUN
dti-3059	102	7	(	(	PUNCT
dti-3059	102	8	p12	p12	NOUN
dti-3059	102	9	)	)	PUNCT
dti-3059	102	10	of	of	ADP
dti-3059	102	11	sars	sar	NOUN
dti-3059	102	12	-	-	PUNCT
dti-3059	102	13	cov-2	cov-2	PART
dti-3059	102	14	variants	variant	NOUN
dti-3059	102	15	has	have	VERB
dti-3059	102	16	five	five	NUM
dti-3059	102	17	amino	amino	NOUN
dti-3059	102	18	acid	acid	NOUN
dti-3059	102	19	mutations	mutation	NOUN
dti-3059	102	20	at	at	ADP
dti-3059	102	21	residues	residue	NOUN
dti-3059	102	22	493	493	NUM
dti-3059	102	23	,	,	PUNCT
dti-3059	102	24	496	496	NUM
dti-3059	102	25	,	,	PUNCT
dti-3059	102	26	498	498	NUM
dti-3059	102	27	,	,	PUNCT
dti-3059	102	28	501	501	NUM
dti-3059	102	29	,	,	PUNCT
dti-3059	102	30	and	and	CCONJ
dti-3059	102	31	505	505	NUM
dti-3059	102	32	,	,	PUNCT
dti-3059	102	33	which	which	PRON
dti-3059	102	34	reduced	reduce	VERB
dti-3059	102	35	the	the	DET
dti-3059	102	36	table	table	NOUN
dti-3059	102	37	2	2	NUM
dti-3059	102	38	clinical	clinical	ADJ
dti-3059	102	39	and	and	CCONJ
dti-3059	102	40	demographic	demographic	ADJ
dti-3059	102	41	details	detail	NOUN
dti-3059	102	42	of	of	ADP
dti-3059	102	43	covid-19	covid-19	PROPN
dti-3059	102	44	recovered	recover	VERB
dti-3059	102	45	patients	patient	NOUN
dti-3059	102	46	and	and	CCONJ
dti-3059	102	47	individuals	individual	NOUN
dti-3059	102	48	who	who	PRON
dti-3059	102	49	have	have	AUX
dti-3059	102	50	received	receive	VERB
dti-3059	102	51	both	both	DET
dti-3059	102	52	doses	dose	NOUN
dti-3059	102	53	of	of	ADP
dti-3059	102	54	covishield	covishield	NOUN
dti-3059	102	55	™	™	PROPN
dti-3059	102	56	characteristics	characteristic	NOUN
dti-3059	102	57	covid-19	covid-19	PROPN
dti-3059	102	58	recovered	recover	VERB
dti-3059	102	59	patients	patient	NOUN
dti-3059	102	60	(	(	PUNCT
dti-3059	102	61	n	n	NOUN
dti-3059	102	62	=	=	SYM
dti-3059	102	63	30	30	NUM
dti-3059	102	64	)	)	PUNCT
dti-3059	102	65	individuals	individual	NOUN
dti-3059	102	66	vaccinated	vaccinate	VERB
dti-3059	102	67	with	with	ADP
dti-3059	102	68	both	both	DET
dti-3059	102	69	doses	dose	NOUN
dti-3059	102	70	of	of	ADP
dti-3059	102	71	covishield	covishield	NOUN
dti-3059	102	72	™	™	PROPN
dti-3059	102	73	(	(	PUNCT
dti-3059	102	74	n	n	NOUN
dti-3059	102	75	=	=	SYM
dti-3059	102	76	30	30	NUM
dti-3059	102	77	)	)	PUNCT
dti-3059	102	78	age	age	NOUN
dti-3059	102	79	 	 	SPACE
dti-3059	102	80	median	median	PROPN
dti-3059	102	81	(	(	PUNCT
dti-3059	102	82	iqr	iqr	NOUN
dti-3059	102	83	)	)	PUNCT
dti-3059	102	84	 	 	SPACE
dti-3059	103	1	<	<	X
dti-3059	103	2	65	65	NUM
dti-3059	103	3	years	year	NOUN
dti-3059	103	4	(	(	PUNCT
dti-3059	103	5	%	%	INTJ
dti-3059	103	6	)	)	PUNCT
dti-3059	103	7	 	 	SPACE
dti-3059	103	8	65	65	NUM
dti-3059	103	9	+	+	NUM
dti-3059	103	10	years	year	NOUN
dti-3059	103	11	(	(	PUNCT
dti-3059	103	12	%	%	INTJ
dti-3059	103	13	)	)	PUNCT
dti-3059	103	14	48.5	48.5	NUM
dti-3059	103	15	(	(	PUNCT
dti-3059	103	16	23	23	NUM
dti-3059	103	17	-	-	SYM
dti-3059	103	18	76	76	NUM
dti-3059	103	19	)	)	PUNCT
dti-3059	103	20	21(70	21(70	NUM
dti-3059	103	21	)	)	PUNCT
dti-3059	103	22	9(30	9(30	NUM
dti-3059	103	23	)	)	PUNCT
dti-3059	103	24	45(18	45(18	NOUN
dti-3059	103	25	-	-	PUNCT
dti-3059	103	26	74	74	NUM
dti-3059	103	27	)	)	PUNCT
dti-3059	103	28	18	18	NUM
dti-3059	103	29	(	(	PUNCT
dti-3059	103	30	60	60	NUM
dti-3059	103	31	)	)	PUNCT
dti-3059	103	32	12	12	NUM
dti-3059	103	33	(	(	PUNCT
dti-3059	103	34	40	40	NUM
dti-3059	103	35	)	)	PUNCT
dti-3059	103	36	female	female	NOUN
dti-3059	103	37	(	(	PUNCT
dti-3059	103	38	%	%	INTJ
dti-3059	103	39	)	)	PUNCT
dti-3059	103	40	10(33.33	10(33.33	NUM
dti-3059	103	41	)	)	PUNCT
dti-3059	103	42	12	12	NUM
dti-3059	103	43	(	(	PUNCT
dti-3059	103	44	40	40	NUM
dti-3059	103	45	)	)	PUNCT
dti-3059	103	46	severity	severity	NOUN
dti-3059	103	47	 	 	SPACE
dti-3059	103	48	severe	severe	ADJ
dti-3059	103	49	(	(	PUNCT
dti-3059	103	50	%	%	INTJ
dti-3059	103	51	)	)	PUNCT
dti-3059	103	52	 	 	SPACE
dti-3059	103	53	mild	mild	ADJ
dti-3059	103	54	(	(	PUNCT
dti-3059	103	55	%	%	NOUN
dti-3059	103	56	)	)	PUNCT
dti-3059	103	57	13(43.33	13(43.33	NUM
dti-3059	103	58	)	)	PUNCT
dti-3059	103	59	17(66.67	17(66.67	NUM
dti-3059	103	60	)	)	PUNCT
dti-3059	103	61	na	na	PART
dti-3059	103	62	na	na	AUX
dti-3059	103	63	hospitalized	hospitalize	VERB
dti-3059	103	64	,	,	PUNCT
dti-3059	103	65	no	no	DET
dti-3059	103	66	icu	icu	PROPN
dti-3059	103	67	(	(	PUNCT
dti-3059	103	68	%	%	INTJ
dti-3059	103	69	)	)	PUNCT
dti-3059	103	70	hospitalized	hospitalize	VERB
dti-3059	103	71	,	,	PUNCT
dti-3059	103	72	required	require	VERB
dti-3059	103	73	icu	icu	PROPN
dti-3059	103	74	(	(	PUNCT
dti-3059	103	75	%	%	INTJ
dti-3059	103	76	)	)	PUNCT
dti-3059	103	77	died	die	VERB
dti-3059	103	78	due	due	ADP
dti-3059	103	79	to	to	ADP
dti-3059	103	80	covid-19	covid-19	PROPN
dti-3059	103	81	(	(	PUNCT
dti-3059	103	82	%	%	INTJ
dti-3059	103	83	)	)	PUNCT
dti-3059	103	84	17	17	NUM
dti-3059	103	85	(	(	PUNCT
dti-3059	103	86	66.67	66.67	NUM
dti-3059	103	87	)	)	PUNCT
dti-3059	103	88	13(43.33	13(43.33	NUM
dti-3059	103	89	)	)	PUNCT
dti-3059	103	90	0(0	0(0	NUM
dti-3059	103	91	)	)	PUNCT
dti-3059	104	1	na	na	PART
dti-3059	104	2	na	na	AUX
dti-3059	104	3	na	na	AUX
dti-3059	104	4	preexisting	preexist	VERB
dti-3059	104	5	conditions	condition	NOUN
dti-3059	104	6	 	 	SPACE
dti-3059	104	7	no	no	DET
dti-3059	104	8	underlying	underlie	VERB
dti-3059	104	9	disease	disease	NOUN
dti-3059	104	10	 	 	SPACE
dti-3059	104	11	hypertension	hypertension	NOUN
dti-3059	104	12	 	 	SPACE
dti-3059	104	13	diabetes	diabetes	NOUN
dti-3059	104	14	 	 	SPACE
dti-3059	104	15	obesity	obesity	NOUN
dti-3059	104	16	 	 	SPACE
dti-3059	104	17	hypothyroidism	hypothyroidism	NOUN
dti-3059	104	18	11(36.67	11(36.67	NUM
dti-3059	104	19	)	)	PUNCT
dti-3059	104	20	2(6.67	2(6.67	NUM
dti-3059	104	21	)	)	PUNCT
dti-3059	104	22	7(23.33	7(23.33	NUM
dti-3059	104	23	)	)	PUNCT
dti-3059	104	24	8(26.67	8(26.67	PROPN
dti-3059	104	25	)	)	PUNCT
dti-3059	104	26	2(6.67	2(6.67	NUM
dti-3059	104	27	)	)	PUNCT
dti-3059	104	28	24	24	NUM
dti-3059	104	29	(	(	PUNCT
dti-3059	104	30	80	80	NUM
dti-3059	104	31	)	)	SYM
dti-3059	104	32	2	2	NUM
dti-3059	104	33	(	(	PUNCT
dti-3059	104	34	6.67	6.67	NUM
dti-3059	104	35	)	)	PUNCT
dti-3059	104	36	1	1	NUM
dti-3059	104	37	(	(	PUNCT
dti-3059	104	38	3.33	3.33	NUM
dti-3059	104	39	)	)	PUNCT
dti-3059	104	40	2	2	NUM
dti-3059	104	41	(	(	PUNCT
dti-3059	104	42	6.67	6.67	NUM
dti-3059	104	43	)	)	PUNCT
dti-3059	104	44	0	0	NUM
dti-3059	104	45	icu	icu	NOUN
dti-3059	104	46	=	=	PUNCT
dti-3059	104	47	intensive	intensive	ADJ
dti-3059	104	48	care	care	NOUN
dti-3059	104	49	unit	unit	NOUN
dti-3059	104	50	;	;	PUNCT
dti-3059	104	51	iqr	iqr	PROPN
dti-3059	104	52	,	,	PUNCT
dti-3059	104	53	interquartile	interquartile	ADJ
dti-3059	104	54	range	range	NOUN
dti-3059	104	55	.	.	PUNCT
dti-3059	105	1	figure	figure	VERB
dti-3059	105	2	1	1	NUM
dti-3059	105	3	serum	serum	NOUN
dti-3059	105	4	levels	level	NOUN
dti-3059	105	5	of	of	ADP
dti-3059	105	6	sars	sar	NOUN
dti-3059	105	7	-	-	PUNCT
dti-3059	105	8	cov-2	cov-2	NOUN
dti-3059	105	9	spike	spike	ADJ
dti-3059	105	10	protein	protein	NOUN
dti-3059	105	11	-	-	PUNCT
dti-3059	105	12	specific	specific	ADJ
dti-3059	105	13	total	total	ADJ
dti-3059	105	14	immunoglobulins	immunoglobulin	NOUN
dti-3059	105	15	(	(	PUNCT
dti-3059	105	16	ig	ig	NOUN
dti-3059	105	17	)	)	PUNCT
dti-3059	105	18	within	within	ADP
dti-3059	105	19	3	3	NUM
dti-3059	105	20	-	-	SYM
dti-3059	105	21	4	4	NUM
dti-3059	105	22	weeks	week	NOUN
dti-3059	105	23	of	of	ADP
dti-3059	105	24	recovery	recovery	NOUN
dti-3059	105	25	from	from	ADP
dti-3059	105	26	sars	sar	NOUN
dti-3059	105	27	-	-	PUNCT
dti-3059	105	28	cov-2	cov-2	NOUN
dti-3059	105	29	infections	infection	NOUN
dti-3059	105	30	from	from	ADP
dti-3059	105	31	the	the	DET
dti-3059	105	32	hospital	hospital	NOUN
dti-3059	105	33	(	(	PUNCT
dti-3059	105	34	n	n	NOUN
dti-3059	105	35	=	=	SYM
dti-3059	105	36	30	30	NUM
dti-3059	105	37	)	)	PUNCT
dti-3059	105	38	and	and	CCONJ
dti-3059	105	39	3	3	NUM
dti-3059	105	40	-	-	SYM
dti-3059	105	41	4	4	NUM
dti-3059	105	42	weeks	week	NOUN
dti-3059	105	43	after	after	ADP
dti-3059	105	44	receiving	receive	VERB
dti-3059	105	45	the	the	DET
dti-3059	105	46	second	second	ADJ
dti-3059	105	47	dose	dose	NOUN
dti-3059	105	48	of	of	ADP
dti-3059	105	49	covishield	covishield	ADJ
dti-3059	105	50	™	™	ADJ
dti-3059	105	51	vaccine	vaccine	NOUN
dti-3059	105	52	.	.	PUNCT
dti-3059	106	1	sars	sar	NOUN
dti-3059	106	2	-	-	PUNCT
dti-3059	106	3	cov-2	cov-2	PART
dti-3059	106	4	variants	variant	NOUN
dti-3059	106	5	and	and	CCONJ
dti-3059	106	6	immune	immune	ADJ
dti-3059	106	7	escape24	escape24	NOUN
dti-3059	107	1	©	©	ADP
dti-3059	107	2	2024	2024	NUM
dti-3059	108	1	the	the	DET
dti-3059	108	2	authors	author	NOUN
dti-3059	108	3	.	.	PUNCT
dti-3059	109	1	drug	drug	NOUN
dti-3059	109	2	target	target	NOUN
dti-3059	109	3	insights	insight	NOUN
dti-3059	109	4	issn	issn	VERB
dti-3059	109	5	1177	1177	NUM
dti-3059	109	6	-	-	SYM
dti-3059	109	7	3928	3928	NUM
dti-3059	109	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	VERB
dti-3059	109	9	immunoreactivity	immunoreactivity	NOUN
dti-3059	109	10	with	with	ADP
dti-3059	109	11	anti	anti	ADJ
dti-3059	109	12	-	-	NOUN
dti-3059	109	13	sera	sera	NOUN
dti-3059	109	14	of	of	ADP
dti-3059	109	15	vaccinated	vaccinated	ADJ
dti-3059	109	16	people	people	NOUN
dti-3059	109	17	and	and	CCONJ
dti-3059	109	18	covid-19	covid-19	PROPN
dti-3059	109	19	recovered	recover	VERB
dti-3059	109	20	patients	patient	NOUN
dti-3059	109	21	.	.	PUNCT
dti-3059	110	1	but	but	CCONJ
dti-3059	110	2	,	,	PUNCT
dti-3059	110	3	it	it	PRON
dti-3059	110	4	was	be	AUX
dti-3059	110	5	found	find	VERB
dti-3059	110	6	to	to	PART
dti-3059	110	7	be	be	AUX
dti-3059	110	8	comparable	comparable	ADJ
dti-3059	110	9	(	(	PUNCT
dti-3059	110	10	p>0.05	p>0.05	NOUN
dti-3059	110	11	)	)	PUNCT
dti-3059	110	12	(	(	PUNCT
dti-3059	110	13	supplementary	supplementary	ADJ
dti-3059	110	14	figure	figure	NOUN
dti-3059	110	15	1c	1c	NOUN
dti-3059	110	16	)	)	PUNCT
dti-3059	110	17	.	.	PUNCT
dti-3059	111	1	finally	finally	ADV
dti-3059	111	2	,	,	PUNCT
dti-3059	111	3	our	our	PRON
dti-3059	111	4	study	study	NOUN
dti-3059	111	5	reported	report	VERB
dti-3059	111	6	that	that	SCONJ
dti-3059	111	7	the	the	DET
dti-3059	111	8	mutations	mutation	NOUN
dti-3059	111	9	in	in	ADP
dti-3059	111	10	the	the	DET
dti-3059	111	11	rbd	rbd	NOUN
dti-3059	111	12	at	at	ADP
dti-3059	111	13	the	the	DET
dti-3059	111	14	residues	residue	NOUN
dti-3059	111	15	k417	k417	PROPN
dti-3059	111	16	,	,	PUNCT
dti-3059	111	17	e484	e484	PROPN
dti-3059	111	18	,	,	PUNCT
dti-3059	111	19	and	and	CCONJ
dti-3059	111	20	n501	n501	PROPN
dti-3059	111	21	in	in	ADP
dti-3059	111	22	sars	sars	PROPN
dti-3059	111	23	-	-	PUNCT
dti-3059	111	24	cov-2	cov-2	PART
dti-3059	111	25	variants	variant	NOUN
dti-3059	111	26	have	have	AUX
dti-3059	111	27	been	be	AUX
dti-3059	111	28	associated	associate	VERB
dti-3059	111	29	with	with	ADP
dti-3059	111	30	reduced	reduced	ADJ
dti-3059	111	31	immunoreactivity	immunoreactivity	NOUN
dti-3059	111	32	with	with	ADP
dti-3059	111	33	anti	anti	ADJ
dti-3059	111	34	-	-	NOUN
dti-3059	111	35	sera	sera	NOUN
dti-3059	111	36	of	of	ADP
dti-3059	111	37	vaccinated	vaccinated	ADJ
dti-3059	111	38	people	people	NOUN
dti-3059	111	39	and	and	CCONJ
dti-3059	111	40	covid-19	covid-19	PROPN
dti-3059	111	41	recovered	recover	VERB
dti-3059	111	42	patients	patient	NOUN
dti-3059	111	43	(	(	PUNCT
dti-3059	111	44	fig	fig	NOUN
dti-3059	111	45	.	.	PUNCT
dti-3059	111	46	2	2	NUM
dti-3059	111	47	)	)	PUNCT
dti-3059	111	48	.	.	PUNCT
dti-3059	112	1	the	the	DET
dti-3059	112	2	amino	amino	NOUN
dti-3059	112	3	acid	acid	NOUN
dti-3059	112	4	substitutions	substitution	NOUN
dti-3059	112	5	at	at	ADP
dti-3059	112	6	k417	k417	PROPN
dti-3059	112	7	,	,	PUNCT
dti-3059	112	8	e484	e484	PROPN
dti-3059	112	9	,	,	PUNCT
dti-3059	112	10	and	and	CCONJ
dti-3059	112	11	n501	n501	NUM
dti-3059	112	12	residues	residue	NOUN
dti-3059	112	13	significantly	significantly	ADV
dti-3059	112	14	reduced	reduce	VERB
dti-3059	112	15	antibody	antibody	NOUN
dti-3059	112	16	binding	bind	VERB
dti-3059	112	17	with	with	ADP
dti-3059	112	18	polyclonal	polyclonal	ADJ
dti-3059	112	19	serum	serum	NOUN
dti-3059	112	20	antibodies	antibody	NOUN
dti-3059	112	21	obtained	obtain	VERB
dti-3059	112	22	from	from	ADP
dti-3059	112	23	people	people	NOUN
dti-3059	112	24	who	who	PRON
dti-3059	112	25	have	have	AUX
dti-3059	112	26	recovered	recover	VERB
dti-3059	112	27	from	from	ADP
dti-3059	112	28	covid-19	covid-19	PROPN
dti-3059	112	29	and	and	CCONJ
dti-3059	112	30	also	also	ADV
dti-3059	112	31	vaccinated	vaccinate	VERB
dti-3059	112	32	with	with	ADP
dti-3059	112	33	chadox1	chadox1	ADJ
dti-3059	113	1	ncov-19	ncov-19	ADJ
dti-3059	113	2	vaccines	vaccine	NOUN
dti-3059	113	3	.	.	PUNCT
dti-3059	114	1	the	the	DET
dti-3059	114	2	findings	finding	NOUN
dti-3059	114	3	indicate	indicate	VERB
dti-3059	114	4	that	that	SCONJ
dti-3059	114	5	vaccination	vaccination	NOUN
dti-3059	114	6	may	may	AUX
dti-3059	114	7	result	result	VERB
dti-3059	114	8	in	in	ADP
dti-3059	114	9	a	a	DET
dti-3059	114	10	decreased	decrease	VERB
dti-3059	114	11	long	long	ADJ
dti-3059	114	12	-	-	PUNCT
dti-3059	114	13	term	term	NOUN
dti-3059	114	14	antibody	antibody	NOUN
dti-3059	114	15	response	response	NOUN
dti-3059	114	16	to	to	ADP
dti-3059	114	17	beta	beta	NOUN
dti-3059	114	18	and	and	CCONJ
dti-3059	114	19	omicron	omicron	PROPN
dti-3059	114	20	rbds	rbds	NOUN
dti-3059	114	21	,	,	PUNCT
dti-3059	114	22	highlighting	highlight	VERB
dti-3059	114	23	the	the	DET
dti-3059	114	24	challenges	challenge	NOUN
dti-3059	114	25	in	in	ADP
dti-3059	114	26	neutralizing	neutralize	VERB
dti-3059	114	27	these	these	DET
dti-3059	114	28	variants	variant	NOUN
dti-3059	114	29	with	with	ADP
dti-3059	114	30	the	the	DET
dti-3059	114	31	existing	exist	VERB
dti-3059	114	32	antibody	antibody	NOUN
dti-3059	114	33	response	response	NOUN
dti-3059	114	34	induced	induce	VERB
dti-3059	114	35	by	by	ADP
dti-3059	114	36	vaccination	vaccination	NOUN
dti-3059	114	37	.	.	PUNCT
dti-3059	115	1	discussion	discussion	NOUN
dti-3059	115	2	we	we	PRON
dti-3059	115	3	analyzed	analyze	VERB
dti-3059	115	4	the	the	DET
dti-3059	115	5	antibody	antibody	NOUN
dti-3059	115	6	response	response	NOUN
dti-3059	115	7	against	against	ADP
dti-3059	115	8	sars	sar	NOUN
dti-3059	115	9	-	-	PUNCT
dti-3059	115	10	cov-2	cov-2	NOUN
dti-3059	115	11	spike	spike	ADJ
dti-3059	115	12	protein	protein	NOUN
dti-3059	115	13	using	use	VERB
dti-3059	115	14	blood	blood	NOUN
dti-3059	115	15	samples	sample	NOUN
dti-3059	115	16	collected	collect	VERB
dti-3059	115	17	at	at	ADV
dti-3059	115	18	least	least	ADJ
dti-3059	115	19	3	3	NUM
dti-3059	115	20	-	-	SYM
dti-3059	115	21	4	4	NUM
dti-3059	115	22	weeks	week	NOUN
dti-3059	115	23	after	after	ADP
dti-3059	115	24	recovery	recovery	NOUN
dti-3059	115	25	from	from	ADP
dti-3059	115	26	nonvaccinated	nonvaccinate	VERB
dti-3059	115	27	individuals	individual	NOUN
dti-3059	115	28	who	who	PRON
dti-3059	115	29	had	have	AUX
dti-3059	115	30	recovered	recover	VERB
dti-3059	115	31	from	from	ADP
dti-3059	115	32	covid-19	covid-19	PROPN
dti-3059	115	33	.	.	PUNCT
dti-3059	116	1	the	the	DET
dti-3059	116	2	serum	serum	NOUN
dti-3059	116	3	levels	level	NOUN
dti-3059	116	4	of	of	ADP
dti-3059	116	5	total	total	ADJ
dti-3059	116	6	antibody	antibody	NOUN
dti-3059	116	7	were	be	AUX
dti-3059	116	8	compared	compare	VERB
dti-3059	116	9	with	with	ADP
dti-3059	116	10	individuals	individual	NOUN
dti-3059	116	11	who	who	PRON
dti-3059	116	12	had	have	AUX
dti-3059	116	13	received	receive	VERB
dti-3059	116	14	both	both	DET
dti-3059	116	15	doses	dose	NOUN
dti-3059	116	16	of	of	ADP
dti-3059	116	17	covishield	covishield	NOUN
dti-3059	116	18	™	™	PROPN
dti-3059	116	19	.	.	PUNCT
dti-3059	117	1	the	the	DET
dti-3059	117	2	findings	finding	NOUN
dti-3059	117	3	of	of	ADP
dti-3059	117	4	the	the	DET
dti-3059	117	5	present	present	ADJ
dti-3059	117	6	study	study	NOUN
dti-3059	117	7	showed	show	VERB
dti-3059	117	8	the	the	DET
dti-3059	117	9	significant	significant	ADJ
dti-3059	117	10	rise	rise	NOUN
dti-3059	117	11	in	in	ADP
dti-3059	117	12	the	the	DET
dti-3059	117	13	levels	level	NOUN
dti-3059	117	14	of	of	ADP
dti-3059	117	15	total	total	ADJ
dti-3059	117	16	antibody	antibody	NOUN
dti-3059	117	17	after	after	ADP
dti-3059	117	18	3	3	NUM
dti-3059	117	19	-	-	SYM
dti-3059	117	20	4	4	NUM
dti-3059	117	21	weeks	week	NOUN
dti-3059	117	22	of	of	ADP
dti-3059	117	23	recovery	recovery	NOUN
dti-3059	117	24	from	from	ADP
dti-3059	117	25	sars	sar	NOUN
dti-3059	117	26	-	-	PUNCT
dti-3059	117	27	cov-2	cov-2	PART
dti-3059	117	28	infections	infection	NOUN
dti-3059	117	29	and	and	CCONJ
dti-3059	117	30	after	after	ADP
dti-3059	117	31	receiving	receive	VERB
dti-3059	117	32	both	both	DET
dti-3059	117	33	doses	dose	NOUN
dti-3059	117	34	of	of	ADP
dti-3059	117	35	covishield	covishield	NOUN
dti-3059	117	36	™	™	PROPN
dti-3059	117	37	(	(	PUNCT
dti-3059	117	38	chadox1	chadox1	ADJ
dti-3059	117	39	ncov19	ncov19	NOUN
dti-3059	117	40	coronavirus	coronavirus	NOUN
dti-3059	117	41	vaccines	vaccine	NOUN
dti-3059	117	42	)	)	PUNCT
dti-3059	117	43	.	.	PUNCT
dti-3059	118	1	the	the	DET
dti-3059	118	2	raised	raise	VERB
dti-3059	118	3	level	level	NOUN
dti-3059	118	4	of	of	ADP
dti-3059	118	5	total	total	ADJ
dti-3059	118	6	antibody	antibody	NOUN
dti-3059	118	7	titer	titer	NOUN
dti-3059	118	8	was	be	AUX
dti-3059	118	9	found	find	VERB
dti-3059	118	10	to	to	PART
dti-3059	118	11	be	be	AUX
dti-3059	118	12	significantly	significantly	ADV
dti-3059	118	13	higher	high	ADJ
dti-3059	118	14	in	in	ADP
dti-3059	118	15	vaccinated	vaccinated	ADJ
dti-3059	118	16	people	people	NOUN
dti-3059	118	17	compared	compare	VERB
dti-3059	118	18	to	to	ADP
dti-3059	118	19	nonvaccinated	nonvaccinate	VERB
dti-3059	118	20	people	people	NOUN
dti-3059	118	21	who	who	PRON
dti-3059	118	22	have	have	AUX
dti-3059	118	23	recovered	recover	VERB
dti-3059	118	24	from	from	ADP
dti-3059	118	25	sars	sar	NOUN
dti-3059	118	26	-	-	PUNCT
dti-3059	118	27	cov-2	cov-2	NOUN
dti-3059	118	28	infections	infection	NOUN
dti-3059	118	29	.	.	PUNCT
dti-3059	119	1	several	several	ADJ
dti-3059	119	2	studies	study	NOUN
dti-3059	119	3	have	have	AUX
dti-3059	119	4	reported	report	VERB
dti-3059	119	5	a	a	DET
dti-3059	119	6	significant	significant	ADJ
dti-3059	119	7	rise	rise	NOUN
dti-3059	119	8	in	in	ADP
dti-3059	119	9	serum	serum	NOUN
dti-3059	119	10	levels	level	NOUN
dti-3059	119	11	of	of	ADP
dti-3059	119	12	total	total	ADJ
dti-3059	119	13	antibodies	antibody	NOUN
dti-3059	119	14	postvaccination	postvaccination	NOUN
dti-3059	119	15	with	with	ADP
dti-3059	119	16	covishield	covishield	NOUN
dti-3059	119	17	™	™	NOUN
dti-3059	119	18	in	in	ADP
dti-3059	119	19	healthy	healthy	ADJ
dti-3059	119	20	individuals	individual	NOUN
dti-3059	119	21	(	(	PUNCT
dti-3059	119	22	20,21	20,21	NUM
dti-3059	119	23	)	)	PUNCT
dti-3059	119	24	.	.	PUNCT
dti-3059	120	1	few	few	ADJ
dti-3059	120	2	studies	study	NOUN
dti-3059	120	3	reported	report	VERB
dti-3059	120	4	a	a	DET
dti-3059	120	5	significant	significant	ADJ
dti-3059	120	6	difference	difference	NOUN
dti-3059	120	7	in	in	ADP
dti-3059	120	8	antibody	antibody	NOUN
dti-3059	120	9	titer	titer	NOUN
dti-3059	120	10	with	with	ADP
dti-3059	120	11	disease	disease	NOUN
dti-3059	120	12	severity	severity	NOUN
dti-3059	120	13	among	among	ADP
dti-3059	120	14	covid-19	covid-19	PROPN
dti-3059	120	15	recovered	recover	VERB
dti-3059	120	16	patients	patient	NOUN
dti-3059	120	17	(	(	PUNCT
dti-3059	120	18	22,23	22,23	NOUN
dti-3059	120	19	)	)	PUNCT
dti-3059	120	20	.	.	PUNCT
dti-3059	121	1	interestingly	interestingly	ADV
dti-3059	121	2	,	,	PUNCT
dti-3059	121	3	among	among	ADP
dti-3059	121	4	the	the	DET
dti-3059	121	5	recovered	recovered	ADJ
dti-3059	121	6	patients	patient	NOUN
dti-3059	121	7	,	,	PUNCT
dti-3059	121	8	those	those	PRON
dti-3059	121	9	who	who	PRON
dti-3059	121	10	had	have	VERB
dti-3059	121	11	severe	severe	ADJ
dti-3059	121	12	covid-19	covid-19	PROPN
dti-3059	121	13	had	have	VERB
dti-3059	121	14	higher	high	ADJ
dti-3059	121	15	levels	level	NOUN
dti-3059	121	16	of	of	ADP
dti-3059	121	17	anti	anti	ADJ
dti-3059	121	18	-	-	ADJ
dti-3059	121	19	spike	spike	ADJ
dti-3059	121	20	total	total	ADJ
dti-3059	121	21	antibody	antibody	NOUN
dti-3059	121	22	compared	compare	VERB
dti-3059	121	23	to	to	ADP
dti-3059	121	24	those	those	PRON
dti-3059	121	25	with	with	ADP
dti-3059	121	26	mild	mild	ADJ
dti-3059	121	27	disease	disease	NOUN
dti-3059	121	28	(	(	PUNCT
dti-3059	121	29	24	24	NUM
dti-3059	121	30	)	)	PUNCT
dti-3059	121	31	.	.	PUNCT
dti-3059	122	1	our	our	PRON
dti-3059	122	2	study	study	NOUN
dti-3059	122	3	also	also	ADV
dti-3059	122	4	reported	report	VERB
dti-3059	122	5	significantly	significantly	ADV
dti-3059	122	6	higher	high	ADJ
dti-3059	122	7	levels	level	NOUN
dti-3059	122	8	of	of	ADP
dti-3059	122	9	sars	sar	NOUN
dti-3059	122	10	-	-	PUNCT
dti-3059	122	11	cov-2	cov-2	NOUN
dti-3059	122	12	spike	spike	ADJ
dti-3059	122	13	protein	protein	NOUN
dti-3059	122	14	-	-	PUNCT
dti-3059	122	15	specific	specific	ADJ
dti-3059	122	16	total	total	ADJ
dti-3059	122	17	antibody	antibody	NOUN
dti-3059	122	18	in	in	ADP
dti-3059	122	19	severe	severe	ADJ
dti-3059	122	20	covid-19	covid-19	PROPN
dti-3059	122	21	recovered	recovered	ADJ
dti-3059	122	22	patients	patient	NOUN
dti-3059	122	23	.	.	PUNCT
dti-3059	123	1	vaccination	vaccination	NOUN
dti-3059	123	2	with	with	ADP
dti-3059	123	3	chadox1	chadox1	ADJ
dti-3059	123	4	ncov-19	ncov-19	PROPN
dti-3059	123	5	coronavirus	coronavirus	NOUN
dti-3059	123	6	vaccines	vaccine	NOUN
dti-3059	123	7	led	lead	VERB
dti-3059	123	8	to	to	ADP
dti-3059	123	9	a	a	DET
dti-3059	123	10	significant	significant	ADJ
dti-3059	123	11	increase	increase	NOUN
dti-3059	123	12	in	in	ADP
dti-3059	123	13	anti	anti	ADJ
dti-3059	123	14	-	-	ADJ
dti-3059	123	15	spike	spike	ADJ
dti-3059	123	16	antibody	antibody	NOUN
dti-3059	123	17	titers	titer	NOUN
dti-3059	123	18	,	,	PUNCT
dti-3059	123	19	indicating	indicate	VERB
dti-3059	123	20	a	a	DET
dti-3059	123	21	robust	robust	ADJ
dti-3059	123	22	humoral	humoral	ADJ
dti-3059	123	23	immune	immune	ADJ
dti-3059	123	24	response	response	NOUN
dti-3059	123	25	.	.	PUNCT
dti-3059	124	1	however	however	ADV
dti-3059	124	2	,	,	PUNCT
dti-3059	124	3	the	the	DET
dti-3059	124	4	raised	raise	VERB
dti-3059	124	5	antibody	antibody	NOUN
dti-3059	124	6	after	after	ADP
dti-3059	124	7	vaccination	vaccination	NOUN
dti-3059	124	8	could	could	AUX
dti-3059	124	9	not	not	PART
dti-3059	124	10	immune	immune	NOUN
dti-3059	124	11	-	-	PUNCT
dti-3059	124	12	react	react	NOUN
dti-3059	124	13	with	with	ADP
dti-3059	124	14	sars	sar	NOUN
dti-3059	124	15	-	-	PUNCT
dti-3059	124	16	cov-2	cov-2	NOUN
dti-3059	124	17	variant	variant	ADJ
dti-3059	124	18	peptides	peptide	NOUN
dti-3059	124	19	.	.	PUNCT
dti-3059	125	1	the	the	DET
dti-3059	125	2	polyclonal	polyclonal	ADJ
dti-3059	125	3	antibody	antibody	NOUN
dti-3059	125	4	response	response	NOUN
dti-3059	125	5	postvaccination	postvaccination	NOUN
dti-3059	125	6	showed	show	VERB
dti-3059	125	7	limitations	limitation	NOUN
dti-3059	125	8	in	in	ADP
dti-3059	125	9	binding	bind	VERB
dti-3059	125	10	the	the	DET
dti-3059	125	11	mutant	mutant	ADJ
dti-3059	125	12	peptides	peptide	NOUN
dti-3059	125	13	of	of	ADP
dti-3059	125	14	rbds	rbds	NOUN
dti-3059	125	15	of	of	ADP
dti-3059	125	16	the	the	DET
dti-3059	125	17	delta	delta	NOUN
dti-3059	125	18	and	and	CCONJ
dti-3059	125	19	omicron	omicron	PROPN
dti-3059	125	20	variants	variant	NOUN
dti-3059	125	21	,	,	PUNCT
dti-3059	125	22	suggesting	suggest	VERB
dti-3059	125	23	a	a	DET
dti-3059	125	24	potential	potential	ADJ
dti-3059	125	25	challenge	challenge	NOUN
dti-3059	125	26	in	in	ADP
dti-3059	125	27	achieving	achieve	VERB
dti-3059	125	28	full	full	ADJ
dti-3059	125	29	protection	protection	NOUN
dti-3059	125	30	against	against	ADP
dti-3059	125	31	these	these	DET
dti-3059	125	32	variants	variant	NOUN
dti-3059	125	33	(	(	PUNCT
dti-3059	125	34	25	25	NUM
dti-3059	125	35	)	)	PUNCT
dti-3059	125	36	.	.	PUNCT
dti-3059	126	1	findings	finding	NOUN
dti-3059	126	2	of	of	ADP
dti-3059	126	3	this	this	DET
dti-3059	126	4	study	study	NOUN
dti-3059	126	5	suggest	suggest	VERB
dti-3059	126	6	that	that	SCONJ
dti-3059	126	7	vaccination	vaccination	NOUN
dti-3059	126	8	elicits	elicit	VERB
dti-3059	126	9	a	a	DET
dti-3059	126	10	lower	low	ADJ
dti-3059	126	11	titer	titer	NOUN
dti-3059	126	12	of	of	ADP
dti-3059	126	13	immune	immune	NOUN
dti-3059	126	14	-	-	PUNCT
dti-3059	126	15	reactive	reactive	ADJ
dti-3059	126	16	antibodies	antibody	NOUN
dti-3059	126	17	against	against	ADP
dti-3059	126	18	the	the	DET
dti-3059	126	19	delta	delta	NOUN
dti-3059	126	20	and	and	CCONJ
dti-3059	126	21	omicron	omicron	PROPN
dti-3059	126	22	rbds	rbds	NOUN
dti-3059	126	23	,	,	PUNCT
dti-3059	126	24	indicating	indicate	VERB
dti-3059	126	25	potential	potential	ADJ
dti-3059	126	26	challenges	challenge	NOUN
dti-3059	126	27	in	in	ADP
dti-3059	126	28	neutralizing	neutralize	VERB
dti-3059	126	29	these	these	DET
dti-3059	126	30	variants	variant	NOUN
dti-3059	126	31	.	.	PUNCT
dti-3059	127	1	overall	overall	ADV
dti-3059	127	2	,	,	PUNCT
dti-3059	127	3	the	the	DET
dti-3059	127	4	results	result	NOUN
dti-3059	127	5	highlight	highlight	VERB
dti-3059	127	6	the	the	DET
dti-3059	127	7	need	need	NOUN
dti-3059	127	8	for	for	ADP
dti-3059	127	9	ongoing	ongoing	ADJ
dti-3059	127	10	monitoring	monitoring	NOUN
dti-3059	127	11	and	and	CCONJ
dti-3059	127	12	adaptation	adaptation	NOUN
dti-3059	127	13	of	of	ADP
dti-3059	127	14	vaccines	vaccine	NOUN
dti-3059	127	15	to	to	PART
dti-3059	127	16	address	address	VERB
dti-3059	127	17	the	the	DET
dti-3059	127	18	evolving	evolve	VERB
dti-3059	127	19	sars	sar	NOUN
dti-3059	127	20	-	-	PUNCT
dti-3059	127	21	cov-2	cov-2	NOUN
dti-3059	127	22	variants	variant	NOUN
dti-3059	127	23	and	and	CCONJ
dti-3059	127	24	their	their	PRON
dti-3059	127	25	impact	impact	NOUN
dti-3059	127	26	on	on	ADP
dti-3059	127	27	antibody	antibody	NOUN
dti-3059	127	28	binding	bind	VERB
dti-3059	127	29	.	.	PUNCT
dti-3059	128	1	the	the	DET
dti-3059	128	2	findings	finding	NOUN
dti-3059	128	3	of	of	ADP
dti-3059	128	4	our	our	PRON
dti-3059	128	5	study	study	NOUN
dti-3059	128	6	are	be	AUX
dti-3059	128	7	supported	support	VERB
dti-3059	128	8	by	by	ADP
dti-3059	128	9	the	the	DET
dti-3059	128	10	study	study	NOUN
dti-3059	128	11	of	of	ADP
dti-3059	128	12	geers	geer	NOUN
dti-3059	128	13	et	et	PROPN
dti-3059	128	14	al	al	PROPN
dti-3059	128	15	2021	2021	NUM
dti-3059	128	16	(	(	PUNCT
dti-3059	128	17	26	26	NUM
dti-3059	128	18	)	)	PUNCT
dti-3059	128	19	.	.	PUNCT
dti-3059	129	1	the	the	DET
dti-3059	129	2	study	study	NOUN
dti-3059	129	3	revealed	reveal	VERB
dti-3059	129	4	structural	structural	ADJ
dti-3059	129	5	analysis	analysis	NOUN
dti-3059	129	6	that	that	SCONJ
dti-3059	129	7	the	the	DET
dti-3059	129	8	delta	delta	NOUN
dti-3059	129	9	and	and	CCONJ
dti-3059	129	10	omicron	omicron	PROPN
dti-3059	129	11	variants	variant	NOUN
dti-3059	129	12	share	share	VERB
dti-3059	129	13	a	a	DET
dti-3059	129	14	common	common	ADJ
dti-3059	129	15	immune	immune	ADJ
dti-3059	129	16	escape	escape	NOUN
dti-3059	129	17	strategy	strategy	NOUN
dti-3059	129	18	figure	figure	NOUN
dti-3059	129	19	2	2	NUM
dti-3059	129	20	immunoreactivity	immunoreactivity	NOUN
dti-3059	129	21	of	of	ADP
dti-3059	129	22	peptides	peptide	NOUN
dti-3059	129	23	(	(	PUNCT
dti-3059	129	24	p1	p1	NOUN
dti-3059	129	25	,	,	PUNCT
dti-3059	129	26	p5	p5	ADJ
dti-3059	129	27	,	,	PUNCT
dti-3059	129	28	p7	p7	ADJ
dti-3059	129	29	)	)	PUNCT
dti-3059	129	30	of	of	ADP
dti-3059	129	31	wildtype	wildtype	NOUN
dti-3059	129	32	sars	sar	NOUN
dti-3059	129	33	-	-	PUNCT
dti-3059	129	34	cov-2	cov-2	NOUN
dti-3059	129	35	and	and	CCONJ
dti-3059	129	36	peptides	peptide	NOUN
dti-3059	129	37	(	(	PUNCT
dti-3059	129	38	p2	p2	X
dti-3059	129	39	,	,	PUNCT
dti-3059	129	40	p6	p6	PROPN
dti-3059	129	41	,	,	PUNCT
dti-3059	129	42	p8	p8	PROPN
dti-3059	129	43	)	)	PUNCT
dti-3059	129	44	of	of	ADP
dti-3059	129	45	sars	sar	NOUN
dti-3059	129	46	-	-	PUNCT
dti-3059	129	47	cov-2	cov-2	NOUN
dti-3059	129	48	variants	variant	NOUN
dti-3059	129	49	with	with	ADP
dti-3059	129	50	anti	anti	ADJ
dti-3059	129	51	-	-	ADJ
dti-3059	129	52	sera	sera	NOUN
dti-3059	129	53	obtained	obtain	VERB
dti-3059	129	54	from	from	ADP
dti-3059	129	55	healthy	healthy	ADJ
dti-3059	129	56	individuals	individual	NOUN
dti-3059	129	57	vaccinated	vaccinate	VERB
dti-3059	129	58	with	with	ADP
dti-3059	129	59	both	both	DET
dti-3059	129	60	doses	dose	NOUN
dti-3059	129	61	of	of	ADP
dti-3059	129	62	covishield	covishield	NOUN
dti-3059	129	63	™	™	PROPN
dti-3059	129	64	(	(	PUNCT
dti-3059	129	65	n	n	NOUN
dti-3059	129	66	=	=	SYM
dti-3059	129	67	30	30	NUM
dti-3059	129	68	)	)	PUNCT
dti-3059	129	69	and	and	CCONJ
dti-3059	129	70	covid-19	covid-19	PROPN
dti-3059	129	71	recovered	recover	VERB
dti-3059	129	72	patients	patient	NOUN
dti-3059	129	73	from	from	ADP
dti-3059	129	74	the	the	DET
dti-3059	129	75	hospital	hospital	NOUN
dti-3059	129	76	(	(	PUNCT
dti-3059	129	77	n	n	NOUN
dti-3059	129	78	=	=	SYM
dti-3059	129	79	30	30	NUM
dti-3059	129	80	)	)	PUNCT
dti-3059	129	81	.	.	PUNCT
dti-3059	130	1	a	a	DET
dti-3059	130	2	,	,	PUNCT
dti-3059	130	3	b	b	NOUN
dti-3059	130	4	,	,	PUNCT
dti-3059	130	5	and	and	CCONJ
dti-3059	130	6	c.	c.	PROPN
dti-3059	131	1	the	the	DET
dti-3059	131	2	immunoreactivity	immunoreactivity	NOUN
dti-3059	131	3	of	of	ADP
dti-3059	131	4	anti	anti	ADJ
dti-3059	131	5	-	-	NOUN
dti-3059	131	6	sera	sera	NOUN
dti-3059	131	7	with	with	ADP
dti-3059	131	8	each	each	DET
dti-3059	131	9	peptide	peptide	NOUN
dti-3059	131	10	(	(	PUNCT
dti-3059	131	11	p1	p1	NOUN
dti-3059	131	12	,	,	PUNCT
dti-3059	131	13	p5	p5	ADJ
dti-3059	131	14	,	,	PUNCT
dti-3059	131	15	p7	p7	ADJ
dti-3059	131	16	)	)	PUNCT
dti-3059	131	17	of	of	ADP
dti-3059	131	18	wild	wild	ADJ
dti-3059	131	19	-	-	PUNCT
dti-3059	131	20	type	type	NOUN
dti-3059	131	21	sars	sar	NOUN
dti-3059	131	22	-	-	PUNCT
dti-3059	131	23	cov-2	cov-2	PUNCT
dti-3059	131	24	and	and	CCONJ
dti-3059	131	25	each	each	DET
dti-3059	131	26	peptide	peptide	NOUN
dti-3059	131	27	(	(	PUNCT
dti-3059	131	28	p2	p2	PROPN
dti-3059	131	29	,	,	PUNCT
dti-3059	131	30	p6	p6	PROPN
dti-3059	131	31	,	,	PUNCT
dti-3059	131	32	p8	p8	PROPN
dti-3059	131	33	)	)	PUNCT
dti-3059	131	34	of	of	ADP
dti-3059	131	35	mutated	mutate	VERB
dti-3059	131	36	sarscov-2	sarscov-2	PROPN
dti-3059	131	37	having	have	VERB
dti-3059	131	38	single	single	ADJ
dti-3059	131	39	amino	amino	NOUN
dti-3059	131	40	acid	acid	NOUN
dti-3059	131	41	mutation	mutation	NOUN
dti-3059	131	42	at	at	ADP
dti-3059	131	43	residues	residue	NOUN
dti-3059	131	44	417	417	NUM
dti-3059	131	45	,	,	PUNCT
dti-3059	131	46	484	484	NUM
dti-3059	131	47	,	,	PUNCT
dti-3059	131	48	and	and	CCONJ
dti-3059	131	49	501	501	NUM
dti-3059	131	50	,	,	PUNCT
dti-3059	131	51	respectively	respectively	ADV
dti-3059	131	52	.	.	PUNCT
dti-3059	132	1	d.	d.	PROPN
dti-3059	132	2	the	the	DET
dti-3059	132	3	immunoreactivity	immunoreactivity	NOUN
dti-3059	132	4	of	of	ADP
dti-3059	132	5	anti	anti	ADJ
dti-3059	132	6	-	-	NOUN
dti-3059	132	7	sera	sera	NOUN
dti-3059	132	8	with	with	ADP
dti-3059	132	9	peptide	peptide	NOUN
dti-3059	132	10	pools	pool	NOUN
dti-3059	132	11	(	(	PUNCT
dti-3059	132	12	p1	p1	NOUN
dti-3059	132	13	,	,	PUNCT
dti-3059	132	14	p5	p5	ADJ
dti-3059	132	15	,	,	PUNCT
dti-3059	132	16	p7	p7	ADJ
dti-3059	132	17	)	)	PUNCT
dti-3059	132	18	of	of	ADP
dti-3059	132	19	wild	wild	ADJ
dti-3059	132	20	-	-	PUNCT
dti-3059	132	21	type	type	NOUN
dti-3059	132	22	sars	sar	NOUN
dti-3059	132	23	-	-	PUNCT
dti-3059	132	24	cov-2	cov-2	PART
dti-3059	132	25	and	and	CCONJ
dti-3059	132	26	peptide	peptide	NOUN
dti-3059	132	27	pools	pool	NOUN
dti-3059	132	28	(	(	PUNCT
dti-3059	132	29	p2	p2	X
dti-3059	132	30	,	,	PUNCT
dti-3059	132	31	p6	p6	PROPN
dti-3059	132	32	,	,	PUNCT
dti-3059	132	33	p8	p8	PROPN
dti-3059	132	34	)	)	PUNCT
dti-3059	132	35	of	of	ADP
dti-3059	132	36	mutated	mutate	VERB
dti-3059	132	37	sars	sar	NOUN
dti-3059	132	38	-	-	PUNCT
dti-3059	132	39	cov-2	cov-2	PART
dti-3059	132	40	having	have	VERB
dti-3059	132	41	mutations	mutation	NOUN
dti-3059	132	42	at	at	ADP
dti-3059	132	43	all	all	DET
dti-3059	132	44	three	three	NUM
dti-3059	132	45	residues	residue	NOUN
dti-3059	132	46	417	417	NUM
dti-3059	132	47	,	,	PUNCT
dti-3059	132	48	484	484	NUM
dti-3059	132	49	,	,	PUNCT
dti-3059	132	50	and	and	CCONJ
dti-3059	132	51	501	501	NUM
dti-3059	132	52	.	.	PUNCT
dti-3059	133	1	gupta	gupta	PROPN
dti-3059	133	2	et	et	PROPN
dti-3059	133	3	al	al	PROPN
dti-3059	133	4	drug	drug	PROPN
dti-3059	133	5	target	target	NOUN
dti-3059	133	6	insights	insight	NOUN
dti-3059	133	7	2024	2024	NUM
dti-3059	133	8	;	;	PUNCT
dti-3059	133	9	18	18	NUM
dti-3059	133	10	:	:	SYM
dti-3059	133	11	25	25	NUM
dti-3059	133	12	©	©	ADP
dti-3059	133	13	2024	2024	NUM
dti-3059	133	14	the	the	DET
dti-3059	133	15	authors	author	NOUN
dti-3059	133	16	.	.	PUNCT
dti-3059	134	1	published	publish	VERB
dti-3059	134	2	by	by	ADP
dti-3059	134	3	aboutscience	aboutscience	NOUN
dti-3059	134	4	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-3059	134	5	involving	involve	VERB
dti-3059	134	6	specific	specific	ADJ
dti-3059	134	7	residues	residue	NOUN
dti-3059	134	8	(	(	PUNCT
dti-3059	134	9	k417	k417	PROPN
dti-3059	134	10	-	-	PUNCT
dti-3059	134	11	e484	e484	PROPN
dti-3059	134	12	-	-	PUNCT
dti-3059	134	13	n501	n501	PROPN
dti-3059	134	14	)	)	PUNCT
dti-3059	134	15	,	,	PUNCT
dti-3059	134	16	allowing	allow	VERB
dti-3059	134	17	them	they	PRON
dti-3059	134	18	to	to	PART
dti-3059	134	19	evade	evade	VERB
dti-3059	134	20	neutralization	neutralization	NOUN
dti-3059	134	21	by	by	ADP
dti-3059	134	22	anti	anti	ADJ
dti-3059	134	23	-	-	ADJ
dti-3059	134	24	rbd	rbd	ADJ
dti-3059	134	25	antibodies	antibody	NOUN
dti-3059	134	26	(	(	PUNCT
dti-3059	134	27	8,26	8,26	NOUN
dti-3059	134	28	)	)	PUNCT
dti-3059	134	29	.	.	PUNCT
dti-3059	135	1	the	the	DET
dti-3059	135	2	study	study	NOUN
dti-3059	135	3	suggests	suggest	VERB
dti-3059	135	4	that	that	SCONJ
dti-3059	135	5	through	through	ADP
dti-3059	135	6	mutations	mutation	NOUN
dti-3059	135	7	of	of	ADP
dti-3059	135	8	this	this	DET
dti-3059	135	9	triad	triad	NOUN
dti-3059	135	10	,	,	PUNCT
dti-3059	135	11	sarscov-2	sarscov-2	NUM
dti-3059	135	12	has	have	AUX
dti-3059	135	13	evolved	evolve	VERB
dti-3059	135	14	to	to	PART
dti-3059	135	15	evade	evade	VERB
dti-3059	135	16	neutralization	neutralization	NOUN
dti-3059	135	17	by	by	ADP
dti-3059	135	18	the	the	DET
dti-3059	135	19	class	class	NOUN
dti-3059	135	20	i	i	PROPN
dti-3059	135	21	/	/	SYM
dti-3059	135	22	ii	ii	PROPN
dti-3059	135	23	anti	anti	ADJ
dti-3059	135	24	-	-	ADJ
dti-3059	135	25	rbd	rbd	ADJ
dti-3059	135	26	antibody	antibody	NOUN
dti-3059	135	27	fraction	fraction	NOUN
dti-3059	135	28	of	of	ADP
dti-3059	135	29	hybrid	hybrid	ADJ
dti-3059	135	30	immunity	immunity	NOUN
dti-3059	135	31	plasma	plasma	NOUN
dti-3059	135	32	.	.	PUNCT
dti-3059	136	1	the	the	DET
dti-3059	136	2	findings	finding	NOUN
dti-3059	136	3	indicate	indicate	VERB
dti-3059	136	4	that	that	SCONJ
dti-3059	136	5	vaccination	vaccination	NOUN
dti-3059	136	6	may	may	AUX
dti-3059	136	7	result	result	VERB
dti-3059	136	8	in	in	ADP
dti-3059	136	9	a	a	DET
dti-3059	136	10	decreased	decrease	VERB
dti-3059	136	11	long	long	ADJ
dti-3059	136	12	-	-	PUNCT
dti-3059	136	13	term	term	NOUN
dti-3059	136	14	antibody	antibody	NOUN
dti-3059	136	15	response	response	NOUN
dti-3059	136	16	to	to	ADP
dti-3059	136	17	delta	delta	NOUN
dti-3059	136	18	and	and	CCONJ
dti-3059	136	19	omicron	omicron	PROPN
dti-3059	136	20	rbds	rbds	PROPN
dti-3059	136	21	,	,	PUNCT
dti-3059	136	22	highlighting	highlight	VERB
dti-3059	136	23	the	the	DET
dti-3059	136	24	challenges	challenge	NOUN
dti-3059	136	25	in	in	ADP
dti-3059	136	26	neutralizing	neutralize	VERB
dti-3059	136	27	these	these	DET
dti-3059	136	28	variants	variant	NOUN
dti-3059	136	29	with	with	ADP
dti-3059	136	30	the	the	DET
dti-3059	136	31	existing	exist	VERB
dti-3059	136	32	antibody	antibody	NOUN
dti-3059	136	33	response	response	NOUN
dti-3059	136	34	induced	induce	VERB
dti-3059	136	35	by	by	ADP
dti-3059	136	36	vaccination	vaccination	NOUN
dti-3059	136	37	.	.	PUNCT
dti-3059	137	1	the	the	DET
dti-3059	137	2	study	study	NOUN
dti-3059	137	3	also	also	ADV
dti-3059	137	4	found	find	VERB
dti-3059	137	5	that	that	SCONJ
dti-3059	137	6	the	the	DET
dti-3059	137	7	interval	interval	NOUN
dti-3059	137	8	between	between	ADP
dti-3059	137	9	vaccination	vaccination	NOUN
dti-3059	137	10	and	and	CCONJ
dti-3059	137	11	blood	blood	NOUN
dti-3059	137	12	draw	draw	NOUN
dti-3059	137	13	did	do	AUX
dti-3059	137	14	not	not	PART
dti-3059	137	15	significantly	significantly	ADV
dti-3059	137	16	impact	impact	VERB
dti-3059	137	17	antibody	antibody	NOUN
dti-3059	137	18	levels	level	NOUN
dti-3059	137	19	,	,	PUNCT
dti-3059	137	20	indicating	indicate	VERB
dti-3059	137	21	the	the	DET
dti-3059	137	22	stability	stability	NOUN
dti-3059	137	23	of	of	ADP
dti-3059	137	24	the	the	DET
dti-3059	137	25	antibody	antibody	NOUN
dti-3059	137	26	response	response	NOUN
dti-3059	137	27	over	over	ADP
dti-3059	137	28	time	time	NOUN
dti-3059	137	29	.	.	PUNCT
dti-3059	138	1	these	these	DET
dti-3059	138	2	findings	finding	NOUN
dti-3059	138	3	highlight	highlight	VERB
dti-3059	138	4	the	the	DET
dti-3059	138	5	need	need	NOUN
dti-3059	138	6	for	for	ADP
dti-3059	138	7	continued	continue	VERB
dti-3059	138	8	monitoring	monitoring	NOUN
dti-3059	138	9	and	and	CCONJ
dti-3059	138	10	adaptation	adaptation	NOUN
dti-3059	138	11	of	of	ADP
dti-3059	138	12	vaccines	vaccine	NOUN
dti-3059	138	13	to	to	PART
dti-3059	138	14	address	address	VERB
dti-3059	138	15	the	the	DET
dti-3059	138	16	evolving	evolve	VERB
dti-3059	138	17	sars	sar	NOUN
dti-3059	138	18	-	-	PUNCT
dti-3059	138	19	cov-2	cov-2	NOUN
dti-3059	138	20	variants	variant	NOUN
dti-3059	138	21	and	and	CCONJ
dti-3059	138	22	their	their	PRON
dti-3059	138	23	immune	immune	ADJ
dti-3059	138	24	evasion	evasion	NOUN
dti-3059	138	25	strategies	strategy	NOUN
dti-3059	138	26	.	.	PUNCT
dti-3059	139	1	findings	finding	NOUN
dti-3059	139	2	of	of	ADP
dti-3059	139	3	our	our	PRON
dti-3059	139	4	study	study	NOUN
dti-3059	139	5	reported	report	VERB
dti-3059	139	6	reduced	reduce	VERB
dti-3059	139	7	immunoreactivity	immunoreactivity	NOUN
dti-3059	139	8	of	of	ADP
dti-3059	139	9	anti	anti	ADJ
dti-3059	139	10	-	-	NOUN
dti-3059	139	11	sera	sera	NOUN
dti-3059	139	12	of	of	ADP
dti-3059	139	13	vaccinated	vaccinated	ADJ
dti-3059	139	14	people	people	NOUN
dti-3059	139	15	and	and	CCONJ
dti-3059	139	16	covid-19	covid-19	PROPN
dti-3059	139	17	recovered	recover	VERB
dti-3059	139	18	patients	patient	NOUN
dti-3059	139	19	with	with	ADP
dti-3059	139	20	a	a	DET
dti-3059	139	21	peptide	peptide	NOUN
dti-3059	139	22	having	have	VERB
dti-3059	139	23	e484k	e484k	VERB
dti-3059	139	24	mutation	mutation	NOUN
dti-3059	139	25	in	in	ADP
dti-3059	139	26	the	the	DET
dti-3059	139	27	rbd	rbd	NOUN
dti-3059	139	28	of	of	ADP
dti-3059	139	29	sars	sar	NOUN
dti-3059	139	30	-	-	PUNCT
dti-3059	139	31	cov-2	cov-2	NOUN
dti-3059	139	32	variants	variant	NOUN
dti-3059	139	33	.	.	PUNCT
dti-3059	140	1	our	our	PRON
dti-3059	140	2	finding	finding	NOUN
dti-3059	140	3	is	be	AUX
dti-3059	140	4	supported	support	VERB
dti-3059	140	5	by	by	ADP
dti-3059	140	6	the	the	DET
dti-3059	140	7	study	study	NOUN
dti-3059	140	8	done	do	VERB
dti-3059	140	9	in	in	ADP
dti-3059	140	10	brazilian	brazilian	ADJ
dti-3059	140	11	/	/	SYM
dti-3059	140	12	japanese	japanese	ADJ
dti-3059	140	13	variants	variant	NOUN
dti-3059	140	14	(	(	PUNCT
dti-3059	140	15	p.2	p.2	NOUN
dti-3059	140	16	and	and	CCONJ
dti-3059	140	17	p.1	p.1	NOUN
dti-3059	140	18	)	)	PUNCT
dti-3059	140	19	with	with	ADP
dti-3059	140	20	the	the	DET
dti-3059	140	21	e484k	e484k	PROPN
dti-3059	140	22	mutation	mutation	NOUN
dti-3059	140	23	,	,	PUNCT
dti-3059	140	24	which	which	PRON
dti-3059	140	25	had	have	AUX
dti-3059	140	26	significantly	significantly	ADV
dti-3059	140	27	decreased	decrease	VERB
dti-3059	140	28	neutralization	neutralization	NOUN
dti-3059	140	29	,	,	PUNCT
dti-3059	140	30	suggesting	suggest	VERB
dti-3059	140	31	evasion	evasion	NOUN
dti-3059	140	32	of	of	ADP
dti-3059	140	33	antibody	antibody	NOUN
dti-3059	140	34	responses	response	NOUN
dti-3059	140	35	(	(	PUNCT
dti-3059	140	36	27	27	NUM
dti-3059	140	37	)	)	PUNCT
dti-3059	140	38	.	.	PUNCT
dti-3059	141	1	the	the	DET
dti-3059	141	2	neutralization	neutralization	NOUN
dti-3059	141	3	of	of	ADP
dti-3059	141	4	the	the	DET
dti-3059	141	5	south	south	ADJ
dti-3059	141	6	african	african	ADJ
dti-3059	141	7	b.1.351	b.1.351	NOUN
dti-3059	141	8	strain	strain	NOUN
dti-3059	141	9	,	,	PUNCT
dti-3059	141	10	which	which	PRON
dti-3059	141	11	has	have	VERB
dti-3059	141	12	three	three	NUM
dti-3059	141	13	mutations	mutation	NOUN
dti-3059	141	14	in	in	ADP
dti-3059	141	15	the	the	DET
dti-3059	141	16	rbd	rbd	NOUN
dti-3059	141	17	and	and	CCONJ
dti-3059	141	18	has	have	AUX
dti-3059	141	19	been	be	AUX
dti-3059	141	20	found	find	VERB
dti-3059	141	21	in	in	ADP
dti-3059	141	22	reinfection	reinfection	NOUN
dti-3059	141	23	cases	case	NOUN
dti-3059	141	24	,	,	PUNCT
dti-3059	141	25	was	be	AUX
dti-3059	141	26	significantly	significantly	ADV
dti-3059	141	27	reduced	reduce	VERB
dti-3059	141	28	for	for	ADP
dti-3059	141	29	two	two	NUM
dti-3059	141	30	-	-	PUNCT
dti-3059	141	31	dose	dose	NOUN
dti-3059	141	32	vaccines	vaccine	NOUN
dti-3059	141	33	,	,	PUNCT
dti-3059	141	34	similar	similar	ADJ
dti-3059	141	35	to	to	ADP
dti-3059	141	36	other	other	ADJ
dti-3059	141	37	distantly	distantly	ADV
dti-3059	141	38	related	relate	VERB
dti-3059	141	39	coronaviruses	coronaviruse	NOUN
dti-3059	141	40	,	,	PUNCT
dti-3059	141	41	indicating	indicate	VERB
dti-3059	141	42	that	that	SCONJ
dti-3059	141	43	a	a	DET
dti-3059	141	44	small	small	ADJ
dti-3059	141	45	number	number	NOUN
dti-3059	141	46	of	of	ADP
dti-3059	141	47	mutations	mutation	NOUN
dti-3059	141	48	can	can	AUX
dti-3059	141	49	lead	lead	VERB
dti-3059	141	50	to	to	PART
dti-3059	141	51	potent	potent	VERB
dti-3059	141	52	humoral	humoral	ADJ
dti-3059	141	53	immune	immune	ADJ
dti-3059	141	54	response	response	NOUN
dti-3059	141	55	escape	escape	NOUN
dti-3059	141	56	(	(	PUNCT
dti-3059	141	57	28,29	28,29	NUM
dti-3059	141	58	)	)	PUNCT
dti-3059	141	59	.	.	PUNCT
dti-3059	142	1	a	a	DET
dti-3059	142	2	considerable	considerable	ADJ
dti-3059	142	3	percentage	percentage	NOUN
dti-3059	142	4	of	of	ADP
dti-3059	142	5	recipients	recipient	NOUN
dti-3059	142	6	did	do	AUX
dti-3059	142	7	not	not	PART
dti-3059	142	8	have	have	VERB
dti-3059	142	9	detectable	detectable	ADJ
dti-3059	142	10	neutralization	neutralization	NOUN
dti-3059	142	11	of	of	ADP
dti-3059	142	12	the	the	DET
dti-3059	142	13	b.1.351	b.1.351	NOUN
dti-3059	142	14	variant	variant	NOUN
dti-3059	142	15	after	after	ADP
dti-3059	142	16	receiving	receive	VERB
dti-3059	142	17	two	two	NUM
dti-3059	142	18	doses	dose	NOUN
dti-3059	142	19	of	of	ADP
dti-3059	142	20	either	either	DET
dti-3059	142	21	vaccine	vaccine	NOUN
dti-3059	142	22	(	(	PUNCT
dti-3059	142	23	22	22	NUM
dti-3059	142	24	)	)	PUNCT
dti-3059	142	25	.	.	PUNCT
dti-3059	143	1	individuals	individual	NOUN
dti-3059	143	2	with	with	ADP
dti-3059	143	3	prior	prior	ADJ
dti-3059	143	4	covid-19	covid-19	PROPN
dti-3059	143	5	infection	infection	NOUN
dti-3059	143	6	or	or	CCONJ
dti-3059	143	7	significant	significant	ADJ
dti-3059	143	8	exposure	exposure	NOUN
dti-3059	143	9	had	have	VERB
dti-3059	143	10	higher	high	ADJ
dti-3059	143	11	neutralization	neutralization	NOUN
dti-3059	143	12	titers	titer	NOUN
dti-3059	143	13	and	and	CCONJ
dti-3059	143	14	cross	cross	NOUN
dti-3059	143	15	-	-	NOUN
dti-3059	143	16	neutralization	neutralization	NOUN
dti-3059	143	17	against	against	ADP
dti-3059	143	18	various	various	ADJ
dti-3059	143	19	variants	variant	NOUN
dti-3059	143	20	,	,	PUNCT
dti-3059	143	21	suggesting	suggest	VERB
dti-3059	143	22	a	a	DET
dti-3059	143	23	combination	combination	NOUN
dti-3059	143	24	of	of	ADP
dti-3059	143	25	prior	prior	ADJ
dti-3059	143	26	infection	infection	NOUN
dti-3059	143	27	and	and	CCONJ
dti-3059	143	28	vaccination	vaccination	NOUN
dti-3059	143	29	may	may	AUX
dti-3059	143	30	result	result	VERB
dti-3059	143	31	in	in	ADP
dti-3059	143	32	broader	broad	ADJ
dti-3059	143	33	neutralizing	neutralize	VERB
dti-3059	143	34	antibody	antibody	NOUN
dti-3059	143	35	responses	response	NOUN
dti-3059	143	36	(	(	PUNCT
dti-3059	143	37	30	30	NUM
dti-3059	143	38	)	)	PUNCT
dti-3059	143	39	.	.	PUNCT
dti-3059	144	1	the	the	DET
dti-3059	144	2	b.1.351	b.1.351	NOUN
dti-3059	144	3	variant	variant	NOUN
dti-3059	144	4	of	of	ADP
dti-3059	144	5	sars	sar	NOUN
dti-3059	144	6	-	-	PUNCT
dti-3059	144	7	cov-2	cov-2	NOUN
dti-3059	144	8	,	,	PUNCT
dti-3059	144	9	also	also	ADV
dti-3059	144	10	known	know	VERB
dti-3059	144	11	as	as	ADP
dti-3059	144	12	the	the	DET
dti-3059	144	13	south	south	ADJ
dti-3059	144	14	african	african	ADJ
dti-3059	144	15	variant	variant	NOUN
dti-3059	144	16	,	,	PUNCT
dti-3059	144	17	exhibits	exhibit	VERB
dti-3059	144	18	resistance	resistance	NOUN
dti-3059	144	19	to	to	PART
dti-3059	144	20	neutralization	neutralization	VERB
dti-3059	144	21	primarily	primarily	ADV
dti-3059	144	22	because	because	SCONJ
dti-3059	144	23	of	of	ADP
dti-3059	144	24	mutations	mutation	NOUN
dti-3059	144	25	in	in	ADP
dti-3059	144	26	the	the	DET
dti-3059	144	27	rbd	rbd	NOUN
dti-3059	144	28	of	of	ADP
dti-3059	144	29	the	the	DET
dti-3059	144	30	spike	spike	ADJ
dti-3059	144	31	protein	protein	NOUN
dti-3059	144	32	.	.	PUNCT
dti-3059	145	1	the	the	DET
dti-3059	145	2	rbd	rbd	NOUN
dti-3059	145	3	mutations	mutation	NOUN
dti-3059	145	4	in	in	ADP
dti-3059	145	5	b.1.351	b.1.351	NOUN
dti-3059	145	6	,	,	PUNCT
dti-3059	145	7	including	include	VERB
dti-3059	145	8	k417n	k417n	PROPN
dti-3059	145	9	,	,	PUNCT
dti-3059	145	10	e484k	e484k	PROPN
dti-3059	145	11	,	,	PUNCT
dti-3059	145	12	and	and	CCONJ
dti-3059	145	13	n501y	n501y	PROPN
dti-3059	145	14	,	,	PUNCT
dti-3059	145	15	contribute	contribute	VERB
dti-3059	145	16	to	to	ADP
dti-3059	145	17	the	the	DET
dti-3059	145	18	observed	observe	VERB
dti-3059	145	19	escape	escape	NOUN
dti-3059	145	20	from	from	ADP
dti-3059	145	21	vaccine	vaccine	NOUN
dti-3059	145	22	-	-	PUNCT
dti-3059	145	23	induced	induce	VERB
dti-3059	145	24	neutralization	neutralization	NOUN
dti-3059	145	25	(	(	PUNCT
dti-3059	145	26	31,32	31,32	NUM
dti-3059	145	27	)	)	PUNCT
dti-3059	145	28	.	.	PUNCT
dti-3059	146	1	variants	variant	NOUN
dti-3059	146	2	like	like	ADP
dti-3059	146	3	p.2	p.2	NOUN
dti-3059	146	4	and	and	CCONJ
dti-3059	146	5	p.1	p.1	NOUN
dti-3059	146	6	with	with	ADP
dti-3059	146	7	specific	specific	ADJ
dti-3059	146	8	rbd	rbd	NOUN
dti-3059	146	9	mutations	mutation	NOUN
dti-3059	146	10	reduce	reduce	VERB
dti-3059	146	11	neutralization	neutralization	NOUN
dti-3059	146	12	potency	potency	NOUN
dti-3059	146	13	and	and	CCONJ
dti-3059	146	14	may	may	AUX
dti-3059	146	15	explain	explain	VERB
dti-3059	146	16	reinfection	reinfection	NOUN
dti-3059	146	17	cases	case	NOUN
dti-3059	146	18	(	(	PUNCT
dti-3059	146	19	33	33	NUM
dti-3059	146	20	)	)	PUNCT
dti-3059	146	21	.	.	PUNCT
dti-3059	147	1	conclusion	conclusion	NOUN
dti-3059	147	2	the	the	DET
dti-3059	147	3	study	study	NOUN
dti-3059	147	4	concludes	conclude	VERB
dti-3059	147	5	that	that	SCONJ
dti-3059	147	6	multiple	multiple	ADJ
dti-3059	147	7	variants	variant	NOUN
dti-3059	147	8	of	of	ADP
dti-3059	147	9	sars	sar	NOUN
dti-3059	147	10	-	-	PUNCT
dti-3059	147	11	cov-2	cov-2	NOUN
dti-3059	147	12	,	,	PUNCT
dti-3059	147	13	including	include	VERB
dti-3059	147	14	the	the	DET
dti-3059	147	15	delta	delta	NOUN
dti-3059	147	16	and	and	CCONJ
dti-3059	147	17	omicron	omicron	PROPN
dti-3059	147	18	variants	variant	NOUN
dti-3059	147	19	,	,	PUNCT
dti-3059	147	20	reduced	reduce	VERB
dti-3059	147	21	immunoreactivity	immunoreactivity	NOUN
dti-3059	147	22	with	with	ADP
dti-3059	147	23	polyclonal	polyclonal	ADJ
dti-3059	147	24	sera	sera	NOUN
dti-3059	147	25	by	by	ADP
dti-3059	147	26	vaccine	vaccine	NOUN
dti-3059	147	27	-	-	PUNCT
dti-3059	147	28	induced	induce	VERB
dti-3059	147	29	humoral	humoral	ADJ
dti-3059	147	30	immunity	immunity	NOUN
dti-3059	147	31	.	.	PUNCT
dti-3059	148	1	the	the	DET
dti-3059	148	2	delta	delta	NOUN
dti-3059	148	3	variant	variant	NOUN
dti-3059	148	4	’s	’s	PART
dti-3059	148	5	neutralization	neutralization	NOUN
dti-3059	148	6	is	be	AUX
dti-3059	148	7	primarily	primarily	ADV
dti-3059	148	8	attributed	attribute	VERB
dti-3059	148	9	to	to	ADP
dti-3059	148	10	mutations	mutation	NOUN
dti-3059	148	11	in	in	ADP
dti-3059	148	12	the	the	DET
dti-3059	148	13	rbd	rbd	NOUN
dti-3059	148	14	of	of	ADP
dti-3059	148	15	the	the	DET
dti-3059	148	16	spike	spike	ADJ
dti-3059	148	17	protein	protein	NOUN
dti-3059	148	18	.	.	PUNCT
dti-3059	149	1	the	the	DET
dti-3059	149	2	rbd	rbd	NOUN
dti-3059	149	3	mutations	mutation	NOUN
dti-3059	149	4	,	,	PUNCT
dti-3059	149	5	such	such	ADJ
dti-3059	149	6	as	as	ADP
dti-3059	149	7	k417n	k417n	NOUN
dti-3059	149	8	,	,	PUNCT
dti-3059	149	9	e484k	e484k	PROPN
dti-3059	149	10	,	,	PUNCT
dti-3059	149	11	and	and	CCONJ
dti-3059	149	12	n501y	n501y	PROPN
dti-3059	149	13	,	,	PUNCT
dti-3059	149	14	play	play	VERB
dti-3059	149	15	a	a	DET
dti-3059	149	16	significant	significant	ADJ
dti-3059	149	17	role	role	NOUN
dti-3059	149	18	in	in	ADP
dti-3059	149	19	the	the	DET
dti-3059	149	20	escape	escape	NOUN
dti-3059	149	21	from	from	ADP
dti-3059	149	22	vaccine	vaccine	NOUN
dti-3059	149	23	-	-	PUNCT
dti-3059	149	24	induced	induce	VERB
dti-3059	149	25	neutralization	neutralization	NOUN
dti-3059	149	26	.	.	PUNCT
dti-3059	150	1	the	the	DET
dti-3059	150	2	study	study	NOUN
dti-3059	150	3	highlights	highlight	VERB
dti-3059	150	4	the	the	DET
dti-3059	150	5	need	need	NOUN
dti-3059	150	6	for	for	ADP
dti-3059	150	7	reformulating	reformulate	VERB
dti-3059	150	8	existing	exist	VERB
dti-3059	150	9	vaccines	vaccine	NOUN
dti-3059	150	10	to	to	PART
dti-3059	150	11	include	include	VERB
dti-3059	150	12	diverse	diverse	ADJ
dti-3059	150	13	spike	spike	ADJ
dti-3059	150	14	sequences	sequence	NOUN
dti-3059	150	15	and	and	CCONJ
dti-3059	150	16	the	the	DET
dti-3059	150	17	development	development	NOUN
dti-3059	150	18	of	of	ADP
dti-3059	150	19	new	new	ADJ
dti-3059	150	20	vaccines	vaccine	NOUN
dti-3059	150	21	capable	capable	ADJ
dti-3059	150	22	of	of	ADP
dti-3059	150	23	eliciting	elicit	VERB
dti-3059	150	24	broadly	broadly	ADV
dti-3059	150	25	neutralizing	neutralize	VERB
dti-3059	150	26	antibodies	antibody	NOUN
dti-3059	150	27	to	to	PART
dti-3059	150	28	effectively	effectively	ADV
dti-3059	150	29	combat	combat	VERB
dti-3059	150	30	the	the	DET
dti-3059	150	31	infection	infection	NOUN
dti-3059	150	32	with	with	ADP
dti-3059	150	33	variants	variant	NOUN
dti-3059	150	34	of	of	ADP
dti-3059	150	35	sars	sar	NOUN
dti-3059	150	36	-	-	PUNCT
dti-3059	150	37	cov-2	cov-2	NUM
dti-3059	150	38	and	and	CCONJ
dti-3059	150	39	possible	possible	ADJ
dti-3059	150	40	future	future	ADJ
dti-3059	150	41	pandemic	pandemic	NOUN
dti-3059	150	42	.	.	PUNCT
dti-3059	151	1	it	it	PRON
dti-3059	151	2	also	also	ADV
dti-3059	151	3	emphasizes	emphasize	VERB
dti-3059	151	4	the	the	DET
dti-3059	151	5	importance	importance	NOUN
dti-3059	151	6	of	of	ADP
dti-3059	151	7	assessing	assess	VERB
dti-3059	151	8	other	other	ADJ
dti-3059	151	9	antibody	antibody	NOUN
dti-3059	151	10	-	-	PUNCT
dti-3059	151	11	mediated	mediate	VERB
dti-3059	151	12	functions	function	NOUN
dti-3059	151	13	and	and	CCONJ
dti-3059	151	14	cellular	cellular	ADJ
dti-3059	151	15	immune	immune	ADJ
dti-3059	151	16	responses	response	NOUN
dti-3059	151	17	mediated	mediate	VERB
dti-3059	151	18	by	by	ADP
dti-3059	151	19	t	t	NOUN
dti-3059	151	20	cells	cell	NOUN
dti-3059	151	21	and	and	CCONJ
dti-3059	151	22	natural	natural	ADJ
dti-3059	151	23	killer	killer	NOUN
dti-3059	151	24	(	(	PUNCT
dti-3059	151	25	nk	nk	PROPN
dti-3059	151	26	)	)	PUNCT
dti-3059	151	27	cells	cell	NOUN
dti-3059	151	28	in	in	ADP
dti-3059	151	29	understanding	understand	VERB
dti-3059	151	30	the	the	DET
dti-3059	151	31	overall	overall	ADJ
dti-3059	151	32	protection	protection	NOUN
dti-3059	151	33	provided	provide	VERB
dti-3059	151	34	by	by	ADP
dti-3059	151	35	vaccines	vaccine	NOUN
dti-3059	151	36	.	.	PUNCT
dti-3059	152	1	acknowledgments	acknowledgment	NOUN
dti-3059	152	2	we	we	PRON
dti-3059	152	3	would	would	AUX
dti-3059	152	4	like	like	VERB
dti-3059	152	5	to	to	PART
dti-3059	152	6	acknowledge	acknowledge	VERB
dti-3059	152	7	the	the	DET
dti-3059	152	8	all	all	DET
dti-3059	152	9	india	india	PROPN
dti-3059	152	10	institute	institute	PROPN
dti-3059	152	11	of	of	ADP
dti-3059	152	12	medical	medical	ADJ
dti-3059	152	13	science	science	PROPN
dti-3059	152	14	,	,	PUNCT
dti-3059	152	15	raipur	raipur	PROPN
dti-3059	152	16	,	,	PUNCT
dti-3059	152	17	for	for	ADP
dti-3059	152	18	providing	provide	VERB
dti-3059	152	19	the	the	DET
dti-3059	152	20	financial	financial	ADJ
dti-3059	152	21	support	support	NOUN
dti-3059	152	22	for	for	ADP
dti-3059	152	23	the	the	DET
dti-3059	152	24	study	study	NOUN
dti-3059	152	25	via	via	ADP
dti-3059	152	26	intramural	intramural	ADJ
dti-3059	152	27	grant	grant	NOUN
dti-3059	152	28	(	(	PUNCT
dti-3059	152	29	no.22/41/2019	no.22/41/2019	NUM
dti-3059	152	30	/	/	SYM
dti-3059	152	31	admin/1346	admin/1346	ADJ
dti-3059	152	32	)	)	PUNCT
dti-3059	152	33	.	.	PUNCT
dti-3059	153	1	disclosures	disclosure	VERB
dti-3059	153	2	conflict	conflict	NOUN
dti-3059	153	3	of	of	ADP
dti-3059	153	4	interest	interest	NOUN
dti-3059	153	5	:	:	PUNCT
dti-3059	153	6	all	all	DET
dti-3059	153	7	the	the	DET
dti-3059	153	8	authors	author	NOUN
dti-3059	153	9	of	of	ADP
dti-3059	153	10	the	the	DET
dti-3059	153	11	manuscript	manuscript	NOUN
dti-3059	153	12	do	do	AUX
dti-3059	153	13	not	not	PART
dti-3059	153	14	have	have	VERB
dti-3059	153	15	any	any	DET
dti-3059	153	16	conflict	conflict	NOUN
dti-3059	153	17	.	.	PUNCT
dti-3059	154	1	financial	financial	ADJ
dti-3059	154	2	support	support	NOUN
dti-3059	154	3	:	:	PUNCT
dti-3059	154	4	the	the	DET
dti-3059	154	5	study	study	NOUN
dti-3059	154	6	was	be	AUX
dti-3059	154	7	supported	support	VERB
dti-3059	154	8	by	by	ADP
dti-3059	154	9	intramural	intramural	ADJ
dti-3059	154	10	research	research	NOUN
dti-3059	154	11	grant	grant	NOUN
dti-3059	154	12	sanctioned	sanction	VERB
dti-3059	154	13	by	by	ADP
dti-3059	154	14	all	all	DET
dti-3059	154	15	india	india	PROPN
dti-3059	154	16	institute	institute	PROPN
dti-3059	154	17	of	of	ADP
dti-3059	154	18	medical	medical	PROPN
dti-3059	154	19	sciences	sciences	PROPN
dti-3059	154	20	,	,	PUNCT
dti-3059	154	21	raipur	raipur	NOUN
dti-3059	154	22	,	,	PUNCT
dti-3059	154	23	chhattisgarh	chhattisgarh	PROPN
dti-3059	154	24	,	,	PUNCT
dti-3059	154	25	india	india	PROPN
dti-3059	154	26	.	.	PUNCT
dti-3059	155	1	references	reference	NOUN
dti-3059	155	2	1	1	NUM
dti-3059	155	3	.	.	PUNCT
dti-3059	155	4	to	to	ADP
dti-3059	155	5	kkw	kkw	PROPN
dti-3059	155	6	,	,	PUNCT
dti-3059	155	7	sridhar	sridhar	NOUN
dti-3059	155	8	s	s	PROPN
dti-3059	155	9	,	,	PUNCT
dti-3059	155	10	chiu	chiu	PROPN
dti-3059	155	11	khy	khy	PROPN
dti-3059	155	12	,	,	PUNCT
dti-3059	156	1	et	et	PROPN
dti-3059	156	2	al	al	PROPN
dti-3059	156	3	.	.	PUNCT
dti-3059	156	4	lessons	lesson	NOUN
dti-3059	156	5	learned	learn	VERB
dti-3059	156	6	1	1	NUM
dti-3059	156	7	year	year	NOUN
dti-3059	156	8	after	after	SCONJ
dti-3059	156	9	sars	sar	NOUN
dti-3059	156	10	-	-	PUNCT
dti-3059	156	11	cov-2	cov-2	PART
dti-3059	156	12	emergence	emergence	NOUN
dti-3059	156	13	leading	lead	VERB
dti-3059	156	14	to	to	ADP
dti-3059	156	15	covid-19	covid-19	PROPN
dti-3059	156	16	pandemic	pandemic	ADJ
dti-3059	156	17	.	.	PUNCT
dti-3059	157	1	emerg	emerg	PROPN
dti-3059	157	2	microbes	microbe	NOUN
dti-3059	157	3	infect	infect	VERB
dti-3059	157	4	.	.	PUNCT
dti-3059	158	1	2021;10(1):507	2021;10(1):507	NOUN
dti-3059	158	2	-	-	SYM
dti-3059	158	3	535	535	NUM
dti-3059	158	4	.	.	PUNCT
dti-3059	159	1	crossref	crossref	PROPN
dti-3059	159	2	pubmed	pubmed	PROPN
dti-3059	159	3	2	2	PROPN
dti-3059	159	4	.	.	PUNCT
dti-3059	160	1	khan	khan	PROPN
dti-3059	160	2	m	m	PROPN
dti-3059	160	3	,	,	PUNCT
dti-3059	160	4	adil	adil	PROPN
dti-3059	160	5	sf	sf	PROPN
dti-3059	160	6	,	,	PUNCT
dti-3059	160	7	alkhathlan	alkhathlan	PROPN
dti-3059	160	8	hz	hz	VERB
dti-3059	160	9	,	,	PUNCT
dti-3059	160	10	et	et	PROPN
dti-3059	160	11	al	al	PROPN
dti-3059	160	12	.	.	PUNCT
dti-3059	161	1	covid-19	covid-19	PROPN
dti-3059	161	2	:	:	PUNCT
dti-3059	161	3	a	a	DET
dti-3059	161	4	global	global	ADJ
dti-3059	161	5	challenge	challenge	NOUN
dti-3059	161	6	with	with	ADP
dti-3059	161	7	old	old	ADJ
dti-3059	161	8	history	history	NOUN
dti-3059	161	9	,	,	PUNCT
dti-3059	161	10	epidemiology	epidemiology	NOUN
dti-3059	161	11	and	and	CCONJ
dti-3059	161	12	progress	progress	NOUN
dti-3059	161	13	so	so	ADV
dti-3059	161	14	far	far	ADV
dti-3059	161	15	.	.	PUNCT
dti-3059	162	1	molecules	molecule	NOUN
dti-3059	162	2	.	.	PUNCT
dti-3059	163	1	2020;26(1):39	2020;26(1):39	NUM
dti-3059	163	2	.	.	PUNCT
dti-3059	163	3	crossref	crossref	PROPN
dti-3059	163	4	pubmed	pubmed	PROPN
dti-3059	163	5	3	3	PROPN
dti-3059	163	6	.	.	PUNCT
dti-3059	164	1	tregoning	tregone	VERB
dti-3059	164	2	js	js	PROPN
dti-3059	164	3	,	,	PUNCT
dti-3059	164	4	flight	flight	NOUN
dti-3059	164	5	ke	ke	NOUN
dti-3059	164	6	,	,	PUNCT
dti-3059	164	7	higham	higham	PROPN
dti-3059	164	8	sl	sl	PROPN
dti-3059	164	9	,	,	PUNCT
dti-3059	164	10	wang	wang	PROPN
dti-3059	164	11	z	z	PROPN
dti-3059	164	12	,	,	PUNCT
dti-3059	164	13	pierce	pierce	PROPN
dti-3059	164	14	bf	bf	PROPN
dti-3059	164	15	.	.	PROPN
dti-3059	164	16	progress	progress	NOUN
dti-3059	164	17	of	of	ADP
dti-3059	164	18	the	the	DET
dti-3059	164	19	covid-19	covid-19	PROPN
dti-3059	164	20	vaccine	vaccine	NOUN
dti-3059	164	21	effort	effort	NOUN
dti-3059	164	22	:	:	PUNCT
dti-3059	164	23	viruses	virus	NOUN
dti-3059	164	24	,	,	PUNCT
dti-3059	164	25	vaccines	vaccine	NOUN
dti-3059	164	26	and	and	CCONJ
dti-3059	164	27	variants	variant	NOUN
dti-3059	164	28	versus	versus	ADP
dti-3059	164	29	efficacy	efficacy	NOUN
dti-3059	164	30	,	,	PUNCT
dti-3059	164	31	effectiveness	effectiveness	NOUN
dti-3059	164	32	and	and	CCONJ
dti-3059	164	33	escape	escape	NOUN
dti-3059	164	34	.	.	PUNCT
dti-3059	165	1	nat	nat	PROPN
dti-3059	165	2	rev	rev	PROPN
dti-3059	165	3	immunol	immunol	NOUN
dti-3059	165	4	.	.	PUNCT
dti-3059	165	5	2021	2021	NUM
dti-3059	165	6	;	;	PUNCT
dti-3059	165	7	21(10):626	21(10):626	NUM
dti-3059	165	8	-	-	SYM
dti-3059	165	9	636	636	NUM
dti-3059	165	10	.	.	PUNCT
dti-3059	166	1	crossref	crossref	PROPN
dti-3059	166	2	pubmed	pubmed	PROPN
dti-3059	166	3	4	4	PROPN
dti-3059	166	4	.	.	PUNCT
dti-3059	167	1	tsurkalenko	tsurkalenko	PROPN
dti-3059	167	2	o	o	NOUN
dti-3059	167	3	,	,	PUNCT
dti-3059	167	4	bulaev	bulaev	PROPN
dti-3059	167	5	d	d	PROPN
dti-3059	167	6	,	,	PUNCT
dti-3059	167	7	o’sullivan	o’sullivan	PROPN
dti-3059	167	8	mp	mp	PROPN
dti-3059	167	9	,	,	PUNCT
dti-3059	167	10	et	et	PROPN
dti-3059	167	11	al	al	PROPN
dti-3059	167	12	;	;	PUNCT
dti-3059	167	13	con	con	ADJ
dti-3059	167	14	-	-	PUNCT
dti-3059	167	15	vince	vince	NOUN
dti-3059	167	16	consortium	consortium	NOUN
dti-3059	167	17	and	and	CCONJ
dti-3059	167	18	the	the	DET
dti-3059	167	19	orchestra	orchestra	PROPN
dti-3059	167	20	working	working	NOUN
dti-3059	167	21	group	group	NOUN
dti-3059	167	22	.	.	PUNCT
dti-3059	168	1	creation	creation	NOUN
dti-3059	168	2	of	of	ADP
dti-3059	168	3	a	a	DET
dti-3059	168	4	pandemic	pandemic	ADJ
dti-3059	168	5	memory	memory	NOUN
dti-3059	168	6	by	by	ADP
dti-3059	168	7	tracing	trace	VERB
dti-3059	168	8	covid-19	covid-19	PROPN
dti-3059	168	9	infections	infection	NOUN
dti-3059	168	10	and	and	CCONJ
dti-3059	168	11	immunity	immunity	NOUN
dti-3059	168	12	in	in	ADP
dti-3059	168	13	luxembourg	luxembourg	PROPN
dti-3059	168	14	(	(	PUNCT
dti-3059	168	15	con	con	NOUN
dti-3059	168	16	-	-	PUNCT
dti-3059	168	17	vince	vince	NOUN
dti-3059	168	18	)	)	PUNCT
dti-3059	168	19	.	.	PUNCT
dti-3059	169	1	bmc	bmc	PROPN
dti-3059	169	2	infect	infect	PROPN
dti-3059	169	3	dis	dis	PROPN
dti-3059	169	4	.	.	PUNCT
dti-3059	170	1	2024;24(1):179	2024;24(1):179	NOUN
dti-3059	170	2	.	.	PUNCT
dti-3059	171	1	crossref	crossref	PROPN
dti-3059	171	2	pubmed	pubmed	PROPN
dti-3059	171	3	5	5	NUM
dti-3059	171	4	.	.	PUNCT
dti-3059	171	5	akhlaghi	akhlaghi	PROPN
dti-3059	172	1	a	a	PRON
dti-3059	172	2	,	,	PUNCT
dti-3059	172	3	darabi	darabi	NOUN
dti-3059	172	4	a	a	NOUN
dti-3059	172	5	,	,	PUNCT
dti-3059	172	6	mahmoodi	mahmoodi	NOUN
dti-3059	172	7	m	m	PROPN
dti-3059	172	8	,	,	PUNCT
dti-3059	172	9	et	et	PROPN
dti-3059	172	10	al	al	PROPN
dti-3059	172	11	.	.	PUNCT
dti-3059	173	1	the	the	DET
dti-3059	173	2	frequency	frequency	NOUN
dti-3059	173	3	and	and	CCONJ
dti-3059	173	4	clinical	clinical	ADJ
dti-3059	173	5	assessment	assessment	NOUN
dti-3059	173	6	of	of	ADP
dti-3059	173	7	covid-19	covid-19	PROPN
dti-3059	173	8	in	in	ADP
dti-3059	173	9	patients	patient	NOUN
dti-3059	173	10	with	with	ADP
dti-3059	173	11	chronic	chronic	ADJ
dti-3059	173	12	rhinosinusitis	rhinosinusitis	NOUN
dti-3059	173	13	.	.	PUNCT
dti-3059	174	1	ear	ear	PROPN
dti-3059	174	2	nose	nose	NOUN
dti-3059	174	3	throat	throat	PROPN
dti-3059	174	4	j.	j.	PROPN
dti-3059	174	5	2024;103(2):np98	2024;103(2):np98	PROPN
dti-3059	174	6	-	-	PUNCT
dti-3059	174	7	np103	np103	PROPN
dti-3059	174	8	.	.	PUNCT
dti-3059	175	1	crossref	crossref	PROPN
dti-3059	175	2	pubmed	pubmed	PROPN
dti-3059	175	3	6	6	NUM
dti-3059	175	4	.	.	PUNCT
dti-3059	175	5	su	su	PROPN
dti-3059	175	6	s	s	PROPN
dti-3059	175	7	,	,	PUNCT
dti-3059	175	8	zhao	zhao	PROPN
dti-3059	175	9	y	y	PROPN
dti-3059	175	10	,	,	PUNCT
dti-3059	175	11	zeng	zeng	PROPN
dti-3059	175	12	n	n	CCONJ
dti-3059	175	13	,	,	PUNCT
dti-3059	175	14	et	et	PROPN
dti-3059	175	15	al	al	PROPN
dti-3059	175	16	.	.	PUNCT
dti-3059	176	1	epidemiology	epidemiology	NOUN
dti-3059	176	2	,	,	PUNCT
dti-3059	176	3	clinical	clinical	ADJ
dti-3059	176	4	presentation	presentation	NOUN
dti-3059	176	5	,	,	PUNCT
dti-3059	176	6	pathophysiology	pathophysiology	NOUN
dti-3059	176	7	,	,	PUNCT
dti-3059	176	8	and	and	CCONJ
dti-3059	176	9	management	management	NOUN
dti-3059	176	10	of	of	ADP
dti-3059	176	11	long	long	ADJ
dti-3059	176	12	covid	covid	NOUN
dti-3059	176	13	:	:	PUNCT
dti-3059	176	14	an	an	DET
dti-3059	176	15	update	update	NOUN
dti-3059	176	16	.	.	PUNCT
dti-3059	177	1	mol	mol	ADP
dti-3059	177	2	psychiatry	psychiatry	NOUN
dti-3059	177	3	.	.	PUNCT
dti-3059	178	1	2023;28(10):4056	2023;28(10):4056	NUM
dti-3059	178	2	-	-	SYM
dti-3059	178	3	4069	4069	NUM
dti-3059	178	4	.	.	PUNCT
dti-3059	179	1	crossref	crossref	PROPN
dti-3059	179	2	pubmed	pubmed	PROPN
dti-3059	179	3	7	7	PROPN
dti-3059	179	4	.	.	PUNCT
dti-3059	180	1	zaidi	zaidi	PROPN
dti-3059	180	2	ak	ak	PROPN
dti-3059	180	3	,	,	PUNCT
dti-3059	180	4	singh	singh	PROPN
dti-3059	180	5	rb	rb	PROPN
dti-3059	180	6	.	.	PUNCT
dti-3059	180	7	epidemiology	epidemiology	NOUN
dti-3059	180	8	of	of	ADP
dti-3059	180	9	covid-19	covid-19	PROPN
dti-3059	180	10	.	.	PUNCT
dti-3059	180	11	prog	prog	PROPN
dti-3059	180	12	mol	mol	ADP
dti-3059	180	13	biol	biol	PROPN
dti-3059	180	14	transl	transl	PROPN
dti-3059	180	15	sci	sci	PROPN
dti-3059	180	16	.	.	PUNCT
dti-3059	180	17	2024;202:25	2024;202:25	NUM
dti-3059	180	18	-	-	SYM
dti-3059	180	19	38	38	NUM
dti-3059	180	20	.	.	PUNCT
dti-3059	181	1	pubmed	pubmed	PROPN
dti-3059	181	2	8	8	PROPN
dti-3059	181	3	.	.	PUNCT
dti-3059	181	4	montezano	montezano	PROPN
dti-3059	181	5	ac	ac	PROPN
dti-3059	181	6	,	,	PUNCT
dti-3059	181	7	camargo	camargo	PROPN
dti-3059	181	8	ll	ll	PROPN
dti-3059	181	9	,	,	PUNCT
dti-3059	181	10	mary	mary	PROPN
dti-3059	181	11	s	s	PROPN
dti-3059	181	12	,	,	PUNCT
dti-3059	181	13	et	et	PROPN
dti-3059	181	14	al	al	PROPN
dti-3059	181	15	.	.	PUNCT
dti-3059	182	1	sars	sars	PROPN
dti-3059	182	2	-	-	PUNCT
dti-3059	182	3	cov-2	cov-2	NOUN
dti-3059	182	4	spike	spike	ADJ
dti-3059	182	5	protein	protein	NOUN
dti-3059	182	6	induces	induce	VERB
dti-3059	182	7	endothelial	endothelial	ADJ
dti-3059	182	8	inflammation	inflammation	NOUN
dti-3059	182	9	via	via	ADP
dti-3059	182	10	ace2	ace2	PROPN
dti-3059	182	11	independently	independently	ADV
dti-3059	182	12	of	of	ADP
dti-3059	182	13	viral	viral	ADJ
dti-3059	182	14	replication	replication	NOUN
dti-3059	182	15	.	.	PUNCT
dti-3059	183	1	sci	sci	PROPN
dti-3059	183	2	rep	rep	PROPN
dti-3059	183	3	.	.	PROPN
dti-3059	183	4	2023;13(1):14086	2023;13(1):14086	PROPN
dti-3059	183	5	.	.	PUNCT
dti-3059	184	1	crossref	crossref	PROPN
dti-3059	184	2	pubmed	pubmed	PROPN
dti-3059	184	3	9	9	PROPN
dti-3059	184	4	.	.	PUNCT
dti-3059	185	1	kibria	kibria	PROPN
dti-3059	185	2	mg	mg	PROPN
dti-3059	185	3	,	,	PUNCT
dti-3059	185	4	lavine	lavine	PROPN
dti-3059	185	5	cl	cl	PROPN
dti-3059	185	6	,	,	PUNCT
dti-3059	185	7	tang	tang	PROPN
dti-3059	185	8	w	w	PROPN
dti-3059	185	9	,	,	PUNCT
dti-3059	185	10	et	et	PROPN
dti-3059	185	11	al	al	PROPN
dti-3059	185	12	.	.	PUNCT
dti-3059	185	13	antibody	antibody	NOUN
dti-3059	185	14	-	-	PUNCT
dti-3059	185	15	mediated	mediate	VERB
dti-3059	186	1	sarscov-2	sarscov-2	NUM
dti-3059	186	2	entry	entry	NOUN
dti-3059	186	3	in	in	ADP
dti-3059	186	4	cultured	cultured	ADJ
dti-3059	186	5	cells	cell	NOUN
dti-3059	186	6	.	.	PUNCT
dti-3059	187	1	embo	embo	PROPN
dti-3059	187	2	rep	rep	PROPN
dti-3059	187	3	.	.	PROPN
dti-3059	187	4	2023;24(12):e57724	2023;24(12):e57724	NOUN
dti-3059	187	5	.	.	PUNCT
dti-3059	188	1	crossref	crossref	PROPN
dti-3059	188	2	pubmed	pubmed	PROPN
dti-3059	188	3	10	10	PROPN
dti-3059	188	4	.	.	PUNCT
dti-3059	189	1	li	li	PROPN
dti-3059	189	2	cj	cj	PROPN
dti-3059	189	3	,	,	PUNCT
dti-3059	189	4	chang	chang	PROPN
dti-3059	189	5	sc	sc	PROPN
dti-3059	189	6	.	.	PUNCT
dti-3059	189	7	sars	sars	PROPN
dti-3059	189	8	-	-	PUNCT
dti-3059	189	9	cov-2	cov-2	PART
dti-3059	189	10	spike	spike	ADJ
dti-3059	189	11	s2	s2	NOUN
dti-3059	189	12	-	-	PUNCT
dti-3059	189	13	specific	specific	ADJ
dti-3059	189	14	neutralizing	neutralize	VERB
dti-3059	189	15	antibodies	antibody	NOUN
dti-3059	189	16	.	.	PUNCT
dti-3059	190	1	emerg	emerg	PROPN
dti-3059	190	2	microbes	microbe	NOUN
dti-3059	190	3	infect	infect	VERB
dti-3059	190	4	.	.	PUNCT
dti-3059	191	1	2023;12(2):2220582	2023;12(2):2220582	NUM
dti-3059	191	2	.	.	PUNCT
dti-3059	192	1	crossref	crossref	PROPN
dti-3059	192	2	pubmed	pubmed	PROPN
dti-3059	192	3	11	11	NUM
dti-3059	192	4	.	.	PUNCT
dti-3059	192	5	akaishi	akaishi	PROPN
dti-3059	192	6	t	t	PROPN
dti-3059	192	7	,	,	PUNCT
dti-3059	192	8	fujiwara	fujiwara	PROPN
dti-3059	192	9	k.	k.	PROPN
dti-3059	192	10	insertion	insertion	PROPN
dti-3059	192	11	and	and	CCONJ
dti-3059	192	12	deletion	deletion	NOUN
dti-3059	192	13	mutations	mutation	NOUN
dti-3059	192	14	preserved	preserve	VERB
dti-3059	192	15	in	in	ADP
dti-3059	192	16	sars	sar	NOUN
dti-3059	192	17	-	-	PUNCT
dti-3059	192	18	cov-2	cov-2	NOUN
dti-3059	192	19	variants	variant	NOUN
dti-3059	192	20	.	.	PUNCT
dti-3059	193	1	arch	arch	PROPN
dti-3059	193	2	microbiol	microbiol	PROPN
dti-3059	193	3	.	.	PUNCT
dti-3059	194	1	2023;205(4	2023;205(4	NUM
dti-3059	194	2	):	):	PUNCT
dti-3059	194	3	154	154	NUM
dti-3059	194	4	.	.	PUNCT
dti-3059	195	1	crossref	crossref	PROPN
dti-3059	195	2	pubmed	pubmed	PROPN
dti-3059	195	3	12	12	NUM
dti-3059	195	4	.	.	PUNCT
dti-3059	196	1	ma	ma	PROPN
dti-3059	196	2	kc	kc	PROPN
dti-3059	196	3	,	,	PUNCT
dti-3059	196	4	shirk	shirk	NOUN
dti-3059	196	5	p	p	NOUN
dti-3059	196	6	,	,	PUNCT
dti-3059	196	7	lambrou	lambrou	NOUN
dti-3059	196	8	as	as	ADP
dti-3059	196	9	,	,	PUNCT
dti-3059	196	10	et	et	PROPN
dti-3059	196	11	al	al	PROPN
dti-3059	196	12	.	.	PUNCT
dti-3059	197	1	genomic	genomic	ADJ
dti-3059	197	2	surveillance	surveillance	NOUN
dti-3059	197	3	for	for	ADP
dti-3059	197	4	sars	sar	NOUN
dti-3059	197	5	-	-	PUNCT
dti-3059	197	6	cov-2	cov-2	NOUN
dti-3059	197	7	variants	variant	NOUN
dti-3059	197	8	:	:	PUNCT
dti-3059	197	9	circulation	circulation	NOUN
dti-3059	197	10	of	of	ADP
dti-3059	197	11	omicron	omicron	PROPN
dti-3059	197	12	lineages	lineage	NOUN
dti-3059	197	13	–	–	PUNCT
dti-3059	197	14	united	united	ADJ
dti-3059	197	15	states	states	PROPN
dti-3059	197	16	,	,	PUNCT
dti-3059	197	17	january	january	PROPN
dti-3059	197	18	2022	2022	NUM
dti-3059	197	19	-	-	PUNCT
dti-3059	197	20	may	may	PROPN
dti-3059	197	21	2023	2023	NUM
dti-3059	197	22	.	.	PUNCT
dti-3059	198	1	mmwr	mmwr	ADJ
dti-3059	198	2	morb	morb	NOUN
dti-3059	198	3	mortal	mortal	ADJ
dti-3059	198	4	wkly	wkly	PROPN
dti-3059	198	5	rep	rep	PROPN
dti-3059	198	6	.	.	PROPN
dti-3059	198	7	2023;72(24):651	2023;72(24):651	PROPN
dti-3059	198	8	-	-	PUNCT
dti-3059	198	9	656	656	NUM
dti-3059	198	10	.	.	PUNCT
dti-3059	199	1	crossref	crossref	PROPN
dti-3059	199	2	pubmed	pubmed	PROPN
dti-3059	199	3	13	13	NUM
dti-3059	199	4	.	.	PUNCT
dti-3059	200	1	aleem	aleem	PROPN
dti-3059	200	2	a	a	PRON
dti-3059	200	3	,	,	PUNCT
dti-3059	200	4	akbar	akbar	PROPN
dti-3059	200	5	samad	samad	PROPN
dti-3059	200	6	ab	ab	PROPN
dti-3059	200	7	,	,	PUNCT
dti-3059	200	8	vaqar	vaqar	PROPN
dti-3059	200	9	s.	s.	PROPN
dti-3059	200	10	emerging	emerge	VERB
dti-3059	200	11	variants	variant	NOUN
dti-3059	200	12	of	of	ADP
dti-3059	200	13	sarscov-2	sarscov-2	NUM
dti-3059	200	14	and	and	CCONJ
dti-3059	200	15	novel	novel	ADJ
dti-3059	200	16	therapeutics	therapeutic	NOUN
dti-3059	200	17	against	against	ADP
dti-3059	200	18	coronavirus	coronavirus	NOUN
dti-3059	200	19	(	(	PUNCT
dti-3059	200	20	covid-19	covid-19	PROPN
dti-3059	200	21	)	)	PUNCT
dti-3059	200	22	.	.	PUNCT
dti-3059	201	1	in	in	ADP
dti-3059	201	2	:	:	PUNCT
dti-3059	201	3	statpearls	statpearl	NOUN
dti-3059	201	4	.	.	PUNCT
dti-3059	202	1	[	[	X
dti-3059	202	2	internet	internet	NOUN
dti-3059	202	3	]	]	X
dti-3059	202	4	statpearls	statpearls	PROPN
dti-3059	202	5	publishing	publishing	NOUN
dti-3059	202	6	;	;	PUNCT
dti-3059	202	7	2024	2024	NUM
dti-3059	202	8	,	,	PUNCT
dti-3059	202	9	available	available	ADJ
dti-3059	202	10	from	from	ADP
dti-3059	202	11	online	online	ADV
dti-3059	202	12	.	.	PUNCT
dti-3059	203	1	accessed	access	VERB
dti-3059	203	2	march	march	PROPN
dti-3059	203	3	1	1	NUM
dti-3059	203	4	,	,	PUNCT
dti-3059	203	5	2024	2024	NUM
dti-3059	203	6	.	.	PUNCT
dti-3059	204	1	https://doi.org/10.1080/22221751.2021.1898291	https://doi.org/10.1080/22221751.2021.1898291	PROPN
dti-3059	204	2	https://www.ncbi.nlm.nih.gov/pubmed/33666147	https://www.ncbi.nlm.nih.gov/pubmed/33666147	NUM
dti-3059	204	3	https://doi.org/10.3390/molecules26010039	https://doi.org/10.3390/molecules26010039	NOUN
dti-3059	204	4	https://www.ncbi.nlm.nih.gov/pubmed/33374759	https://www.ncbi.nlm.nih.gov/pubmed/33374759	NUM
dti-3059	204	5	https://doi.org/10.1038/s41577-021-00592-1	https://doi.org/10.1038/s41577-021-00592-1	NUM
dti-3059	204	6	https://www.ncbi.nlm.nih.gov/pubmed/34373623	https://www.ncbi.nlm.nih.gov/pubmed/34373623	NUM
dti-3059	205	1	https://doi.org/10.1186/s12879-024-09055-z	https://doi.org/10.1186/s12879-024-09055-z	INTJ
dti-3059	205	2	https://www.ncbi.nlm.nih.gov/pubmed/38336649	https://www.ncbi.nlm.nih.gov/pubmed/38336649	NUM
dti-3059	205	3	https://doi.org/10.1177/01455613211038070	https://doi.org/10.1177/01455613211038070	NOUN
dti-3059	205	4	https://www.ncbi.nlm.nih.gov/pubmed/34414811	https://www.ncbi.nlm.nih.gov/pubmed/34414811	PRON
dti-3059	205	5	https://doi.org/10.1038/s41380-023-02171-3	https://doi.org/10.1038/s41380-023-02171-3	NUM
dti-3059	205	6	https://www.ncbi.nlm.nih.gov/pubmed/37491461	https://www.ncbi.nlm.nih.gov/pubmed/37491461	X
dti-3059	205	7	https://www.ncbi.nlm.nih.gov/pubmed/38237988	https://www.ncbi.nlm.nih.gov/pubmed/38237988	NUM
dti-3059	205	8	https://doi.org/10.1038/s41598-023-41115-3	https://doi.org/10.1038/s41598-023-41115-3	NOUN
dti-3059	205	9	https://www.ncbi.nlm.nih.gov/pubmed/37640791	https://www.ncbi.nlm.nih.gov/pubmed/37640791	ADP
dti-3059	205	10	https://doi.org/10.15252/embr.202357724	https://doi.org/10.15252/embr.202357724	PROPN
dti-3059	205	11	https://www.ncbi.nlm.nih.gov/pubmed/38277394	https://www.ncbi.nlm.nih.gov/pubmed/38277394	NOUN
dti-3059	205	12	https://doi.org/10.1080/22221751.2023.2220582	https://doi.org/10.1080/22221751.2023.2220582	NOUN
dti-3059	205	13	https://www.ncbi.nlm.nih.gov/pubmed/37254830	https://www.ncbi.nlm.nih.gov/pubmed/37254830	VERB
dti-3059	205	14	https://doi.org/10.1007/s00203-023-03493-0	https://doi.org/10.1007/s00203-023-03493-0	NOUN
dti-3059	205	15	https://www.ncbi.nlm.nih.gov/pubmed/37000302	https://www.ncbi.nlm.nih.gov/pubmed/37000302	X
dti-3059	205	16	https://doi.org/10.15585/mmwr.mm7224a2	https://doi.org/10.15585/mmwr.mm7224a2	PROPN
dti-3059	205	17	https://www.ncbi.nlm.nih.gov/pubmed/37319011	https://www.ncbi.nlm.nih.gov/pubmed/37319011	NUM
dti-3059	205	18	http://www.ncbi.nlm.nih.gov/books/nbk570580/	http://www.ncbi.nlm.nih.gov/books/nbk570580/	NOUN
dti-3059	205	19	sars	sar	NOUN
dti-3059	205	20	-	-	PUNCT
dti-3059	205	21	cov-2	cov-2	NOUN
dti-3059	205	22	variants	variant	NOUN
dti-3059	205	23	and	and	CCONJ
dti-3059	205	24	immune	immune	ADJ
dti-3059	205	25	escape26	escape26	NOUN
dti-3059	205	26	©	©	ADP
dti-3059	205	27	2024	2024	NUM
dti-3059	205	28	the	the	DET
dti-3059	205	29	authors	author	NOUN
dti-3059	205	30	.	.	PUNCT
dti-3059	206	1	drug	drug	NOUN
dti-3059	206	2	target	target	NOUN
dti-3059	206	3	insights	insight	NOUN
dti-3059	206	4	issn	issn	VERB
dti-3059	206	5	1177	1177	NUM
dti-3059	206	6	-	-	SYM
dti-3059	206	7	3928	3928	NUM
dti-3059	206	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	VERB
dti-3059	206	9	14	14	NUM
dti-3059	206	10	.	.	PUNCT
dti-3059	207	1	roemer	roemer	PROPN
dti-3059	207	2	c	c	PROPN
dti-3059	207	3	,	,	PUNCT
dti-3059	207	4	sheward	sheward	NOUN
dti-3059	207	5	dj	dj	NOUN
dti-3059	207	6	,	,	PUNCT
dti-3059	207	7	hisner	hisner	NOUN
dti-3059	207	8	r	r	NOUN
dti-3059	207	9	,	,	PUNCT
dti-3059	207	10	et	et	PROPN
dti-3059	207	11	al	al	PROPN
dti-3059	207	12	.	.	PUNCT
dti-3059	208	1	sars	sars	PROPN
dti-3059	208	2	-	-	PUNCT
dti-3059	208	3	cov-2	cov-2	PART
dti-3059	208	4	evolution	evolution	NOUN
dti-3059	208	5	in	in	ADP
dti-3059	208	6	the	the	DET
dti-3059	208	7	omicron	omicron	PROPN
dti-3059	208	8	era	era	NOUN
dti-3059	208	9	.	.	PUNCT
dti-3059	209	1	nat	nat	PROPN
dti-3059	209	2	microbiol	microbiol	PROPN
dti-3059	209	3	.	.	PUNCT
dti-3059	210	1	2023;8(11):1952	2023;8(11):1952	NUM
dti-3059	210	2	-	-	PUNCT
dti-3059	210	3	1959	1959	NUM
dti-3059	210	4	.	.	PUNCT
dti-3059	211	1	crossref	crossref	PROPN
dti-3059	211	2	pubmed	pubmed	PROPN
dti-3059	211	3	15	15	PROPN
dti-3059	211	4	.	.	PUNCT
dti-3059	212	1	carabelli	carabelli	PROPN
dti-3059	212	2	am	be	AUX
dti-3059	212	3	,	,	PUNCT
dti-3059	212	4	peacock	peacock	NOUN
dti-3059	212	5	tp	tp	NOUN
dti-3059	212	6	,	,	PUNCT
dti-3059	212	7	thorne	thorne	PROPN
dti-3059	212	8	lg	lg	PROPN
dti-3059	212	9	,	,	PUNCT
dti-3059	212	10	et	et	PROPN
dti-3059	212	11	al	al	PROPN
dti-3059	212	12	;	;	PUNCT
dti-3059	212	13	covid-19	covid-19	PROPN
dti-3059	212	14	genomics	genomics	PROPN
dti-3059	212	15	uk	uk	PROPN
dti-3059	212	16	consortium	consortium	PROPN
dti-3059	212	17	.	.	PUNCT
dti-3059	213	1	sars	sar	NOUN
dti-3059	213	2	-	-	PUNCT
dti-3059	213	3	cov-2	cov-2	NOUN
dti-3059	213	4	variant	variant	ADJ
dti-3059	213	5	biology	biology	NOUN
dti-3059	213	6	:	:	PUNCT
dti-3059	213	7	immune	immune	ADJ
dti-3059	213	8	escape	escape	NOUN
dti-3059	213	9	,	,	PUNCT
dti-3059	213	10	transmission	transmission	NOUN
dti-3059	213	11	and	and	CCONJ
dti-3059	213	12	fitness	fitness	NOUN
dti-3059	213	13	.	.	PUNCT
dti-3059	214	1	nat	nat	PROPN
dti-3059	214	2	rev	rev	PROPN
dti-3059	214	3	microbiol	microbiol	PROPN
dti-3059	214	4	.	.	PUNCT
dti-3059	215	1	2023;21(3):162177	2023;21(3):162177	NUM
dti-3059	215	2	.	.	PUNCT
dti-3059	216	1	crossref	crossref	PROPN
dti-3059	216	2	pubmed	pubmed	PROPN
dti-3059	216	3	16	16	NUM
dti-3059	216	4	.	.	PUNCT
dti-3059	217	1	pather	pather	PROPN
dti-3059	217	2	s	s	PROPN
dti-3059	217	3	,	,	PUNCT
dti-3059	217	4	madhi	madhi	PROPN
dti-3059	217	5	sa	sa	PROPN
dti-3059	217	6	,	,	PUNCT
dti-3059	217	7	cowling	cowl	VERB
dti-3059	217	8	bj	bj	NOUN
dti-3059	217	9	,	,	PUNCT
dti-3059	217	10	et	et	PROPN
dti-3059	217	11	al	al	PROPN
dti-3059	217	12	.	.	PUNCT
dti-3059	218	1	sars	sars	PROPN
dti-3059	218	2	-	-	PUNCT
dti-3059	218	3	cov-2	cov-2	NOUN
dti-3059	218	4	omicron	omicron	NOUN
dti-3059	218	5	variants	variant	NOUN
dti-3059	218	6	:	:	PUNCT
dti-3059	218	7	burden	burden	NOUN
dti-3059	218	8	of	of	ADP
dti-3059	218	9	disease	disease	NOUN
dti-3059	218	10	,	,	PUNCT
dti-3059	218	11	impact	impact	NOUN
dti-3059	218	12	on	on	ADP
dti-3059	218	13	vaccine	vaccine	NOUN
dti-3059	218	14	effectiveness	effectiveness	NOUN
dti-3059	218	15	and	and	CCONJ
dti-3059	218	16	need	need	VERB
dti-3059	218	17	for	for	ADP
dti-3059	218	18	variant	variant	NOUN
dti-3059	218	19	-	-	PUNCT
dti-3059	218	20	adapted	adapt	VERB
dti-3059	218	21	vaccines	vaccine	NOUN
dti-3059	218	22	.	.	PUNCT
dti-3059	219	1	front	front	ADJ
dti-3059	219	2	immunol	immunol	NOUN
dti-3059	219	3	.	.	PUNCT
dti-3059	220	1	2023;14:1130539	2023;14:1130539	NUM
dti-3059	220	2	.	.	X
dti-3059	221	1	crossref	crossref	PROPN
dti-3059	221	2	pubmed	pubmed	PROPN
dti-3059	221	3	17	17	NUM
dti-3059	221	4	.	.	PUNCT
dti-3059	222	1	yadav	yadav	PROPN
dti-3059	222	2	t	t	PROPN
dti-3059	222	3	,	,	PUNCT
dti-3059	222	4	kumar	kumar	PROPN
dti-3059	222	5	s	s	PROPN
dti-3059	222	6	,	,	PUNCT
dti-3059	222	7	mishra	mishra	PROPN
dti-3059	222	8	g	g	PROPN
dti-3059	222	9	,	,	PUNCT
dti-3059	222	10	saxena	saxena	PROPN
dti-3059	222	11	sk	sk	PROPN
dti-3059	222	12	.	.	PUNCT
dti-3059	223	1	tracking	track	VERB
dti-3059	223	2	the	the	DET
dti-3059	223	3	covid19	covid19	NOUN
dti-3059	223	4	vaccines	vaccine	NOUN
dti-3059	223	5	:	:	PUNCT
dti-3059	223	6	the	the	DET
dti-3059	223	7	global	global	ADJ
dti-3059	223	8	landscape	landscape	NOUN
dti-3059	223	9	.	.	PUNCT
dti-3059	224	1	hum	hum	PROPN
dti-3059	224	2	vaccin	vaccin	PROPN
dti-3059	224	3	immunother	immunother	PROPN
dti-3059	224	4	.	.	PUNCT
dti-3059	225	1	2023;19(1):2191577	2023;19(1):2191577	NUM
dti-3059	225	2	.	.	PUNCT
dti-3059	226	1	crossref	crossref	PROPN
dti-3059	226	2	pubmed	pubmed	PROPN
dti-3059	226	3	18	18	NUM
dti-3059	226	4	.	.	PUNCT
dti-3059	227	1	wahid	wahid	PROPN
dti-3059	227	2	m	m	PROPN
dti-3059	227	3	,	,	PUNCT
dti-3059	227	4	jawed	jaw	VERB
dti-3059	227	5	a	a	DET
dti-3059	227	6	,	,	PUNCT
dti-3059	227	7	mandal	mandal	ADJ
dti-3059	227	8	rk	rk	NOUN
dti-3059	227	9	,	,	PUNCT
dti-3059	227	10	et	et	PROPN
dti-3059	227	11	al	al	PROPN
dti-3059	227	12	.	.	PROPN
dti-3059	228	1	role	role	NOUN
dti-3059	228	2	of	of	ADP
dti-3059	228	3	available	available	ADJ
dti-3059	228	4	covid19	covid19	NOUN
dti-3059	228	5	vaccines	vaccine	NOUN
dti-3059	228	6	in	in	ADP
dti-3059	228	7	reducing	reduce	VERB
dti-3059	228	8	deaths	death	NOUN
dti-3059	228	9	and	and	CCONJ
dti-3059	228	10	perspective	perspective	NOUN
dti-3059	228	11	for	for	ADP
dti-3059	228	12	next	next	ADJ
dti-3059	228	13	generation	generation	NOUN
dti-3059	228	14	vaccines	vaccine	NOUN
dti-3059	228	15	and	and	CCONJ
dti-3059	228	16	therapies	therapy	NOUN
dti-3059	228	17	to	to	PART
dti-3059	228	18	counter	counter	VERB
dti-3059	228	19	emerging	emerge	VERB
dti-3059	228	20	viral	viral	ADJ
dti-3059	228	21	variants	variant	NOUN
dti-3059	228	22	:	:	PUNCT
dti-3059	228	23	an	an	DET
dti-3059	228	24	update	update	NOUN
dti-3059	228	25	.	.	PUNCT
dti-3059	229	1	minerva	minerva	PROPN
dti-3059	229	2	med	med	PROPN
dti-3059	229	3	.	.	PUNCT
dti-3059	230	1	2023;114(5):683	2023;114(5):683	X
dti-3059	230	2	-	-	SYM
dti-3059	230	3	697	697	NUM
dti-3059	230	4	.	.	PUNCT
dti-3059	231	1	crossref	crossref	PROPN
dti-3059	231	2	pubmed	pubmed	PROPN
dti-3059	231	3	19	19	NUM
dti-3059	231	4	.	.	PROPN
dti-3059	231	5	bostanghadiri	bostanghadiri	PROPN
dti-3059	231	6	n	n	CCONJ
dti-3059	231	7	,	,	PUNCT
dti-3059	231	8	ziaeefar	ziaeefar	PROPN
dti-3059	231	9	p	p	PROPN
dti-3059	231	10	,	,	PUNCT
dti-3059	231	11	mofrad	mofrad	PROPN
dti-3059	231	12	mg	mg	PROPN
dti-3059	231	13	,	,	PUNCT
dti-3059	231	14	yousefzadeh	yousefzadeh	NOUN
dti-3059	231	15	p	p	X
dti-3059	231	16	,	,	PUNCT
dti-3059	231	17	hashemi	hashemi	X
dti-3059	231	18	a	a	DET
dti-3059	231	19	,	,	PUNCT
dti-3059	231	20	darban	darban	NOUN
dti-3059	231	21	-	-	PUNCT
dti-3059	231	22	sarokhalil	sarokhalil	NOUN
dti-3059	231	23	d.	d.	PROPN
dti-3059	231	24	covid-19	covid-19	PROPN
dti-3059	231	25	:	:	PUNCT
dti-3059	231	26	an	an	DET
dti-3059	231	27	overview	overview	NOUN
dti-3059	231	28	of	of	ADP
dti-3059	231	29	sars	sar	NOUN
dti-3059	231	30	-	-	PUNCT
dti-3059	231	31	cov-2	cov-2	PART
dti-3059	231	32	variants	variant	NOUN
dti-3059	231	33	–	–	PUNCT
dti-3059	231	34	the	the	DET
dti-3059	231	35	current	current	ADJ
dti-3059	231	36	vaccines	vaccine	NOUN
dti-3059	231	37	and	and	CCONJ
dti-3059	231	38	drug	drug	NOUN
dti-3059	231	39	development	development	NOUN
dti-3059	231	40	.	.	PUNCT
dti-3059	231	41	biomed	biome	VERB
dti-3059	231	42	res	re	NOUN
dti-3059	231	43	int	int	NOUN
dti-3059	231	44	.	.	PUNCT
dti-3059	232	1	2023;2023:1879554	2023;2023:1879554	NUM
dti-3059	232	2	.	.	PUNCT
dti-3059	233	1	crossref	crossref	PROPN
dti-3059	233	2	pubmed	pubmed	PROPN
dti-3059	233	3	20	20	NUM
dti-3059	233	4	.	.	PUNCT
dti-3059	234	1	nanda	nanda	PROPN
dti-3059	234	2	r	r	PROPN
dti-3059	234	3	,	,	PUNCT
dti-3059	234	4	gupta	gupta	PROPN
dti-3059	234	5	p	p	NOUN
dti-3059	234	6	,	,	PUNCT
dti-3059	234	7	giri	giri	PROPN
dti-3059	234	8	ak	ak	PROPN
dti-3059	234	9	,	,	PUNCT
dti-3059	234	10	patel	patel	PROPN
dti-3059	234	11	s	s	PART
dti-3059	234	12	,	,	PUNCT
dti-3059	234	13	shah	shah	PROPN
dti-3059	234	14	s	s	PROPN
dti-3059	234	15	,	,	PUNCT
dti-3059	234	16	mohapatra	mohapatra	PROPN
dti-3059	234	17	e.	e.	PROPN
dti-3059	234	18	serological	serological	PROPN
dti-3059	234	19	evaluation	evaluation	NOUN
dti-3059	234	20	of	of	ADP
dti-3059	234	21	antibody	antibody	NOUN
dti-3059	234	22	titers	titer	NOUN
dti-3059	234	23	after	after	ADP
dti-3059	234	24	vaccination	vaccination	NOUN
dti-3059	234	25	against	against	ADP
dti-3059	234	26	covid-19	covid-19	PROPN
dti-3059	234	27	in	in	ADP
dti-3059	234	28	18	18	NUM
dti-3059	234	29	-	-	SYM
dti-3059	234	30	44	44	NUM
dti-3059	234	31	-	-	PUNCT
dti-3059	234	32	year	year	NOUN
dti-3059	234	33	-	-	PUNCT
dti-3059	234	34	old	old	ADJ
dti-3059	234	35	individuals	individual	NOUN
dti-3059	234	36	at	at	ADP
dti-3059	234	37	a	a	DET
dti-3059	234	38	tertiary	tertiary	ADJ
dti-3059	234	39	care	care	NOUN
dti-3059	234	40	center	center	NOUN
dti-3059	234	41	.	.	PUNCT
dti-3059	235	1	cureus	cureus	NOUN
dti-3059	235	2	.	.	PUNCT
dti-3059	236	1	2023;15(6):e40543	2023;15(6):e40543	X
dti-3059	236	2	.	.	PUNCT
dti-3059	236	3	crossref	crossref	PROPN
dti-3059	236	4	pubmed	pubmed	PROPN
dti-3059	236	5	21	21	NUM
dti-3059	236	6	.	.	PUNCT
dti-3059	237	1	dimitroff	dimitroff	PROPN
dti-3059	237	2	sj	sj	PROPN
dti-3059	237	3	,	,	PUNCT
dti-3059	237	4	würfel	würfel	PROPN
dti-3059	237	5	l	l	PROPN
dti-3059	237	6	,	,	PUNCT
dti-3059	237	7	meier	meier	PROPN
dti-3059	237	8	m	m	PROPN
dti-3059	237	9	,	,	PUNCT
dti-3059	237	10	et	et	PROPN
dti-3059	237	11	al	al	PROPN
dti-3059	237	12	.	.	PUNCT
dti-3059	237	13	estimation	estimation	NOUN
dti-3059	237	14	of	of	ADP
dti-3059	237	15	antibody	antibody	NOUN
dti-3059	237	16	levels	level	NOUN
dti-3059	237	17	after	after	ADP
dti-3059	237	18	covid-19	covid-19	PROPN
dti-3059	237	19	vaccinations	vaccination	NOUN
dti-3059	237	20	:	:	PUNCT
dti-3059	237	21	preliminary	preliminary	ADJ
dti-3059	237	22	evidence	evidence	NOUN
dti-3059	237	23	for	for	ADP
dti-3059	237	24	immune	immune	ADJ
dti-3059	237	25	interoception	interoception	NOUN
dti-3059	237	26	.	.	PUNCT
dti-3059	238	1	biol	biol	PROPN
dti-3059	238	2	psychol	psychol	PROPN
dti-3059	238	3	.	.	PUNCT
dti-3059	239	1	2023;182:108636	2023;182:108636	NUM
dti-3059	239	2	.	.	PUNCT
dti-3059	240	1	crossref	crossref	PROPN
dti-3059	240	2	pubmed	pubmed	PROPN
dti-3059	240	3	22	22	NUM
dti-3059	240	4	.	.	PUNCT
dti-3059	241	1	huang	huang	PROPN
dti-3059	241	2	c	c	PROPN
dti-3059	241	3	,	,	PUNCT
dti-3059	241	4	huang	huang	PROPN
dti-3059	241	5	l	l	PROPN
dti-3059	241	6	,	,	PUNCT
dti-3059	241	7	wang	wang	PROPN
dti-3059	241	8	y	y	PROPN
dti-3059	241	9	,	,	PUNCT
dti-3059	241	10	et	et	PROPN
dti-3059	241	11	al	al	PROPN
dti-3059	241	12	.	.	PROPN
dti-3059	241	13	6	6	NUM
dti-3059	241	14	-	-	PUNCT
dti-3059	241	15	month	month	NOUN
dti-3059	241	16	consequences	consequence	NOUN
dti-3059	241	17	of	of	ADP
dti-3059	241	18	covid-19	covid-19	PROPN
dti-3059	241	19	in	in	ADP
dti-3059	241	20	patients	patient	NOUN
dti-3059	241	21	discharged	discharge	VERB
dti-3059	241	22	from	from	ADP
dti-3059	241	23	hospital	hospital	NOUN
dti-3059	241	24	:	:	PUNCT
dti-3059	241	25	a	a	DET
dti-3059	241	26	cohort	cohort	NOUN
dti-3059	241	27	study	study	NOUN
dti-3059	241	28	.	.	PUNCT
dti-3059	242	1	lancet	lancet	NOUN
dti-3059	242	2	.	.	PUNCT
dti-3059	243	1	2023;401(10393):e21	2023;401(10393):e21	NUM
dti-3059	243	2	-	-	PUNCT
dti-3059	243	3	e33	e33	NOUN
dti-3059	243	4	.	.	PUNCT
dti-3059	244	1	crossref	crossref	PROPN
dti-3059	244	2	pubmed	pubmed	PROPN
dti-3059	244	3	23	23	NUM
dti-3059	244	4	.	.	PUNCT
dti-3059	245	1	amrutha	amrutha	PROPN
dti-3059	245	2	s	s	PROPN
dti-3059	245	3	,	,	PUNCT
dti-3059	245	4	kaur	kaur	PROPN
dti-3059	245	5	k	k	PROPN
dti-3059	245	6	,	,	PUNCT
dti-3059	245	7	aggarwal	aggarwal	PROPN
dti-3059	245	8	d	d	PROPN
dti-3059	245	9	,	,	PUNCT
dti-3059	245	10	sodhi	sodhi	VERB
dti-3059	245	11	mk	mk	PROPN
dti-3059	245	12	,	,	PUNCT
dti-3059	245	13	jaswal	jaswal	PROPN
dti-3059	245	14	s	s	PROPN
dti-3059	245	15	,	,	PUNCT
dti-3059	245	16	saini	saini	PROPN
dti-3059	245	17	v.	v.	ADP
dti-3059	245	18	serial	serial	ADJ
dti-3059	245	19	evaluation	evaluation	NOUN
dti-3059	245	20	of	of	ADP
dti-3059	245	21	antibody	antibody	NOUN
dti-3059	245	22	titres	titre	NOUN
dti-3059	245	23	in	in	ADP
dti-3059	245	24	patients	patient	NOUN
dti-3059	245	25	recovered	recover	VERB
dti-3059	245	26	from	from	ADP
dti-3059	245	27	covid-19	covid-19	PROPN
dti-3059	245	28	and	and	CCONJ
dti-3059	245	29	their	their	PRON
dti-3059	245	30	correlation	correlation	NOUN
dti-3059	245	31	with	with	ADP
dti-3059	245	32	disease	disease	NOUN
dti-3059	245	33	severity	severity	NOUN
dti-3059	245	34	.	.	PUNCT
dti-3059	246	1	monaldi	monaldi	PROPN
dti-3059	246	2	arch	arch	VERB
dti-3059	246	3	chest	chest	NOUN
dti-3059	246	4	dis	dis	PROPN
dti-3059	246	5	2023	2023	NUM
dti-3059	246	6	nov	nov	NOUN
dti-3059	246	7	3	3	NUM
dti-3059	246	8	.	.	PUNCT
dti-3059	247	1	crossref	crossref	PROPN
dti-3059	247	2	24	24	NUM
dti-3059	247	3	.	.	PUNCT
dti-3059	248	1	de	de	PROPN
dti-3059	248	2	oliveira	oliveira	PROPN
dti-3059	248	3	mi	mi	PROPN
dti-3059	248	4	,	,	PUNCT
dti-3059	248	5	aciole	aciole	PROPN
dti-3059	248	6	mr	mr	PROPN
dti-3059	248	7	,	,	PUNCT
dti-3059	248	8	neves	neves	PROPN
dti-3059	248	9	paf	paf	PROPN
dti-3059	248	10	,	,	PUNCT
dti-3059	248	11	et	et	PROPN
dti-3059	248	12	al	al	PROPN
dti-3059	248	13	.	.	PUNCT
dti-3059	249	1	a	a	DET
dti-3059	249	2	stronger	strong	ADJ
dti-3059	249	3	antibody	antibody	NOUN
dti-3059	249	4	response	response	NOUN
dti-3059	249	5	in	in	ADP
dti-3059	249	6	increased	increase	VERB
dti-3059	249	7	disease	disease	NOUN
dti-3059	249	8	severity	severity	NOUN
dti-3059	249	9	of	of	ADP
dti-3059	249	10	sars	sar	NOUN
dti-3059	249	11	-	-	PUNCT
dti-3059	249	12	cov-2	cov-2	NOUN
dti-3059	249	13	.	.	PUNCT
dti-3059	250	1	bmc	bmc	PROPN
dti-3059	250	2	infect	infect	PROPN
dti-3059	250	3	dis	dis	PROPN
dti-3059	250	4	.	.	PUNCT
dti-3059	251	1	2024;24(1):17	2024;24(1):17	X
dti-3059	251	2	.	.	PUNCT
dti-3059	251	3	crossref	crossref	PROPN
dti-3059	251	4	pubmed	pubmed	PROPN
dti-3059	251	5	25	25	NUM
dti-3059	251	6	.	.	PUNCT
dti-3059	252	1	lavezzo	lavezzo	PROPN
dti-3059	252	2	e	e	PROPN
dti-3059	252	3	,	,	PUNCT
dti-3059	252	4	pacenti	pacenti	PROPN
dti-3059	252	5	m	m	PROPN
dti-3059	252	6	,	,	PUNCT
dti-3059	252	7	manuto	manuto	PROPN
dti-3059	252	8	l	l	PROPN
dti-3059	252	9	,	,	PUNCT
dti-3059	252	10	et	et	PROPN
dti-3059	252	11	al	al	PROPN
dti-3059	252	12	.	.	PUNCT
dti-3059	253	1	neutralising	neutralise	VERB
dti-3059	253	2	reactivity	reactivity	NOUN
dti-3059	253	3	against	against	ADP
dti-3059	253	4	sars	sar	NOUN
dti-3059	253	5	-	-	PUNCT
dti-3059	253	6	cov-2	cov-2	NOUN
dti-3059	253	7	delta	delta	NOUN
dti-3059	253	8	and	and	CCONJ
dti-3059	253	9	omicron	omicron	PROPN
dti-3059	253	10	variants	variant	NOUN
dti-3059	253	11	by	by	ADP
dti-3059	253	12	vaccination	vaccination	NOUN
dti-3059	253	13	and	and	CCONJ
dti-3059	253	14	infection	infection	NOUN
dti-3059	253	15	history	history	NOUN
dti-3059	253	16	.	.	PUNCT
dti-3059	254	1	genome	genome	NOUN
dti-3059	254	2	med	me	VERB
dti-3059	254	3	.	.	PUNCT
dti-3059	255	1	2022;14(1):61	2022;14(1):61	X
dti-3059	255	2	.	.	PUNCT
dti-3059	256	1	crossref	crossref	PROPN
dti-3059	256	2	pubmed	pubmed	PROPN
dti-3059	256	3	26	26	NUM
dti-3059	256	4	.	.	PUNCT
dti-3059	257	1	geers	geer	NOUN
dti-3059	257	2	d	d	NOUN
dti-3059	257	3	,	,	PUNCT
dti-3059	257	4	shamier	shami	ADJ
dti-3059	257	5	mc	mc	PROPN
dti-3059	257	6	,	,	PUNCT
dti-3059	257	7	bogers	bogers	PROPN
dti-3059	257	8	s	s	PART
dti-3059	257	9	,	,	PUNCT
dti-3059	257	10	et	et	PROPN
dti-3059	257	11	al	al	PROPN
dti-3059	257	12	.	.	PUNCT
dti-3059	258	1	sars	sars	PROPN
dti-3059	258	2	-	-	PUNCT
dti-3059	258	3	cov-2	cov-2	PART
dti-3059	258	4	variants	variant	NOUN
dti-3059	258	5	of	of	ADP
dti-3059	258	6	concern	concern	NOUN
dti-3059	258	7	partially	partially	ADV
dti-3059	258	8	escape	escape	VERB
dti-3059	258	9	humoral	humoral	ADJ
dti-3059	258	10	but	but	CCONJ
dti-3059	258	11	not	not	PART
dti-3059	258	12	t	t	NOUN
dti-3059	258	13	-	-	PUNCT
dti-3059	258	14	cell	cell	NOUN
dti-3059	258	15	responses	response	NOUN
dti-3059	258	16	in	in	ADP
dti-3059	258	17	covid-19	covid-19	PROPN
dti-3059	258	18	convalescent	convalescent	NOUN
dti-3059	258	19	donors	donor	NOUN
dti-3059	258	20	and	and	CCONJ
dti-3059	258	21	vaccinees	vaccinee	NOUN
dti-3059	258	22	.	.	PUNCT
dti-3059	259	1	sci	sci	PROPN
dti-3059	259	2	immunol	immunol	NOUN
dti-3059	259	3	.	.	PUNCT
dti-3059	260	1	2021	2021	NUM
dti-3059	260	2	may	may	AUX
dti-3059	260	3	25;6(59):eabj1750	25;6(59):eabj1750	NUM
dti-3059	260	4	.	.	PUNCT
dti-3059	261	1	crossref	crossref	PROPN
dti-3059	261	2	27	27	NUM
dti-3059	261	3	.	.	PUNCT
dti-3059	262	1	ma	ma	PROPN
dti-3059	262	2	ql	ql	PROPN
dti-3059	262	3	,	,	PUNCT
dti-3059	262	4	huang	huang	PROPN
dti-3059	262	5	fm	fm	PROPN
dti-3059	262	6	,	,	PUNCT
dti-3059	262	7	guo	guo	PROPN
dti-3059	262	8	w	w	PROPN
dti-3059	262	9	,	,	PUNCT
dti-3059	262	10	feng	feng	PROPN
dti-3059	262	11	ky	ky	PROPN
dti-3059	262	12	,	,	PUNCT
dti-3059	262	13	huang	huang	PROPN
dti-3059	262	14	t	t	PROPN
dti-3059	262	15	,	,	PUNCT
dti-3059	262	16	cai	cai	PROPN
dti-3059	262	17	yd	yd	PROPN
dti-3059	262	18	.	.	PROPN
dti-3059	262	19	machine	machine	NOUN
dti-3059	262	20	learning	learn	VERB
dti-3059	262	21	classification	classification	NOUN
dti-3059	262	22	of	of	ADP
dti-3059	262	23	time	time	NOUN
dti-3059	262	24	since	since	SCONJ
dti-3059	262	25	bnt162b2	bnt162b2	PROPN
dti-3059	262	26	covid-19	covid-19	PROPN
dti-3059	262	27	vaccination	vaccination	NOUN
dti-3059	262	28	based	base	VERB
dti-3059	262	29	on	on	ADP
dti-3059	262	30	array	array	NOUN
dti-3059	262	31	-	-	PUNCT
dti-3059	262	32	measured	measure	VERB
dti-3059	262	33	antibody	antibody	NOUN
dti-3059	262	34	activity	activity	NOUN
dti-3059	262	35	.	.	PUNCT
dti-3059	263	1	life	life	NOUN
dti-3059	263	2	(	(	PUNCT
dti-3059	263	3	basel	basel	PROPN
dti-3059	263	4	)	)	PUNCT
dti-3059	263	5	.	.	PUNCT
dti-3059	264	1	2023;13(6):1304	2023;13(6):1304	PROPN
dti-3059	264	2	.	.	PUNCT
dti-3059	265	1	crossref	crossref	PROPN
dti-3059	265	2	pubmed	pubmed	PROPN
dti-3059	265	3	28	28	PROPN
dti-3059	265	4	.	.	PUNCT
dti-3059	266	1	edara	edara	PROPN
dti-3059	266	2	vv	vv	PROPN
dti-3059	266	3	,	,	PUNCT
dti-3059	266	4	norwood	norwood	PROPN
dti-3059	266	5	c	c	PROPN
dti-3059	266	6	,	,	PUNCT
dti-3059	266	7	floyd	floyd	PROPN
dti-3059	266	8	k	k	PROPN
dti-3059	266	9	,	,	PUNCT
dti-3059	266	10	et	et	PROPN
dti-3059	266	11	al	al	PROPN
dti-3059	266	12	.	.	PROPN
dti-3059	266	13	reduced	reduce	VERB
dti-3059	266	14	binding	bind	VERB
dti-3059	266	15	and	and	CCONJ
dti-3059	266	16	neutralization	neutralization	NOUN
dti-3059	266	17	of	of	ADP
dti-3059	266	18	infectionand	infectionand	NOUN
dti-3059	266	19	vaccine	vaccine	NOUN
dti-3059	266	20	-	-	PUNCT
dti-3059	266	21	induced	induce	VERB
dti-3059	266	22	antibodies	antibody	NOUN
dti-3059	266	23	to	to	ADP
dti-3059	266	24	the	the	DET
dti-3059	266	25	b.1.351	b.1.351	NOUN
dti-3059	266	26	(	(	PUNCT
dti-3059	266	27	south	south	ADJ
dti-3059	266	28	african	african	ADJ
dti-3059	266	29	)	)	PUNCT
dti-3059	266	30	sars	sar	NOUN
dti-3059	266	31	-	-	PUNCT
dti-3059	266	32	cov-2	cov-2	NOUN
dti-3059	266	33	variant	variant	NOUN
dti-3059	266	34	.	.	PUNCT
dti-3059	267	1	biorxiv	biorxiv	NOUN
dti-3059	268	1	[	[	X
dti-3059	268	2	preprint	preprint	NOUN
dti-3059	268	3	]	]	X
dti-3059	268	4	.	.	PUNCT
dti-3059	269	1	2021	2021	NUM
dti-3059	269	2	feb	feb	NOUN
dti-3059	269	3	22	22	NUM
dti-3059	269	4	.	.	PUNCT
dti-3059	270	1	crossref	crossref	PROPN
dti-3059	270	2	pubmed	pubmed	PROPN
dti-3059	270	3	29	29	NUM
dti-3059	270	4	.	.	PUNCT
dti-3059	271	1	ryu	ryu	PROPN
dti-3059	271	2	dk	dk	PROPN
dti-3059	271	3	,	,	PUNCT
dti-3059	271	4	song	song	NOUN
dti-3059	271	5	r	r	PROPN
dti-3059	271	6	,	,	PUNCT
dti-3059	271	7	kim	kim	PROPN
dti-3059	271	8	m	m	PROPN
dti-3059	271	9	,	,	PUNCT
dti-3059	271	10	et	et	PROPN
dti-3059	271	11	al	al	PROPN
dti-3059	271	12	.	.	PUNCT
dti-3059	272	1	therapeutic	therapeutic	ADJ
dti-3059	272	2	effect	effect	NOUN
dti-3059	272	3	of	of	ADP
dti-3059	272	4	ct	ct	NOUN
dti-3059	272	5	-	-	PUNCT
dti-3059	272	6	p59	p59	NOUN
dti-3059	272	7	against	against	ADP
dti-3059	272	8	sars	sar	NOUN
dti-3059	272	9	-	-	PUNCT
dti-3059	272	10	cov-2	cov-2	NOUN
dti-3059	272	11	south	south	ADJ
dti-3059	272	12	african	african	ADJ
dti-3059	272	13	variant	variant	NOUN
dti-3059	272	14	.	.	PUNCT
dti-3059	273	1	biochem	biochem	PROPN
dti-3059	273	2	biophys	biophys	PROPN
dti-3059	273	3	res	re	NOUN
dti-3059	273	4	commun	commun	PROPN
dti-3059	273	5	.	.	PUNCT
dti-3059	274	1	2021;566:135	2021;566:135	NUM
dti-3059	274	2	-	-	SYM
dti-3059	274	3	140	140	NUM
dti-3059	274	4	.	.	PUNCT
dti-3059	275	1	crossref	crossref	PROPN
dti-3059	275	2	pubmed	pubmed	PROPN
dti-3059	275	3	30	30	NUM
dti-3059	275	4	.	.	PUNCT
dti-3059	276	1	sette	sette	PROPN
dti-3059	276	2	a	a	PROPN
dti-3059	276	3	,	,	PUNCT
dti-3059	276	4	crotty	crotty	PROPN
dti-3059	276	5	s.	s.	PROPN
dti-3059	276	6	immunological	immunological	ADJ
dti-3059	276	7	memory	memory	NOUN
dti-3059	276	8	to	to	ADP
dti-3059	276	9	sars	sar	NOUN
dti-3059	276	10	-	-	PUNCT
dti-3059	276	11	cov-2	cov-2	PART
dti-3059	276	12	infection	infection	NOUN
dti-3059	276	13	and	and	CCONJ
dti-3059	276	14	covid-19	covid-19	PROPN
dti-3059	276	15	vaccines	vaccine	NOUN
dti-3059	276	16	.	.	PUNCT
dti-3059	277	1	immunol	immunol	PROPN
dti-3059	277	2	rev	rev	PROPN
dti-3059	277	3	.	.	PROPN
dti-3059	277	4	2022;310(1):27	2022;310(1):27	PROPN
dti-3059	277	5	-	-	SYM
dti-3059	277	6	46	46	NUM
dti-3059	277	7	.	.	PUNCT
dti-3059	278	1	crossref	crossref	PROPN
dti-3059	278	2	pubmed	pubmed	PROPN
dti-3059	278	3	31	31	NUM
dti-3059	278	4	.	.	PUNCT
dti-3059	279	1	viana	viana	PROPN
dti-3059	279	2	r	r	PROPN
dti-3059	279	3	,	,	PUNCT
dti-3059	279	4	moyo	moyo	PROPN
dti-3059	279	5	s	s	PROPN
dti-3059	279	6	,	,	PUNCT
dti-3059	279	7	amoako	amoako	PROPN
dti-3059	279	8	dg	dg	PROPN
dti-3059	279	9	,	,	PUNCT
dti-3059	279	10	et	et	PROPN
dti-3059	279	11	al	al	PROPN
dti-3059	279	12	.	.	PROPN
dti-3059	279	13	rapid	rapid	ADJ
dti-3059	279	14	epidemic	epidemic	NOUN
dti-3059	279	15	expansion	expansion	NOUN
dti-3059	279	16	of	of	ADP
dti-3059	279	17	the	the	DET
dti-3059	279	18	sars	sar	NOUN
dti-3059	279	19	-	-	PUNCT
dti-3059	279	20	cov-2	cov-2	NOUN
dti-3059	279	21	omicron	omicron	PROPN
dti-3059	279	22	variant	variant	NOUN
dti-3059	279	23	in	in	ADP
dti-3059	279	24	southern	southern	PROPN
dti-3059	279	25	africa	africa	PROPN
dti-3059	279	26	.	.	PUNCT
dti-3059	280	1	nature	nature	NOUN
dti-3059	280	2	.	.	PUNCT
dti-3059	281	1	2022	2022	NUM
dti-3059	281	2	mar;603(7902):679	mar;603(7902):679	NOUN
dti-3059	281	3	-	-	PUNCT
dti-3059	281	4	686	686	NUM
dti-3059	281	5	.	.	PUNCT
dti-3059	282	1	crossref	crossref	PROPN
dti-3059	282	2	32	32	NUM
dti-3059	282	3	.	.	PUNCT
dti-3059	283	1	wibmer	wibmer	PROPN
dti-3059	283	2	ck	ck	PROPN
dti-3059	283	3	,	,	PUNCT
dti-3059	283	4	ayres	ayres	PROPN
dti-3059	283	5	f	f	PROPN
dti-3059	283	6	,	,	PUNCT
dti-3059	283	7	hermanus	hermanus	PROPN
dti-3059	283	8	t	t	PROPN
dti-3059	283	9	,	,	PUNCT
dti-3059	283	10	et	et	PROPN
dti-3059	283	11	al	al	PROPN
dti-3059	283	12	.	.	PUNCT
dti-3059	284	1	sars	sars	PROPN
dti-3059	284	2	-	-	PUNCT
dti-3059	284	3	cov-2	cov-2	NUM
dti-3059	284	4	501y	501y	NUM
dti-3059	284	5	.	.	PUNCT
dti-3059	285	1	v2	v2	PROPN
dti-3059	285	2	escapes	escape	VERB
dti-3059	285	3	neutralization	neutralization	NOUN
dti-3059	285	4	by	by	ADP
dti-3059	285	5	south	south	ADJ
dti-3059	285	6	african	african	PROPN
dti-3059	285	7	covid-19	covid-19	PROPN
dti-3059	285	8	donor	donor	NOUN
dti-3059	285	9	plasma	plasma	NOUN
dti-3059	285	10	.	.	PUNCT
dti-3059	286	1	nat	nat	PROPN
dti-3059	286	2	med	med	PROPN
dti-3059	286	3	.	.	PUNCT
dti-3059	287	1	2021	2021	NUM
dti-3059	287	2	mar	mar	PROPN
dti-3059	287	3	1;27:622	1;27:622	NUM
dti-3059	287	4	-	-	SYM
dti-3059	287	5	625	625	NUM
dti-3059	287	6	.	.	PUNCT
dti-3059	287	7	33	33	NUM
dti-3059	287	8	.	.	PUNCT
dti-3059	288	1	wahid	wahid	PROPN
dti-3059	288	2	m	m	PROPN
dti-3059	288	3	,	,	PUNCT
dti-3059	288	4	jawed	jaw	VERB
dti-3059	288	5	a	a	DET
dti-3059	288	6	,	,	PUNCT
dti-3059	288	7	mandal	mandal	ADJ
dti-3059	288	8	rk	rk	NOUN
dti-3059	288	9	,	,	PUNCT
dti-3059	288	10	et	et	PROPN
dti-3059	288	11	al	al	PROPN
dti-3059	288	12	.	.	PUNCT
dti-3059	289	1	variants	variant	NOUN
dti-3059	289	2	of	of	ADP
dti-3059	289	3	sars	sar	NOUN
dti-3059	289	4	-	-	PUNCT
dti-3059	289	5	cov-2	cov-2	NOUN
dti-3059	289	6	,	,	PUNCT
dti-3059	289	7	their	their	PRON
dti-3059	289	8	effects	effect	NOUN
dti-3059	289	9	on	on	ADP
dti-3059	289	10	infection	infection	NOUN
dti-3059	289	11	,	,	PUNCT
dti-3059	289	12	transmission	transmission	NOUN
dti-3059	289	13	and	and	CCONJ
dti-3059	289	14	neutralization	neutralization	NOUN
dti-3059	289	15	by	by	ADP
dti-3059	289	16	vaccine	vaccine	NOUN
dti-3059	289	17	-	-	PUNCT
dti-3059	289	18	induced	induce	VERB
dti-3059	289	19	antibodies	antibody	NOUN
dti-3059	289	20	.	.	PUNCT
dti-3059	290	1	eur	eur	PROPN
dti-3059	290	2	rev	rev	PROPN
dti-3059	290	3	med	med	PROPN
dti-3059	290	4	pharmacol	pharmacol	PROPN
dti-3059	290	5	sci	sci	PROPN
dti-3059	290	6	.	.	PUNCT
dti-3059	291	1	2021;25(18):5857	2021;25(18):5857	PROPN
dti-3059	291	2	-	-	SYM
dti-3059	291	3	5864	5864	NUM
dti-3059	291	4	.	.	PUNCT
dti-3059	292	1	pubmed	pubmed	PROPN
dti-3059	292	2	https://doi.org/10.1038/s41564-023-01504-w	https://doi.org/10.1038/s41564-023-01504-w	PROPN
dti-3059	293	1	https://www.ncbi.nlm.nih.gov/pubmed/37845314	https://www.ncbi.nlm.nih.gov/pubmed/37845314	NUM
dti-3059	293	2	https://doi.org/10.1038/s41579-022-00841-7	https://doi.org/10.1038/s41579-022-00841-7	NUM
dti-3059	293	3	https://www.ncbi.nlm.nih.gov/pubmed/36653446	https://www.ncbi.nlm.nih.gov/pubmed/36653446	X
dti-3059	293	4	https://doi.org/10.3389/fimmu.2023.1130539	https://doi.org/10.3389/fimmu.2023.1130539	PROPN
dti-3059	294	1	https://www.ncbi.nlm.nih.gov/pubmed/37287979	https://www.ncbi.nlm.nih.gov/pubmed/37287979	X
dti-3059	294	2	https://doi.org/10.1080/21645515.2023.2191577	https://doi.org/10.1080/21645515.2023.2191577	PROPN
dti-3059	295	1	https://www.ncbi.nlm.nih.gov/pubmed/36995773	https://www.ncbi.nlm.nih.gov/pubmed/36995773	PROPN
dti-3059	295	2	https://doi.org/10.23736/s0026-4806.23.08509-9	https://doi.org/10.23736/s0026-4806.23.08509-9	PROPN
dti-3059	295	3	https://www.ncbi.nlm.nih.gov/pubmed/37293890	https://www.ncbi.nlm.nih.gov/pubmed/37293890	VERB
dti-3059	295	4	https://doi.org/10.1155/2023/1879554	https://doi.org/10.1155/2023/1879554	PROPN
dti-3059	295	5	https://www.ncbi.nlm.nih.gov/pubmed/37674935	https://www.ncbi.nlm.nih.gov/pubmed/37674935	NUM
dti-3059	295	6	https://doi.org/10.7759/cureus.40543	https://doi.org/10.7759/cureus.40543	ADJ
dti-3059	295	7	https://www.ncbi.nlm.nih.gov/pubmed/37465786	https://www.ncbi.nlm.nih.gov/pubmed/37465786	NUM
dti-3059	295	8	https://doi.org/10.1016/j.biopsycho.2023.108636	https://doi.org/10.1016/j.biopsycho.2023.108636	PROPN
dti-3059	295	9	https://www.ncbi.nlm.nih.gov/pubmed/37544268	https://www.ncbi.nlm.nih.gov/pubmed/37544268	NOUN
dti-3059	295	10	https://doi.org/10.1016/s0140-6736(23)00810-3	https://doi.org/10.1016/s0140-6736(23)00810-3	NOUN
dti-3059	295	11	https://www.ncbi.nlm.nih.gov/pubmed/37321233	https://www.ncbi.nlm.nih.gov/pubmed/37321233	ADP
dti-3059	295	12	https://doi.org/10.4081/monaldi.2023.2677	https://doi.org/10.4081/monaldi.2023.2677	PROPN
dti-3059	295	13	https://doi.org/10.1186/s12879-023-08923-4	https://doi.org/10.1186/s12879-023-08923-4	PROPN
dti-3059	295	14	https://www.ncbi.nlm.nih.gov/pubmed/38166763	https://www.ncbi.nlm.nih.gov/pubmed/38166763	PROPN
dti-3059	295	15	https://doi.org/10.1186/s13073-022-01066-2	https://doi.org/10.1186/s13073-022-01066-2	NUM
dti-3059	295	16	https://www.ncbi.nlm.nih.gov/pubmed/35689243	https://www.ncbi.nlm.nih.gov/pubmed/35689243	NUM
dti-3059	296	1	https://doi.org/10.1126/sciimmunol.abj1750	https://doi.org/10.1126/sciimmunol.abj1750	PROPN
dti-3059	296	2	https://doi.org/10.3390/life13061304	https://doi.org/10.3390/life13061304	PROPN
dti-3059	296	3	https://www.ncbi.nlm.nih.gov/pubmed/37374086	https://www.ncbi.nlm.nih.gov/pubmed/37374086	PROPN
dti-3059	297	1	https://doi.org/10.1101/2021.02.20.432046	https://doi.org/10.1101/2021.02.20.432046	PROPN
dti-3059	297	2	https://pubmed.ncbi.nlm.nih.gov/33655254/	https://pubmed.ncbi.nlm.nih.gov/33655254/	PROPN
dti-3059	297	3	https://doi.org/10.1016/j.bbrc.2021.06.016	https://doi.org/10.1016/j.bbrc.2021.06.016	PROPN
dti-3059	297	4	https://www.ncbi.nlm.nih.gov/pubmed/34119826	https://www.ncbi.nlm.nih.gov/pubmed/34119826	PROPN
dti-3059	297	5	https://doi.org/10.1111/imr.13089	https://doi.org/10.1111/imr.13089	PROPN
dti-3059	297	6	https://www.ncbi.nlm.nih.gov/pubmed/35733376	https://www.ncbi.nlm.nih.gov/pubmed/35733376	PROPN
dti-3059	297	7	https://doi.org/10.1038/s41586-022-04411-y	https://doi.org/10.1038/s41586-022-04411-y	VERB
dti-3059	297	8	https://www.ncbi.nlm.nih.gov/pubmed/34604978	https://www.ncbi.nlm.nih.gov/pubmed/34604978	NUM